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ABSTRACT
In recent years, self-medication products have undergone a dramatic change due

to the advent of herbal medicines, dietary supplements, nutraceuticals and health foods
in addition to traditional nonprescription medicines and the increasing societal
preferences towards greater individual control over the use of medicines. Globally, the
role and importance of nonprescription medicines in healthcare delivery is also rapidly
increasing due to the potential cost-savings. Hence, this area is beginning to receive
much attention from regulatory authorities, academia and professional/industry/trade
organizations.
This dissertation presents a comprehensive analysis of the classification of
nonprescription medicines and Rx-to-OTC switch criteria/policy in the United States,
United Kingdom, Canada, Japan and Australia. A new approach to investigating US
FDA's overall switch regulatory policies through the combined application of casehistory evaluations, electronic survey questionnaire and telephone interviews has been
utilized.
This investigation was conducted in three phases. Phase-1 involved information
retrieval and a critical review of existing literature, phase-2 applied switch case history
analyses pertinent to US FDA and phase-3 measured the attitudes/opinions of the
academic/professional community and key opinion leaders in nonprescription medicines
across the US, Canada, UK and Australia on important questions.
The subject matter of this dissertation is of enormous current interest in the
global nonprescription medicines arena. The significance of the results presented in this

dissertation is amplified as this area has received little academic attention and this is
perhaps the first comprehensive treatment of this subject.
Overall, inferences based on the information elicited have been summarized to
provide data-based responses to questions of global interest in the self-medication
arena. This information is especially valuable to the US FDA as they are currently
seeking public comment. Data shows that the OTC regulatory model in the United
States may be improved. Evidence indicates that principles upon which approaches for
improvement of the US regulatory system must be based should include: an objective
evaluation of pharmacist class of OTC medicines, development of effective consumer
education tools, increase in regulation of non-traditional OTC medicines, acknowledge
that not all disease conditions and drug classes are suitable for self-treatment, a
collaborative approach by FDA towards switching that includes all stakeholders is more
favored, decisions on switch petitions must be case-specific without a presumptive bias
and public health benefit must be the paramount evaluation criterion.
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PREFACE

This document has been prepared in the format of the manuscript plan in
accordance to section 11-3 of the Graduate Manual at the University of Rhode Island.
This dissertation has been divided into three sections.
Section I contains the statement of the problem and a brief introduction to the
objectives of this research. Section II forms the central part of this dissertation and is
composed of eight manuscripts written in the format prescribed by the scientific journal
to which they have been or will be submitted for publication. Section III contains
appendices that include the list of publications, methodological details and
supplementary material useful for clearer understanding of the results described in the
preceding manuscripts. One of the appendices presents a brief chronological list of
some key milestones in the history of food and drug regulation in the United States to
assist the reader in developing a historical perspective. An overall summary of
conclusions and bibliography for the entire dissertation follows this section.
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SECTION I

INTRODUCTION
In recent years, self-medication products have undergone a dramatic change due
to the advent of herbal medicines, dietary supplements, nutraceuticals and health foods
in addition to traditional nonprescription medicines and the increasing societal
preferences towards greater individual control over the use of medicines (1,2).
Conventional regulations seem inadequate to address the complex challenges and
regulatory needs of today's self-medication arena leading to a regulatory vacuum. Some
important discrepancies associated with the regulation of nonprescription medicines are:
(1) Globally, there exists no uniformity in the classification of nonprescription
medicines. For example, over-the-counter (OTC), pharmacy medicine (P) and quasidrugs (QD) are variations of nonprescription drug products available within the
developed world.
(2) Scientific methodologies to assess the risks and benefit to individuals/general
public health associated with use of OTC drug products (in terms of pharmacological
profile of active moieties, their dosage or disease conditions) are unclear. There exist
inadequacies to facilitate an efficient Rx-to-OTC switch driven by science-based, datadriven decision making processes.
(3) The role of the US Food and Drug Administration (FDA) in the Rx-to-OTC
switch process in the absence of support from a sponsor is unclear.
Globally, the role and importance of nonprescription medicines in healthcare
delivery is rapidly increasing due to the shift in societal attitudes towards selfmedication and the associated cost-savings (3). In 1999, global sales of nonprescription
medicines grew by 4.7% to US $49.2 billion following the trend in recent years (4). The
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growing global interest in self-medication and related economic benefits emphasize the
importance of and necessity for a regulatory framework developed on the basis of sound
scientific principles. Hence, this area is beginning to receive much attention from
regulatory authorities, academia and professional/industry/trade organizations.
Also, the US FDA recently initiated a comprehensive review of the Agency's
approach to regulating over-the-counter (OTC) drug products, that is ongoing and
conducted a public hearing on this subject in June, 2000 (5). The purpose of the hearing
was to solicit information from interested persons including scientists, professional
groups and consumers. FDA's intention is to elicit comments on general issues
regarding the status of OTC drug products, including the criteria the Agency should
consider in rendering decisions on OTC availability of drugs, the classes of products, if
any, that are not currently available OTC that should or should not be available OTC,
how FDA can be assured that consumers understand the issues relating to OTC
availability of drug products, how rational treatment decisions are affected by
coexisting prescription and OTC therapies for a given disease, whether the current
structure for marketing OTC products in the United States is adequate, and FDA's role
in switching products from prescription to OTC status.
As per the Food and Drug Administration Modernization Act of 1997
(FDAMA), the US FDA held a series of public meetings in the summer of 1999 to
obtain stakeholder views on how FDA can best meet its statutory obligations (6). In
response, the Consumer Healthcare Products Association (CHP A) representing
producers of nonprescription medicines and dietary supplements provided comments
emphasizing the need for science-based regulatory framework for OTC medicines and
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especially for the OTC switch process (7). These recent developments clearly justify the
need for a detailed investigation of the regulatory aspects of OTC medicines with an
emphasis on the Rx-to-OTC switch process.
This investigation addresses issues central to the regulatory aspects of OTC
products. Considering the rapidly increasing global interest in responsible selfmedication and the recent call for proposals from all interested parties by the US FDA
on this topic, the timing of this study is very appropriate.
This investigation was conducted in three phases. Phase-1 involved the
completion of: (a) a critical review of existing literature related to this investigation, and
(b) information retrieval. During information retrieval, data describing the regulatory
aspects of nonprescription medicines from various sources (including governmental
regulatory authorities, trade/industry organizations, pharmaceutical companies and
academia) were collected. Special emphasis was placed on collecting data related to the
regulatory environments in United States, Canada, United Kingdom, The European
Union, Japan and Australia. The completion of a critical, comparative evaluation of the
regulatory frameworks across these countries marked the culmination of Phase-1.
During Phase-2, case history analyses of drugs to represent a broad variety of Rx-toOTC switches of contemporary interest within the US FDA context were examined. A
secondary goal was to use these switch case studies to illustrate and analyze the
application of Rx-to-OTC switch regulatory policy by the US FDA in the recent past.
An appropriate number of drugs that were selected and studied are: (a) successful Rx-

to-OTC switch (nicotine) (b) unsuccessful Rx-to-OTC switch (lovastatin) (c) initially
approved Rx-to-OTC switch that was later reverted to Rx status (metaproterenol), and
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(d) switch proposal initiated by a party other than the sponsor (non-sedating
antihistamines). In Phase-3, the attitudes/opinions of the academic/professional
community with expertise in nonprescription medicines across the US, Canada, UK and
Australia on important questions posed by the US FDA were measured using an
internet-based electronic survey questionnaire instrument. The responses of the survey
participants were analyzed using appropriate statistical techniques. Also, the opinions of
a small group of key opinion leaders across the previously mentioned four countries
selected to represent the diverse viewpoints of stakeholders in this area were studied
using telephone interviews. Overall, conclusions and inferences based on the
comparative literature review, investigation of OTC switch case histories, analysis of
survey questionnaire and telephone interview responses have been summarized to
provide data-based, rational answers to questions posed by the US FDA.
References
1. E.E. Bachrach, Drug Inf.,

11. 805-810 (1999).

2. R.W. Soller, Clin. Ther., 20, C134-C140 (1998).
3. K.K. Knapp, The OTC Movement, Internet address,
http://www.medscape.com/medscape/CN0/2000/APHNAPHA-1 O.html
4. Marketletter, NewsEdge Corporation, Burlington, MA, May, 2000.
5. Federal Register, 65(81), 24704-24706 (2000).
6. A Message to FDA Stakeholders: FDA's Progress in Implementing FDAMA,
Internet address, http://www.fda. govI oc/fdam a/comm/message99 .html
7. Response of CHP A, Internet address,
http://www.fda.govI ohrms/dockets/dockets/99n03 86/c000009 .doc
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OBJECTIVES
The salient objectives of this study are listed below:
1. Perform an examination of the current global regulatory environment of
nonprescription medicines. To conduct a detailed review and comparative
evaluation of the US OTC regulations with those in other comparable developed
nations (Australia, United Kingdom, European Union, Canada and Japan) by
focusing on: (a) classification of medicines (for human use) and the underlying
scientific rationale, and (b) regulatory policies affecting prescription to
nonprescription reclassification (Rx-to-OTC switch) of medicines.
2. To study the application of US FDA OTC switch regulatory policy in the recent
past to obtain learning and make inferences that may be applied to answer
questions of current interest, using the following case history evaluations as
illustrative examples:
a. Nicotine: a habit-forming drug that was successfully switched to OTC
status.
b. Metaproterenol: a bronchodilator that was switched to OTC status by the
FDA upon its own initiative and was later reverted back to prescription
status.
c. Lovastatin: a cholesterol-lowering drug for which OTC status was
requested and was not granted by the US FDA.
d. Second generation nonsedating antihistamines: loratadine, fexofenidine
and cetirizine, three nonsedating antihistamines for which OTC status
was requested by an independent party over the objections of the
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manufacturers that are currently being considered for OTC status by the
US FDA.
3. To measure the attitudes and opinions of experts in the area of nonprescription
medicines in the US , UK, Canada and Australia on regulatory aspects of OTC
medicines on which the US FDA has requested information through the
administration of an internet based electronic survey questionnaire instrument
and telephone interviews.
4. To use the observations, learning and results of the above examinations in the
development of rational, data-based recommendations related to important
regulatory questions on OTC medicines in the US FDA context.
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SECTION II

8

MANUSCRIPT I
EXAMINATION OF REGULATORY ASPECTS OF NONPRESCRIPTION
MEDICINES IN THE UNITED STATES
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Abstract
Growing patient involvement in diagnosis and treatment coupled with easy
information access has increased interest in self-care and use of nonprescription
medicines globally. The mounting interest in self-medication and potential economic
benefits highlight the importance of and necessity for a regulatory framework
developed on sound scientific principles. Hence, this area is receiving attention from
regulatory authorities, academia and industry. The US Food and Drug Administration
(FDA) recently announced a public hearing to evaluate its approach to regulating overthe-counter (OTC) drug products. The main objectives of this study are to review and
compare: (a) classification of medicines, and (b) regulatory policies affecting
prescription to nonprescription reclassification (Rx-to-OTC switch) of medicines,
among major developed nations along with the World Health Organization (WHO)
perspective. This paper presents an analysis of the regulatory environment in the United
States.
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Introduction
Growing patient involvement in the diagnosis and treatment of common
ailments coupled with easy access to reliable information is leading to increasing
interest in

self-care

and

the

use

of nonprescription medicines

worldwide.

Nonprescription medicines now account for about 60% of all medications used in the
United States and may be used to treat or cure about 400 ailments (1). In 1999, global
sales of nonprescription medicines grew by 4.7% to US $49.2 billion in line with the
trend in recent years (2). The role and importance of nonprescription medicines in
healthcare delivery all over the world is rapidly increasing due to the shift in attitude
towards self-medication and the potential cost-savings (3). In recent years, the
landscape of self-medication products has undergone a dramatic change due to the rapid
advent of herbal medicines, dietary supplements, nutraceuticals and health foods in
addition to traditional "pharmaceutical" nonprescription medicines (4). Conventional
regulations were not designed to address the complex challenges and regulatory
requirements of today's self-medication arena precipitating the need for concomitant
evolution in regulatory policies.
The growing global interest in self-medication and related economic benefits
accentuate the importance of and necessity for a regulatory framework developed on the
basis of sound scientific principles. Hence, this area is beginning to receive much
attention from global regulatory authorities, academia and related industry/professional
organizations. The US Food and Drug Administration (FDA) recently announced a
public hearing to evaluate the Agency's approach to regulating over-the-counter (OTC)
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drug products (5). The purpose of the hearing is to solicit information from interested
persons including scientists, professional groups and consumers.
Consequently, an examination of the current global regulatory environment of
nonprescription medicines has been undertaken to review and compare the US OTC
regulations with those in other comparable developed nations. The central focus of this
exegesis is on: (a) classification of medicines (for human use) and the underlying
scientific rationale, and (b) regulatory policies affecting prescription to nonprescription
reclassification (Rx-to-OTC switch) of medicines, in the United States.
State of nonprescription medicines
The usual perception of nonprescription medicines as pharmaceutical medicines
available without a prescription has undergone a dramatic change due to the rapid
advent of complementary and alternative medicines (CAM). This shift in societal
preferences has increased the scope of nonprescription medicines to include dietary
supplements, herbal medicines, folk remedies and other traditional ethnic medicines (6).
Eisenberg et.al. studied the trends in CAM use in the US between 1990 and 1997 (7).
Their results show that CAM use and expenditures substantially increased between
1990 and 1997 attributable primarily to an increase in the proportion of population
seeking alternative therapies and the pertinent data is summarized in table 1.
The significance of nonprescription medicines in public health care is also
reaching unprecedented levels. In the US, approximately 60% of all medicine dosage
units consumed are nonprescription medicines. Of approximately 3.5 billion health
problems treated annually in the US, some 2 billion (57%) are treated with a
nonprescription medicine. About a third (33%) of all nonprescription medicines are
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consumed by the rapidly growing demographic group of older Americans. The benefitcost ratio of responsibly used nonprescription medicines is very favorable.
Nonprescription medicines account for less than three cents of every dollar spent on
healthcare in the US, yet the benefit derived is vast (8). These observations are in
agreement with global trends in support of self-medication. In the United Kingdom,
evidence indicates that growing numbers of general practitioners and consumers are in
favor of increased responsible self-medication. Positive support by physicians for selfmedication is growing and research shows that more than half the general practitioners
expect to increase their recommendations of nonprescription medicines in the next year
(9). It is reasonable to conclude that due to the onset of the information age, change in
consumer preferences and the availability of new nonprescription medicines that were
previously unavailable, the significance of nonprescription medicines in overall health
care is bound to increase in the future.
Regulation of nonprescription medicines in the US
In the United States, the original Food and Drugs Act was passed m 1906
prohibiting interstate commerce in misbranded and adulterated foods, drinks and drugs
(10,11). This law only ensured purity and did not address the important issue of
truthfulness of health claims among other inadequacies. Following the Sulfanilamide
tragedy, The Federal Food, Drug and Cosmetic Act (FD&C Act) was passed in 1938 as
the foundation of present day drug laws (12). This law contained many new provisions
such as, requiring new drugs to be shown safe before marketing (starting a new system
of drug regulation), eliminating the earlier requirement to prove intent to defraud in
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drug misbranding cases, requiring human drugs to bear label warnings against habit
formation and requiring FDA to enforce the law.
Arguably, the most important amendment to the FD&C Act in this context is the
Durham-Humphrey Amendment of 1951. This amendment clarified the dispensing
obligations of the pharmacist by defining the kinds of drugs that cannot be safely used
without medical supervision and restricting their sale to prescription by a licensed
practitioner (13). This amendment also serves as the foundational basis for the current
classification system of drug products in the United States into, prescription medicine
and nonprescription medicine (or OTC). Section 503(b)(l) of FD&C Act states:
"A drug intended for use by man which (A) because of its toxicity or other potentiality for harmful effect, or the method
of its use, or the collateral measures necessary to its use, is not safe for use
except under the supervision of a practitioner licensed by law to administer such
drug; or
(BJ is limited by an approved application under section 505 to use under the
professional supervision of a practitioner licensed by law to administer such
drug; shall be dispensed only
(i)

upon a written prescription of a practitioner licensed by law to
administer such drug, or

(ii)

upon an oral prescription ofsuch practitioner which is reduced promptly
to writing and filed by the pharmacist, or

(iii)

by refilling any such written or oral prescription if such refilling is
authorized by the prescriber either in the original prescription or by oral
order which is reduced promptly to writing and filed by the pharmacist.

The act of dispensing a drug contrary to the provisions of this paragraph shall be
deemed to be an act which results in the drug being misbranded while held for sale. "

Hence, the need for medical supervision and prescription requirement for a drug
product may arise due to: (a) the drug characteristics or the method of use necessary for
its safe use, or, (b) the new drug application (Section 505 of FD&C Act) under which it
received approval. An implication of section 503(b)(1) that needs emphasis is that, only
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drugs meeting above stated conditions reqmre the additional control of medical
supervision and prescription requirement, otherwise they may be sold without a
prescription. Alternately stated, drug products are inherently presumed to be
nonprescription unless otherwise required, as per FD&C Act. This assertion may be
tersely stated as, "if it can be OTC, it must be OTC" to illustrate the inherent bias for
"nonprescriptionness" arising from the law and is critical in the comprehension of this
classification system (4).
Another important legislative development in this context is the Kefauver-Harris
Drug Amendments of 1962, enacted as a result of the Thalidomide disaster (14). As per
these amendments, manufacturers were required to prove the safety and efficacy of any
new drug before its marketing, and FDA approval of the new drug application (NDA)
became a necessary prerequisite to marketing. These amendments required an
unprecedented program of accountability from the manufacturers. To fulfill its
obligations under these amendments, the FDA contracted with the National Academy of
Sciences/National Research Council to evaluate the effectiveness of 4000 drugs
approved only on the basis of safety between 1938 and 1962, under the so called Drug
Efficacy Study Implementation or DESI Review in 1966 (11).
Further the FDA in 1972, initiated rulemaking procedures to determine which
nonprescription medicines (The OTC Drug Review) can be generally recognized among
qualified experts as safe and effective and not misbranded under prescribed,
recommended, or suggested conditions of use (5). Through the OTC Drug review
process, FDA established monographs for classes of nonprescription medicines (such as
antacids etc.) that were generally recognized as safe and effective and not misbranded

15

when the products contained the ingredients and are labeled as per the monograph. OTC
drug monographs describe the active ingredients, amount of drug, formulation, labeling
and other general requirements for drugs to be lawfully sold OTC. In all 722 active
ingredients for different uses were reviewed by 17 expert advisory panels through the
public review and comment process of OTC Review. About a third of all the drugs
reviewed were found to be generally recognized as safe and effective for OTC use (15).
The OTC Drug Review marked the onset of the era of rational regulation of
nonprescription medicines on the basis of sound scientific evidence. It is generally
agreed that the OTC Review created: (a) a claims structure based on scientific evidence
and rational regulatory policy (b) a safety standard that is equal to or higher than that for
prescription medicines ( c) an increase in consumer confidence by ensuring
nonprescription medicines deliver the benefits advertised, and (d) an emphasis on
comprehensive labeling, with clearly defined policies for OTC warnings (4).
Considering the rapidly growmg segment of the nonprescription medicine
market that is comprised of CAM, it is important to also discuss the state of their
regulation in the US. Kottke has recently published an elaborate review of the scientific
basis and the regulatory state of nutraceutical products. It is suggested that readers
peruse that report and other references for a comprehensive study of this subject
(16,17,18,19). FDA's concern to regulate vitamins and dietary products in a manner
similar to drug regulation has been ongoing for many years. But, unfortunately such
attempts have only been unsuccessful, for instance, FDA withdrew proposed regulation
requiring minimum and maximum levels of dietary supplements in the face of severe
consumer protest in 1962 and federal courts disallowed FDA from regulating high
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dosage vitamins as drugs based on the toxic impacts of such products in late 1970s. An
immensely counteracting force restraining FDA's attempts from regulating dietary
supplements and vitamins based on scientific evidence has been the lack of
Congressional support due to intense advocacy by the dietary supplement industry.
Such lobbying and effective grass roots level campaigning led to the enactment of the
Dietary Supplement Health and Education Act (DSHEA) of 1994 causing dramatic
changes in the regulatory framework. Most importantly, DSHEA resulted in: (a) a clear,
but very broad, definition for a "dietary supplement" (b) changing the rules surrounding
the labeling of dietary supplements, and (c) shifting the burden of proof of product
safety from the manufacturer to the FDA.
As per DSHEA, a dietary supplement is a product (other than tobacco) that is
intended to supplement the diet that bears or contains one or more of the following
dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid, a
dietary substance for use by man to supplement the diet by increasing the total daily
intake, or a concentrate, metabolite, constituent, extract, or combinations of these
ingredients. Further, the term is defined to include products such as an approved new
drug, certified antibiotic, or licensed biologic that was marketed as a dietary supplement
or food before approval, certification, or license. This very broad definition has had the
unintended consequence of including even prescription medicines under the term
"dietary supplements" raising public health concerns (17,18). Cholestin® is a red yeast
rice product marketed as a dietary supplement, and is a natural source of lovastatin
which is the active drug in the prescription medicine Mevacor® used for lowering
cholesterol levels. Before DSHEA, FDA contended that "labeling" of dietary
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supplements included not only the actual product label, but also any other written,
printed or graphic matter accompanying the product. DSHEA explicitly exempted from
"labeling", any such accompanying written matter provided that such written matter is
truthful and not misleading, effectively preventing the FDA from regulating
supplements as drugs based on the claims made in accompanying material about cure,
mitigation, treatment or prevention of any disease. As a result of such promotional
literature being permissible, studies have found that significant proportions of public
believe, quite often wrongfully, the ability of supplements in being helpful with
illnesses (20).
The shifting of burden of proof of product safety from the manufacturer to the
FDA is in stark contrast to the conventional regulatory philosophy of FDA with drugs
(wherein a manufacturer has to demonstrate product safety and efficacy in a premarket
review) and has left FDA with the authority only for postmarket surveillance. This
observation is particularly important as per recent evidence showing an increasing
number of adverse event reports associated with the use of supplements (21 ). Further,
studies also show that frequently public fails to inform their physicians of the use of
supplements, leading to an increase in potential for adverse events (7,21). The issue of
claims for dietary supplements remains to be an extremely contentious one (22).
Clearly, the rigorousness of regulatory evaluation of alternative medicines and
supplements does not match the same for traditional prescription and nonprescription
medicines that are preapproved on the basis of elaborate scientific data and evidence to
prove product safety and efficacy. Further, the level of scientific advancement amongst
traditional pharmaceutical nonprescription medicines is much greater than that of
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supplements and alternative medicines. To strengthen the scientific foundation of
alternative medicines, DSHEA has mandated the creation of an office within the
National Institutes of Health (NIH) to explore the potential role of supplements to
improve health care in the U.S. The office will also need to: (a) promote scientific study
of supplements and their value in preventing chronic diseases (b) collect and compile
scientific research, including data from foreign sources and the NIH-Office of
Alternative Medicine (c) serve as a scientific adviser to Secretary of Health and Human
Services and FDA, and (d) compile a database of scientific research on supplements and
individual nutrients. These initiatives will, hopefully, help strengthen the scientific
foundation driving regulatory policy concerning nontraditional nonprescription
medicines. It is also hoped that as traditional pharmaceutical companies enter the arena
of developing supplement products for economic benefits, they will extend their
science-based and data driven product development philosophy to the supplements
industry.
Reclassification of medicinal products in the US
Reclassification is the process of removing the prescription requirement and
need for medical supervision for a marketed drug product (for human use) that was
previously available only through a legitimate prescription and making it available
over-the-counter. It is commonly referred to as "Rx-to-OTC switch" or simply "the
switch". One major factor responsible for the rapid growth of responsible selfmedication via use of nonprescription medicines is the recent reclassification of
previously prescription medicines to OTC status that have been very successful, both
medically and commercially. It may be helpful to divide this subject into, (a) regulatory
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mechanisms through which a marketed prescription drug product may be reclassified as
an OTC product, and (b) scientific evidence or data required in support of the petition
requesting such a reclassification.
An excellent review of the Rx-to-OTC switch process, related procedures and

the underlying statutory scheme has been presented by Wion (23). There are essentially
four regulatory mechanisms through which reclassification may be achieved. They are:
•

filing of an NDA (NDA approach)

•

filing of a supplement to an approved NDA (sNDA approach)

•

as per section 503(b)(3) ofFD&C Act (switch regulation approach), and

•

the OTC Drug Review (monograph approach).

In the NDA approach, either a traditional NDA (per section 505(b)(l) of FD&C
Act) or a "paper" NDA (per section 505(b)(2) of FD&C Act) may be filed. The NDA
route is suitable in the event where the proposed OTC product is of a lesser strength or
for a different indication than its prescription counterpart, in which event efficacy and
safety need to be established. The switch of Ibuprofen at the 200 mg dose to OTC status
utilized the NDA approach for reclassification. Under the sNDA approach, a
supplement to the original NDA under which the drug product was approved may be
filed demonstrating the suitability of the product for OTC use to request reclassification.
Benylin® cough syrup containing diphenhydramine hydrochloride was switched to OTC
status using the sNDA approach. It must be noted that upon successful reclassification
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via the NDA approach or sNDA approach, the drug product in the OTC status is
considered to be a new drug.
The Durham-Humphrey amendments to the FD&C Act were enacted to state clearly
the criteria useful in limiting drug products to sale by prescription only. These
amendments eliminated the confusion prevalent before their enactment and are
contained in section 503 ofFD&C Act. Section 503(b)(3) of FD&C Act states:
"The Secretary may by regulation remove drugs subject to sections 502(d) and 505
from the requirements ofparagraph (1) of this subsection when such requirements are
not necessary for the protection of the public health. "

This statement authorizes the Secretary of Department of Health and Human
Services to remove the prescription requirement and need for medical supervision
arising from NDA approval for prescription use (section 505) or for habit-forming drugs
(section 502(d)) or the drug characteristics or method of its use necessary for its safe
use (section 503(b)(l)) when the determination is made that such requirements are not
needed to protect public health. Using this authority, FDA in 1956 issued the so-called
"switch regulation" that is now codified in 21 CFR 310.200. Subsection (b) of 21 CFR
310.200 states:
"Prescription-exemption procedure.
(b) Prescription-exemption procedure for drugs limited by a new drug
application. Any drug limited to prescription use under section 503(b)(J)(C) of the act
shall be exempted from prescription-dispensing requirements when the Commissioner
finds such requirements are not necessary for the protection of the public health by
reason of the drug's toxicity or other potentiality for harmful effect, or the method of its
use, or the collateral measures necessary to its use, and he finds that the drug is safe
and effective for use in self-medication as directed in proposed labeling. A proposal to
exempt a drug from the prescription-dispensing requirements of section 503(b)(l)(C) of
the act may be initiated by the Commissioner or by any interested person. Any
interested person may file a petition seeking such exemption, which petition may be
pursuant to part 10 of this chapter, or in the form of a supplement to an approved new
drug application. "
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Hence, using the switch regulation the FDA or any interested person may initiate the
reclassification process and drugs so switched to OTC status also are considered to be
new drugs (see 21 CFR 310.200(c)). Prior to 1971, the FDA switched 25 ingredients to
OTC status using the switch regulation (listed in 21 CFR 310.201). The NDA or sNDA
approaches to reclassification are useful if there exist only a few manufacturers of the
drug product whereas broad rulemaking and promulgating a switch regulation is
preferred if the product has a large number of manufacturers. Subsection (e) of 21 CFR
310.200 states:
"Prescription-exemption procedure.
(e) Prescription-exemption procedure of OTC drug review. A drug limited to
prescription use under section 503(b)(l)(C) of the act may also be exempted from
prescription-dispensing requirements by the procedure set forth in Sec. 330.13 of this
chapter."
21 CFR 330.13 describes the conditions for marketing ingredients

recommended for over-the-counter (OTC) use under the OTC Drug Review
(monograph approach). As discussed earlier, this is the mechanism that FDA used in
1972 to initiate the OTC Drug review through the use of Expert Advisory Panels for the
establishment of OTC monographs for classes of drugs (such as antacids). Concurrent
to the OTC review, the FDA also invited views from interested persons on prescription
drugs that may be suitable for OTC use, initiating the deliberation process for potential
switches. The administrative procedures for classifying OTC drugs as generally
recognized as safe and effective and not misbranded, and for establishing monographs
are described in 21 CFR 330.10. The monograph rulemaking process was essentially a
three-step process, where: (a) FDA Commissioner appointed advisory review panels for
each designated area of OTC drugs and all areas of OTC drugs were considered. Also,
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requests for data and views on OTC drugs were made. (b) The review panels upon
completion of their evaluation submitted to the FDA Commissioner their report of
recommendations covering all areas of OTC drugs reviewed. They classified all the
reviewed OTC drugs into the following three categories, (i) Category I, where category
of drugs were found to be suitable for OTC use and a recommended monograph was
established (ii) Category II, a statement of all active ingredients, labeling claims or
other statements, or other conditions reviewed and excluded from the monograph on the
basis of the panel's determination that they would result in the drug's not being
generally recognized as safe and effective or would result in misbranding, and (iii)
Category III, a statement of all active ingredients, labeling claims or other statements, or
other conditions reviewed and excluded from the monograph on the basis of the panel's
determination that the available data are insufficient to classify such condition and for
which further testing is therefore required. (c) The FDA then used the panel's
recommendations to publish initially, tentative final monographs for public evaluation
that were later published as final monographs upon consideration of public views.
The drugs switched to OTC status via the monograph approach, in contrast to
the other approaches, are not considered as new drugs. A summary of the regulatory
mechanisms that may be employed to facilitate reclassification of an approved
prescription human drug to OTC status in the US has been presented in figure 1. In
recent times, the NDA approach has been the most frequently used mechanism for
obtaining approval for an Rx-to-OTC switch. MAPP 6020.5 in the Manual of Policies
and Procedures of Center for Drug Evaluation and Research establishes the Office of
Review Management (ORM) procedures for assessing investigational new drugs (IND)
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and marketing applications for OTC drugs to be marketed under the authority of an
approved NDA, either initially or as Rx-to-OTC switch (24). These procedures describe
how the ORM interacts with the sponsors who intend to market OTC drug products
(initially or as a switch) during the IND/NDA review, and the relevant post approval
oversight necessary.
The FDA has not published any formal guidance describing the data
requirements (scientific evidence) it deems as necessary for a switch petition to receive
approval. The FDA has, instead, taken the position that switch petitions will be
reviewed on a case-by-case basis, based on the weight of scientific evidence presented
to demonstrate general suitability for OTC use. Hence, there does not exist any
universally applicable guidance useful in the preparation of a switch petition. However,
helpful insights into the general requirements and standards for safety, effectiveness and
labeling in the OTC context may be gained by studying the procedures for classifying
OTC drugs as generally recognized as safe and effective and not misbranded, and for
establishing monographs described in 21 CFR 330.10. These procedures were codified
in 21 CFR 330.10(a)(4) as instructions to the advisory review panels as:
"(4) Standards for safety, effectiveness, and labeling. The advisory review
panel, in reviewing the data submitted to it and preparing its conclusions and
recommendations, and the Commissioner, in reviewing the conclusions and
recommendations of the panel and the published proposed, tentative, and the final
monographs, shall apply the following standards to determine general recognition that
a category of OTC drugs is safe and effective and not misbranded:
(i)Safety means a low incidence of adverse reactions or significant side effects under
adequate directions for use and warnings against unsafe use as well as low potential for
harm which may result from abuse under conditions of widespread availability. Proof
of safety shall consist of adequate tests by methods reasonably applicable to show the
drug is safe under the prescribed, recommended, or suggested conditions of use. This
proof shall include results of significant human experience during marketing. General
recognition of safety shall ordinarily be based upon published studies which may be
corroborated by unpublished studies and other data.
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(ii)Effectiveness means a reasonable expectation that, in a significant proportion of the
target population, the pharmacological effect of the drug, when used under adequate
directions for use and warnings against unsafe use, will provide clinically significant
relief of the type claimed. Proof of effectiveness shall consist of controlled clinical
investigations as defined in Sec. 314.126(b) of this chapter, unless this requirement is
waived on the basis of a showing that it is not reasonably applicable to the drug or
essential to the validity of the investigation and that an alternative method of
investigation is adequate to substantiate effectiveness. Investigations may be
corroborated by partially controlled or uncontrolled studies, documented clinical
studies by qualified experts, and reports of significant human experience during
marketing. Isolated case reports, random experience, and reports lacking the details
which permit scientific evaluation will not be considered. General recognition of
effectiveness shall ordinarily be based upon published studies which may be
corroborated by unpublished studies and other data.
(iii)The benefit-to-risk ratio of a drug shall be considered in determining safety and
effectiveness.
(iv)An OTC drug may combine two or more safe and effective active ingredients and
may be generally recognized as safe and effective when each active ingredient makes a
contribution to the claimed effect(s); when combining of the active ingredients does not
decrease the safety or effectiveness of any of the individual active ingredients; and
when the combination, when used under adequate directions for use and warnings
against unsafe use, provides rational concurrent therapy for a significant proportion of
the target population.
(v)Labeling shall be clear and truthful in all respects and may not be false or
misleading in any particular. It shall state the intended uses and results of the product;
adequate directions for proper use; and warnings against unsafe use, side effects, and
adverse reactions in such terms as to render them likely to be read and understood by
the ordinary individual, including individuals of low comprehension, under customary
conditions ofpurchase and use.
(vi)A drug shall be permitted for OTC sale and use by the laity unless, because of its
toxicity or other potential for harmful effect or because of the method or collateral
measures necessary to its use, it may safely be sold and used only under the supervision
of a practitioner licensed by law to administer such drugs."
Further, elaboration of specific criteria used by the FDA to determine the

adequacy of scientific evidence (with regards to safety, effectiveness and labeling)
required for reclassification may be found in the presentation of the Director of Office
of Drug Standards at the US FDA, who elucidated the above statements as per his
comprehension during a workshop on reclassification (25). Also, the Senior Vice
President of Consumer Health Products Association (CHP A, the trade association
representing the manufacturers and distributors of nonprescription medicines and dietary
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supplements with members representing over 90 percent of retail sales in the US OTC
marketplace) recently authored an excellent article describing, as per his view, the
specific scientific data requirements applicable in the determination of "OTCness" of a
drug being considered for reclassification (26). The scientific evidence deemed
necessary for successful reclassification as per these two articles have been summarized
in table 2.
Contemporary topics of interest and importance
In describing the scope of the public hearing earlier this year, FDA solicited
comments on general issues regarding OTC drug products such as: (a) criteria used to
decide on the availability of OTC drug products (b) classes of products that should or
should not be available OTC (c) consumer understanding of OTC issues (d) selection of
treatment (e) current US OTC marketing system, and (f) FDA's role in switching
products from prescription to OTC status. The specific issues under each of these
general categories upon which the FDA requested views have been listed in table 3. The
list of issues presented by the FDA is not complete and other important topics also need
to be addressed.
The scope of this public hearing as published by the FDA focuses on
regulation of OTC drug products treating pharmaceutical nonprescription medicines in
an isolated manner. As stated, the notion of OTC drug products being construed only as
traditional pharmaceutical medicines is changing fast. It is perhaps beneficial to review
and examine the regulatory aspects of OTC drug products considering them as a portion
of the present day self-medication armamentarium that includes dietary supplements
and other traditional medicines. In this regard, initiatives to market at least some of the
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nontraditional medicines as regular OTC drug products by subjecting them to the same
rigorous scientific evaluation and review criteria should be promoted upon careful
consideration. Otherwise, FDA's general product approval philosophy based only on
sound scientific evidence will continue to be compromised.
Another important factor, the influence of which upon availability of new
OTC drug products and reclassification needs to be clarified, is the direct-to-consumer
marketing of prescription drug products. Some questions that need to be addressed are:
Are any of such drug products suitable candidates for reclassification?; If, only a
physician may write a prescription upon diagnosis, why are such promotional activities
aimed at consumers creating a "quasi self-medication" possibility?; In the process of a
consumer initiated enquiry resulting in a responsible medication choice upon
consultation with a physician, can the physician be replaced by the pharmacist, at least
in some cases? The Jack of dedicated initiatives aiming at global harmonization of
reclassification policy is a cause for concern as globalization is a rising trend among the
industry. Subsequently, some key issues that need to be addressed are: Why is there
variation in the dosage strength of certain medicines approved for OTC use between
nations? Why are certain medicines OTC in some nations, whereas they are prescription
only in others? Is it possible to develop and establish globally acceptable monographs
for OTC drug products, at least within the developed world? Lastly, the application of
information technology to promote and achieve responsible self-medication through
enhanced and effective consumer education needs to be explored. The authors intend to
address some of the above issues in this, and subsequent articles.
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One noteworthy issue concerns the clarity of FD A's role in the reclassification
process. In particular, FDA asks: Under what circumstances should FDA actively
propose OTC marketing for a drug in the absence of support from a sponsor?, and,
Should FDA be more active initiating switches of prescription products for OTC use?

Before addressing these questions, FDA's legal authority to initiate a switch proposal
under the current framework needs to be examined. Of the four regulatory mechanisms
discussed through which reclassification may be achieved, FDA has unambiguous
authority to initiate a switch proposal via the switch regulation as per 21 CFR 310.200
(b) and section 503(b )(3) of FD&C Act. As for the NDA or sNDA approaches, section
505 of FD&C Act describes the details of the new drug application and related
processes. More specifically, subsection 505(b)(l) while explaining the details of the
NDA filing process states:
"(b)(l) Any person may file with the Secretary an application with respect to
any drug subject to the provisions of subsection (a). Such person shall submit to the
Secretary as a part of the application (A) full reports of investigations which have been
made to show whether or not such drug is safe for use and whether such drug is
,ffiect"ive m. use; ... .. . "
e11

It is important to focus on the term "person" to understand who qualifies for filing an

NDA. Subsection 20l(b)(e) of the FD&C Act in defining this term states:
"The term ''person" includes individual, partnership, corporation, and
association".

It does not appear that FDA fits into the definition of "person" as per FD&C Act, as

FDA is not an individual, partnership, corporation or an association. Under this premise,
it seems reasonable to conclude that the Act did not envision FDA itself filing an NDA,
hence disallowing FDA to do so. Consequently, FDA does not qualify to file an NDA
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or an sNDA seeking reclassification. Finally, under the OTC Drug Review procedures
stated in 21 CFR 330.10 there do not exist any statements suggesting unambiguously
the authority of FDA to initiate a switch process. 21 CFR 330.1 O(a)(2) states:
"Request for data and views. The Commissioner will publish a notice in the
Federal Register requesting interested persons to submit, for review and evaluation by
an advisory review panel, published and unpublished data and information pertinent to
a designated category of OTC drugs ... ... "

Again, use of the "interested persons" terminology perhaps disqualifies FDA
from submitting switch proposals via the monograph system and delegates to FDA the
role of a facilitator rather than a participant. From this discussion, it may be inferred
that FDA has legal authority to promulgate regulation for reclassification to OTC status
of prescription medicines only via the switch regulation mechanism under the current
legislative framework. At this juncture, it is appropriate to consider the issue of whether
FDA should exercise its authority to switch products only in collaboration with the
sponsor. In the interest of public health and fairness to industry, the FDA should
undertake any initiatives to switch products only in collaboration with the sponsor based
on their active support. This approach is most desirable and offers the benefit of FDA
being able to utilize the sponsor's vast knowledge database related to the development
and marketing of the product.
The undesirable action of FDA switching a product despite the sponsor's
objection to do so should be carried out only under very limited and unusual
circumstances. Such a situation may be enormous and overwhelming public support for
OTC availability of a certain product, assuming it meets all the safety, effectiveness and
labeling standards required of OTC products. The inherent difficulty in such an
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approach would be that the burden of proving suitability for OTC use would lie on FDA
and such a task may be formidable in the absence of support from the sponsor. Further,
it is very difficult to envision FDA being able to prove suitability for OTC use without
access to data from the original NDA (which is the sponsor's intellectual property).
Further, FDA should also present a cogent argument demonstrating the need for such
radical regulatory action and subsequent benefit to overall public health. This should be
done in an open and transparent process that includes all interested persons prior to such
a decision taking effect.
Conclusion
The role and significance of nonprescription medicines in overall health care
delivery worldwide is mounting rapidly due to changing social preferences and
associated economic benefits. The US FDA has initiated the desirable program of
announcing a public hearing to evaluate its approach to regulating OTC products. In this
regard, the authors have undertaken a comparative evaluation of regulatory aspects of
nonprescription medicines within major developed nations. An examination of the
regulatory environment of nonprescription medicines in the United States shows that
there exists a wide gap in the scientific basis supporting the regulatory principles for
traditional pharmaceutical nonprescription medicines and alternative medicines or
herbal remedies. There exist many challenging issues related to the reclassification of
products to OTC status in the United States. The authors believe that FDA should
invoke its authority to switch products to OTC status in collaboration with the sponsor
using their support and expertise.
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Table 1: Trends in Alternative Medicine Use in the United States, 1990-1997 (data
summarized from reference 7)

Measured Outcome

1990

1997

Use of at least one form
of alternative therapy in
the_E!evious year
Probability of users
visiting an alternative
medicine Factitioner
Total visits to an
alternative medicine
practitioner (extrapolated
to US _Qq£_ulationl
Concurrent use of
prescription medications
with herbal remedies
and/or h!_g_h dose vitamins
Estimated expenditures
for alternative medicine
FOfessional services

33.8% of population
surveyed

42.1 % of
population
surv~ed

36.3%

46.3%

427 million

629 million--.

Not available

15 million adults
(18.4% of all
prescription

Not available

US $ 21.2 billion

user~

* This estimate exceeds the total visits to all the US primary care physicians
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Table 2: Description of scientific evidence necessary for justifying reclassification of an
approved prescription drug product to the OTC status in the United States
EJkcliveness

Sefety
I. Toxicity and potential for hannful effect
Clinical phannacology data (LD50, subacute
and chronic toxicity)
• Phannacokinetics (absorption, excretion,
accumulation, metabolism, protein binding)
• Potential drug interactions
• Carcinogenicity/teratogenicity/mutagenicity( esp
ecially in chronic use situations)
• Complete analysis of adverse event data from
postmarl<eting experience, controlled clinical
trials, voluntary reports during marl<eting and
experience with overdoses not only in the
United States but also from foreign sources such
as Medicines Control Agency of U.K.
• Assessment of safety in special populations
such as pediatrics, geriatrics and pregnant
women

I.

The proposed OTC use should
be substantially similar to the
approved prescription use.

2.

Controlled Clinical
investigations in the target
populations proving clinically
significant relief of the type
claimed in labeling.

•

2. Overall benefit/risk assessment
• Low incidence of overall adverse events or
substantial side effects under use with adequate
directions
• Possible reduced dosage (with demonstrated
effectiveness)
• Low potential for hann from abuse upon
widespread availability

labeli'!G__
I.

2.

3.
3.

If OTC use is at a lower dosage
than approved for prescription,
then efficacy needs to be
demonstrated at the new dosage.

4.

How broad of a patient
population was included in the
prescription clinical trial ?

5.

Corroboration of effectiveness
under partially controlled or
uncontrolled studies by qualified
experts and reports of significant
human experience during
marketing (so called "actual use
study" setting).

4.

3. Abuse/misuse potential
Can the conditions be self-treated without prior
diagnosis by a physician? (or)
• Can the conditions be self-treated after
diagnosis by a physician?

•

4. Are routine medical examination or laboratory
work needed for continued safe use of the drug?
•
Do these factors alone preclude the drug from
OTC availability?
5. Method of use and collateral measures necessary to
use
• Can the condition being treated be selfdiagnosed? if not,
Are the symptoms to be treated selfrecognizable?
• Can the condition be self-treated?

•

5.
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Intended uses
and results of
the product and
ability to
control that
labeling .
Adequate
directions for
proper use .
Adequate
warning against
use in those
pathological
conditions, or
by chi ldren, or
against unsafe
dosage or
methods or
duration of
administration
or application.
Warnings
against unsafe
use, side
effects, and
adverse
reactions
should be stated
to facilitate
accurate
communication
to individuals
oflow
comprehension
under
conditions of
customary
purchase and
use. These
warnings must
be scientifically
documented,
clinically
significant and
important to the
safe and
effective use of
the product by
the consumer.
include general
OTC
pregnancy/nursi
ng warnings
unless drug is
exempt and
limitations on
how long the
OTC drug
product should
be used before
seeking medical
attention.

Figure 1: Summary of regulatory mechanisms through which an approved prescription
drug product may be reclassified as an OTC drug product. As all prescription drugs are
considered to be new drugs, box 2 does not contain any products

Rx (prescription)

OTC
J!!,on_!!!escrPJion)_

Box 1

Box3

New drug

Box 1 to Box 3
(through NDA, sNDA
or the switch
re~ation ~oachetl

Not a new drug
Box2
(Empty)

Box4
Box 1 to Box 4
(through the OTC
Dru_g_ Review Procestl
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Table 3: Specific issues upon which FDA intends to solicit comments
through the Over-the-counter Drug Products Public Hearing

•

•

•

•

What
criteria
should
FDA
consider in
rendering
decisions
on OTC
availability
of drug
products?
What types
of drugs
are or are
not
appropriate
for OTC
distribution
?
What types
of diseases
are or are
not suitable
for
treatment
with
products
marketed
OTC (e.g.,
chronic
illnesses;
diseases
that require
initial
diagnosis
by a
physician;
diseases
that if left
untreated,
or are
inadequate!
y treated,
can lead to
serious
morbidity
or
mortality)?
How
should the
risks and
benefits to

Consumer
Understanding

Classes ofProducts

Criteria

•

•

Are there
specific classes
of products that
are not currently
marketed OTC
that should be
available OTC?
Are there
specific classes
of products that
should not be
ava ilable OTC?
What specific
concerns do
these classes
raise? (Examples
of specific
classes that
might be
discussed in
brief include:
Diuretics,
antihypertensive
agents,
cholesterollowering drugs,
oral antidiabetic
agents,
treatments for
osteoporosis
(i ncluding its
prevention),
antimicrobial s,an
d oral
contraceptives.

•

•

•

•

How can
FDA be
assured of
consumer
understanding
of the benefits
and risks of
specific drug
products and
the abi li ty of
consumers to
use products
safely and
effectively
were the drug
products to be
marketed
OTC?
What
methodologie
scan be
employed to
demonstrate
consumer
understanding
?
How can
information
on efficacy be
adequately
conveyed to
consumers
through
labeling?
Can
prevention
claims
encourage illadvised
behavior, and
if so, how
could this
potential be
minimized?
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Selection of
Treatment

•

•

•

•

How can
rational
selection be
ensured
when there
are
coexisting
prescription
and OTC
therapies
for a given
disease?
In an
environ men
t with
coexisting
products,
what are
the most
effective
means to
ensure that
patients
know the
best ways
to treat
their
illnesses?
How
should the
availability
of OTC
options and
prescription
options for
the same
indication
be
reconciled?
How
should the
availability
ofa
" better"
OTC
product, in
terms of
efficacy or
safety,
affect the
status of
_Qroducts

OTC
Marketing
system and
FDA 's role in
switching_
• ls the
current
structure
for
marketing
OTC
products
in the
United
States
adequate?
• What
lessons
can we
learn from
different
OTC
marketing
systems?
• What can
be learned
from the
countries
and those
U.S. states
where
some
nonprescri
ption drug
products
are sold
OTC and
others are
sold
" behind
the
counter"?
• Under
what
circumsta
nces
should
FDA
actively
propose
OTC
marketing
for a drug
in the
absence of
support
from the

Table 3: Specific issues upon which FDA intends to solicit comments
through the Over-the-counter Drug Products Public Hearing
Criteria

Classes of Products

Consumer
Understanding

individuals
and risks
and
benefits to
the public
health be
assessed
and
weighed in
any
decision on
OTC
marketing?
For
example,
how should
the Agency
balance the
potential
benefits of
OTC
antimicrobi
al agents
with the
potential
risks to
society at
large of the
developme
nt of
resistant
organisms
associated
with
increased,
and
potentially
improper,
use?

Selection of
Treatm ent

•
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already on
the OTC
market for
treatment
of the same
condition?
Should
older
therapies
that may
provide
less benefit
or more
risk be
removed
from the
OTC
market, or
should the
labeling be
revised?
Suppose
the more
effective
drug is
more
difficult to
use and
must
remain
prescription
-might that
encourage
use of the
less
satisfactory
drug?

OTC
Marketing
system and
FDA 's role in
switch inf:
drug
sponsor?
• Should
FDA be
more
active in
initiating
switches
of
prescriptio
n products
to OTC
use?

MANUSCRIPT II
EXAMINATION OF GLOBAL REGULATORY ASPECTS OF
NONPRESCRIPTION MEDICINES
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Abstract
Globally, rising interest in self-medication and related economic benefits highlight the
importance of and necessity for a regulatory framework developed on sound scientific
principles for nonprescription medicines. This area is receiving attention from
regulatory authorities, academia and industry. The US Food and Drug Administration
(FDA) recently announced a public hearing to evaluate its approach to regulating overthe-counter (OTC) drug products. This study aims to review and compare: (a)
classification of medicines, and (b) regulatory policies affecting prescription to
nonprescription reclassification (Rx-to-OTC switch) of medicines, among major
developed nations along with the World Health Organization (WHO) perspective. This
paper presents an analysis of the contemporary regulatory environment in Australia,
Canada, European Union, United Kingdom and Japan with the WHO position. The
regulatory model in the United States has been evaluated with that in comparable
developed nations to draw pertinent inferences.
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Introduction
Growing global interest in self-medication and potential economic benefits draw
attention to the necessity for a regulatory framework developed on the basis of sound
scientific principles. Hence, this area is beginning to receive much attention from global
regulatory authorities, academia, industry and other stakeholders. The US Food and
Drug Administration (FDA) recently announced a public hearing to evaluate the
Agency's approach to regulating over-the-counter (OTC) drug products and solicit
information from interested persons including scientists professional groups, and
consumers (1). Specifically, two important questions that FDA asks are: (a) Is the
current structure for marketing OTC products in the United States adequate? (b) What
lessons can we learn from different OTC marketing systems?

Consequently, an examination of the current global regulatory environment of
nonprescription medicines has been undertaken to review and compare the US OTC
regulations with those in other comparable developed nations. The central focus of this
exegesis is on: (a) classification of medicines (for human use) and the underlying
scientific rationale, and (b) regulatory policies affecting prescription to nonprescription
reclassification (Rx-to-OTC switch) of medicines. An earlier article examined the
regulatory environment in the United States and this article presents the same in
Australia, Canada, European Union, United Kingdom and Japan along with the World
Health Organization (WHO) perspective (2). The overall object is to learn from various
global regulatory models and draw inferences that may be beneficial when applied in
the United States context.
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Classification of medicines
Australia
In Australia, the Therapeutic Goods Act of 1989 (TG Act) aims at providing a

national framework for the regulation of therapeutic goods to ensure their quality,
safety, efficacy and timely availability. The Therapeutic Goods Administration (TGA)
as part of the Commonwealth Department of Health and Aged Care has the
responsibility for administering the Act and ensuring that the necessary evaluation and
assessment procedures are conducted to enable access to the latest treatments available
that are safe, effective and of good quality. A general introduction to the regulatory
process for all medicines in Australia and other pertinent matters including the role of
TGA is presented in one of TGA publications (3).
The TGA uses a risk-management approach to regulating medicines that forms
the basis of the Australian classification system. Accordingly, risk is determined by a
number of factors such as: (a) the medicine containing a scheduled substance (discussed
later) (b) medicine's use can result in significant side-effects ( c) the medicine is used to
treat life-threatening or very serious illnesses, and (d) there may be any adverse effects
from chronic use or inappropriate self-medication. Essentially, any product for which
therapeutic claims may be made must be either listed or registered in the Australian
Register of Therapeutic Goods (ARTG) before being marketed in Australia. ARTG was
established under Part 3 of the Therapeutic Goods Act to include a computer database
of information about therapeutic goods for human use that are approved for supply in,
or export from Australia (4).
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Listed medicines are considered to be of lower risk than registered medicines, so

the regulations allow for sponsors to self-evaluate (in terms of efficacy) their products
in some situations and majority of listed medicines are used for self-medication without
a prescription being required. Listed medicines only contain well known established
ingredients with long history of use, most complementary medicines (such as herbal,
vitamin and mineral products), medicines that are intended only for export and if they
do not contain any scheduled substances. The TGA assesses listed medicines only for
quality, safety and not efficacy, but sponsors are legally mandated to hold information
to substantiate their product's claims. Registered medicines are assessed as having a
higher level of risk. The degree of assessment and regulation they undergo is rigorous
and detailed, with sponsors being required to provide comprehensive safety, quality and
efficacy data prior to receiving marketing approval. Registered medicines include both
prescription and nonprescription medicines (to include both traditional pharmaceutical
OTC products and complementary or alternative medicines). In rare instances, some
products may qualify for exemption from being listed or registered in the ARTG.
The registration process for entry into ARTG is determined in part by the
poisons classification system of the National Drugs and Poisons Schedule Committee
(NDPSC) for inclusion in the Standard for Uniform Scheduling of Drugs and Poisons
(SUSDP) based on their toxicity, purpose of use, potential for abuse, safety in use and
need for the substance. The National Drugs and Poisons Schedule Committee (NDPSC)
is a standing committee of the Australian Health Minister's Advisory Council
(AHMAC) and determines the classification and thus, the appropriate schedule, of a
substance (NDPSC also determines classification of veterinary drugs, agricultural and
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household chemicals in addition to human drugs). The SUSDP includes a number of
provisions (such as labeling, packaging and advertising) that relate to the level of
control intended to apply to the scheduled substances (3,5). NDPSC decisions have no
effect and do not attract controls until they are included in state and territory legislation.
While generally, NDPSC decisions are automatically adopted by reference in most
jurisdictions (unless action is specifically taken not to accept a specific scheduling
decision), others require publication in the Australian Gazette before scheduling
decisions come into force.
The NDPSC has published guidelines for classification of drugs and poisons that
it follows in rendering decisions related to the scheduling of substances (6). As per this
guidance, scheduling applications are reviewed by considering all relevant information
like: (a) need for access to a substance in context of its toxicity relative to substances
available for a similar purpose (b) purpose of use (c) method of use (d) dosage form or
formulation type (e) extent, pattern of use and proposed use in the community (f)
misuse (g) drug interactions and adverse events (h) package type and size to prevent
childhood poisoning, and (i) bioaccumulation. Based on this scientific rationale, a total
of nine schedules have been developed by the NDPSC. Of these nine schedules,
schedules 2,3,4 and 8 (S2, S3, S4 and S8) describe medicines for human use, Sl is not
presently under use and S9 covers prohibited substances (SS, S6 and S7 describe
poisons for agricultural, veterinary and domestic use). Among human drugs, substances
classified under S2 and S3 do not require a prescription whereas availability of S4 and
S8 substances is through prescription only. Further, NDPSC describes for each
schedule, the general description, purpose, assessment factors (drug's characteristics,
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indications for use), public health consideration and marketing experience. A summary
of the schedules relevant to substances for human use is presented in table 1 and the
assessment factors used in the scheduling of human medicines are tabulated in table 2.
Canada

The Health Protection Branch (HPB) of Health Canada is responsible for drug
quality, safety and efficacy. It regulates drugs imported into and manufactured for sale
in Canada, and drug distribution including conditions of sale. At the federal level, drug
products are classified into prescription and nonprescription products (7). Schedule F to
the Food and Drug Regulations is a listing of chemical entities or classes of drugs that,
with exceptions, are required by regulation to be sold under prescription (8). The factors
that are used by HPB to restrict drugs to Schedule Fare presented in table 3.
Additionally, Provincial Pharmacy Acts, enforced by provincial pharmacy
regulatory authorities (PRAs), regulate the profession and the practice of pharmacy and
may further specify conditions of sale. Within these acts, drugs are classified into
categories (called drug schedules) with conditions imposed on their sale (9). Prior to
1995, five provinces had provisions in their Pharmacy Acts controlling the distribution
of drugs that provided additional levels of control to those already contained in the
federal legislation and they did not regulate additional location of sale. This situation
led to disharmony in how drugs were scheduled and controlled across Canada.
The necessity for drug schedule harmonization in Canada was addressed and the
Canadian Pharmaceutical Association (CPhA) proposed a mechanism be established to
assess the existing scheduling system and consider the benefits derived from greater
consistency in drug scheduling. This proposal also recommended the assessment of the
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legislation, procedures and criteria generating these schedules. Subsequently, as a result
of the collaborative efforts between HPB, PRAs, CPhA and other interested parties the
final report "Harmonized Drug Schedules in Canada" was released and subsequently
endorsed by the National Association of Pharmacy Regulatory Authorities (NAPRA).
This proposal called for a national drug-scheduling model, to align the provincial drug
schedules so that the conditions for the sale of drugs would be consistent across Canada.
This harmonized national model consists of three schedules or four categories of drugs,
consistent inclusion factors for each schedule, a standard process for scheduling, and a
national advisory committee (National Drug Scheduling Advisory Committee, NDSAC)
to make scheduling placement recommendations to the provincial regulatory authorities
(7,10).

•

Schedule I drugs require a prescription for sale and are provided to the public by
the pharmacist following the diagnosis and professional intervention of a
practitioner. The sale is controlled in a regulated environment as defined by
provincial pharmacy legislation.

•

Schedule II drugs, while less strictly regulated, do require professional intervention
from the pharmacist at the point of sale and possibly referral to a practitioner.
While a prescription is not required, the drugs are available only from the
pharmacist and must be retained within an area of the pharmacy where there is no
public access and no opportunity for patient self-selection.

•

Schedule III drugs may present risks to certain populations in self-selection .
Although available without a prescription, these drugs are to be sold from the self-
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selection area of the pharmacy that is operated under the direct supervision of the
pharmacist, subject to any local professional discretionary requirements which may
increase the degree of control. Such an environment is accessible to the patient and
clearly identified as the ''professional services area" of the pharmacy. The
pharmacist is available, accessible and approachable to assist the patient in making
an appropriate self-medication selection.
•

Unscheduled drugs can be sold without professional supervision. Adequate
information is available for the patient to make a safe and effective choice and
labeling is deemed sufficient to ensure the appropriate use of the drug. These drugs
are not included in Schedules L II or Ill and may be sold from any retail outlet.
NAPRA has developed and published national standards of practice for

pharmacists, corresponding to the level of professional intervention and advice
necessary for the safe and effective use of drugs by the Canadian consumer. The
National Drug Scheduling Advisory Committee (NDSAC) functions to make drug
scheduling recommendations to NAPRA and its member provincial pharmacy
regulatory authorities. The model for making drug scheduling recommendations
embodies a "cascading principle" in which a drug is first assessed using the factors for
Schedule I. Should sufficient factors pertain, the drug remains in this schedule. If not,
the drug is compared to the factors for Schedule II and if appropriate, subsequently
assessed against the factors for Schedule III. Should the drug not meet the factors for
any schedule, it becomes unscheduled. The factors that serve as the foundational basis
for scheduling decisions by the NDSAC have been summarized in table 4.
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The European Union

In 1995, a new European System for the authorization of medicinal products
came into operation. After several years of cooperation between national regulatory
authorities at European Union (EU) level, the EU Council adopted three directives and a
regulation in June-1993 when combined form the legal basis of the system. The
European Agency for the Evaluation of Medicinal Products (EMEA) was established by
the Council Regulation (EEC) 2309/93 . The European system offers, a centralized
procedure (covering all member nations) and a decentralized procedure (covering a
specific member nation that may then be extended to other member nations via mutual
recognition) for authorization of medicinal products.
In the European Union, Council Directive 92/26/EEC of 31 March-1992

describes in detail the classification system for supply of medicinal products for human
use (11,12). Article 1(1) of this Directive classifies medicinal products into, medicinal
products subject to medical prescription and medicinal products not subject to medical
prescription. Further, Article 3(1) of this Directive provides the criteria under which
medicinal products are subject to medical prescription and states:
Medicinal products shall be subject to medical prescription where they:
•

are likely to present a danger either directly or indirectly, even when used correctly,

if utilized without medical supervision, or
•

are frequently and to a very wide extent used incorrectly, and as a result are likely
to present a direct or indirect danger to human health, or

•

contain substances or preparations thereof of the activity and/or side effects of
which require further investigation, or
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•

are normally prescribed by a doctor to be administered parenterally
Also, Article 3(2) and Article 3(3) of this Directive state the necessary criteria

for the sub-category of medicinal products that should be subject to special medical
prescription or restricted medical prescription as may be required in certain member
States. Article 4 of this Directive states:
Medicinal products not subject to prescription shall be those which do not meet the
criteria listed in Article 3.
Thus, the Directive implicitly states that medicinal products should be subject to
a prescription only when they meet the specifically defined criteria. Hence, the
European Union classifies medicinal products into two categories, prescription
medicines and nonprescription medicines, with the prescription requirement being
applicable only when medicines meet certain defined criteria.
The United Kingdom
In the United Kingdom, Medicines Control Agency (MCA) is an Executive
Agency of the Department of Health responsible to promote and safeguard public health
through ensuring appropriate standards of safety, quality and efficacy for all medicines
on the UK market. Additionally, the Agency is required to advise Ministers on policy
relating to pharmaceuticals and regulatory systems and assist Ministers in achieving
their high level objectives on health. The EU Directive on classification of medicines
has been implemented in the United Kingdom. Medicinal products are classified into
three different categories (13,14):
1. Prescription-only Medicines (POM under section 59 of the Medicines Act,
1968): Ingredients limited to prescription supply are listed in The Prescription
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Only Medicines (Human Use) Order, 1997. This order specifies three categories
of POM: parenteral products, controlled drugs and radioactive medicinal
products. There are two other ways in which substances or products may be
made POM. These are either by listing the substance in Schedule 1 of the POM
Order or temporarily through the first Marketing Authorization (MA) for a new
product.
2. General Sale List Medicines (GSL under section 51 of the Medicines Act, 1968):
Medicines that contain ingredients on the General Sale List (The Medicines
(Products other than Veterinary Drugs) General Sales List Order, 1984) are
nonprescription medicines that may be sold from any lockable shop. GSL may
be appropriate for medicines "which can with reasonable safety be sold or
supplied otherwise than by or under the supervision of a pharmacist" and
"where the hazard to health, the risk of misuse, or the need to take special
precautions in handling is small and where wider sales would be a convenience
for the purchaser".
3. Pharmacy Medicines (P): Any medicine that is not a POM or a GSL medicine is

classified as pharmacy medicine. These medicines can be sold only from
pharmacies under the supervision of a pharmacist. There is no list of these
medicines in UK legislation.
Japan
Drugs are classified into prescription drugs, non-prescription drugs (or
proprietary drugs) and quasi-drugs (15). Nonprescription drugs are defined as those,
which have a mild action and a high degree of safety if used correctly within a fixed
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range of directions and dosage. They can be purchased directly from a pharmacy or a
drugstore and used freely in self-medication by the consumers.
The examination for approval of proprietary drugs is based on the following
principles (16):
•

The ingredients and quantities of proprietary drugs should be within a scope that
assures the safety and efficacy of the products. Their action should be mild,
products having a strong action or causing habituation or dependence should not be
included.

•

Their indications should be within the scope of preventing or treating minor
diseases or maintenance and improvement of health. Diseases deemed to be treated
by physicians should not be recognized as indications of proprietary drugs. Their
indications should be mainly described by the symptoms that are easily
understandable to the general public.

•

Directions for administration, dosage and dosage forms shall be described in such a
manner as to be easily understood by the general public on their own judgment.
Products that may cause misuse or abuse, and those in such dosage forms (such as
injections) as not used safely and effectively without the direction of physicians or
other specialists are not recommended as proprietary drugs.

Proprietary drugs are divided into six classes according to conditions in the
approval application (such as ingredients, quantity, indications) and have been
summarized in table 8 (16, 17). Also, the data requirements and clinical trial data
necessary for the registration for each class of proprietary drugs have been presented in
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tables 9 and 10 respectively. Quasi-drugs as stipulated by the law are: (a) products
having fixed purposes of use (b) products having a mild action on the human body, and
(c) products other than instruments and apparatus. For a product to be designated as a
quasi-drug all three conditions must be satisfied (18). Quasi-drugs have been specified
for:
•

Prevention of nausea and other indispositions, foul breath or body odor

•

Prevention of prickly heat, sore and the like

•

Prevention ofloss of hair, promotion of hair growth or removal of hair

•

Eradication or repellence of rats, flies, mosquitoes, fleas etc. for the health of man or
other animals

•

Other articles designated by the Minister of Health and Welfare (MHW) as similar
to the items specified above
To facilitate rapid examination of proprietary drug approval applications, the

MHW at the national level has been transferring the authority to prefectural governors,
provided they adhere to uniform examinations as per established standards. Only the
MHW may approve prescription medicines and quasi-drugs whereas nonprescription
medicines may be approved either by the MHW or by the prefectural governments (15).
Recently, the MHW approved fifteen categories of medicines under the quasi-drug
status. These products are for minor ailments (sore throat, stomach discomfort),
vitamins/minerals and for external use (topical ointments) in general. The distribution
system in Japan is rather unique as about 66% of all prescription medicines are both
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written and dispensed by physicians or dentists and only 1 in 3 prescription medicines is
dispensed by pharmacists. Quasi-drugs may be sold at any retail outlet. Nonprescription
medicines are sold through a variety of outlets such as a pharmacy, drugstore with a
pharmacist and drugstore without a pharmacist. Additionally, outlets with special
limited license and for household distribution also exist but are relatively uncommon.
Reclassification of medicines
Australia

Reclassification (or rescheduling) of medicines in Australia is also governed by
NDPSC guidelines for classification of medicines and poisons (6). The process of
rescheduling may be initiated by the evaluating Agency (TGA), product sponsor, state
and territory authorities and occasionally by NDPSC itself. If an applicant believes that
they can justify an alternative schedule entry for any medicine, an application may be
submitted for review to the NDPSC with suitable evidence. For rescheduling of a drug
substance from prescription only (S4) to a lower nonprescription (S2 or S3) or exempt
from scheduling, NDPSC usually requires at least two years of local clinical use or local
post-marketing surveillance of the drug substance before the proposal is considered.
Suitable evidence for rescheduling could include: (a) evidence from comparable nations
where the drug substance is available without a prescription (b) relevant public
exposure information in other nations with a population base greater than Australia (c)
any available information from post-marketing surveillance (local and overseas) (d) any
relevant previous Australian consideration of scheduling of the drug substance, ( e) any
relevant Australian experience with the drug including a different route of
administration. If the rescheduling application is for a new indication, then applications
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need to be submitted to obtain approvals from the TGA and NDPSC. A detailed
tabulation of suitable evidence justifying a rescheduling application is presented in table
5.

Canada
Reclassification (or de-scheduling) to nonprescription status in Canada has been
addressed by the HPB in an information letter issued in June-1990 (19). The purpose of
this information letter was to inform interested parties of the data requirements for
applications to remove drugs for human use from Schedule F to the Food and Drug
Regulations and outline the internal mechanism for handling such applications.
Applications must demonstrate that a favorable ratio exists between the benefit to
patients that will occur versus the risk to their health that may be inherent in permitting
the nonprescription sale of the drug product. HPB requests the following information
for assessment of the reclassification applications:

•

Efficacy data f or new indications and safety data
Efficacy data will be required if the indications of use or dosage differ from those
approved fo r prescription use. A summary of all animal and human clinical safety
data, including data that may have been part of an original submission and the data
accumulated after the product's introduction.

•

Drug adverse reaction data
A summary of all known domestic and foreign adverse drug reaction reports since
the introduction of the medicinal ingredient, adverse effects with their frequency
and the dose at which they occurred. Any adverse effects that could require patient
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monitoring by a physician should be clearly described. Any potential for misuse or
abuse and actual occurrences should also be discussed.
•

Labeling

All proposed nonprescription labeling and promotional material demonstrating that
the safe and effective use of the product can be assured by nonprescription labeling
rather than depending upon the professional judgment of a physician. Appropriate
cautions and contraindications must be addressed in lay terms.

•

Chemistry and manufacturing data

Differences from the original submission and supplements must be identified.
Chemistry and manufacturing data will be required where they differ from the
prescription drug.
•

Market data

Date of introduction of the prescription drug in the Canadian market and a summary
of sales data must be included. If the product in consideration was not the first
product introduced as a prescription drug, then date of introduction of the first
product also must be provided. A summary of international market status (countries
where requests for prescription or nonprescription status have been made, approved,
rejected or are pending) is required. If a request has been refused, the reason for
refusal is required. If the request was approved, the date of introduction in that
market and confirmation that the product is currently marketed is required.
Additionally, the Drug Evaluation Unit of the HPB also published an
information pamphlet on the subject of prescription to nonprescription switches in
April-1999 (20). In this publication, HPB took the position that the switch process be
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initiated by the manufacturer only, through the filing a supplemental new drug
submission (SNDS) with HPB performing the assessment of the evidence provided to
determine the suitability of the product and its indication for OTC use. The factors to be
considered while evaluating the suitability for a switch and the data requirements for
switch SNDS have also been briefly listed in this pamphlet. Also, HPB recently
finalized revised guidelines for preparing submissions seeking to change the status of a
drug from prescription to nonprescription. These guidelines for a switch divide switches
into two types, Type I and Type II, based on the nature of the switch and complexity of
the review.
Type I switch is for drugs which have same strength, dose, dosage form,
indication and route of administration as the prescription product. Type I switches
usually do not require the submission of new clinical trials or chemistry and
manufacturing data. The review is mainly of the safety profile and whether selfmedication is effective. Type II switch is for drugs which have a change in, the
indication, dosage form, strength or dose, route of administration, relative to the
prescription product. Hence, a type II switch request requires data from clinical trials to
support the new strength or dosage formulation as a nonprescription product.
Removal of drugs from Schedule F, or addition of a qualifier to Schedule F (for
dual status products) requires the promulgation of a regulatory amendment which is
subject to federal regulatory process and involves several stages and levels of approvals,
that include the Minister and the Governor-in-Council who are advised by the Special
Committee of c

·

ounc1l (SCC). The steps involved in the regulatory amendment process

are outlined in table 6. A switch becomes law at the federal level once registered at the
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SCC. After the drug is reclassified at the federal level, each province must then
determine how the product will be sold and this determination is made by the National
Drug Scheduling Advisory Committee (NDSAC) at the provincial level as discussed
earlier.
The European Union

Reclassification within the EU has been addressed by the issuance of a guideline
on changing the cl assification for the supply of a medicinal product for human use in
September-1998 (2 1). This guideline is divided into two parts. Part one concerns the
criteria for classifying a medicinal product as subject to medical prescription or not. Part
two describes the data requirements for an application requesting reclassification of a
prescription product to nonprescription status. As per this guideline, suitability of a
medicinal product for nonprescription status is elaborated by examining the converse of
each criterion (discussed earlier) that justifies the prescription requirement. A medicinal
product not subject to a prescription should have the following characteristics under
each specified attribute:
Direct danger/safety profile

•

Low general toxicity and no relevant reproductive toxicity, genotoxic or
carcinogenic properties

•

Low risk of serious type A adverse reactions (those that result from exaggeration of
a drug's expected pharmacological actions when given in the usual therapeutic dose;
normally dose-dependent) in the general population

•

Very low risk of serious type B reactions (those that represent a novel response not
expected from known pharmacological action)
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•

No interactions with commonly used medicines which can produce serious adverse
reactions

Indirect danger/safety profile

•

No indirect danger such as hiding/masking an underlying condition requmng
medical attention and supervision even when the product is used as directed.
Nonprescription medicines should be approved primarily for short-term treatment
when the possibility of "masking" could occur.

•

No increased risk of resistance to product with a wider use of a product within the
general population to such an extent that the usefulness of any medicinal product is
likely to be compromised.

Self-assessment

•

Conditions or symptoms should be such that can be correctly assessed by the patient
and the product can be used without medical supervision. Consumer communication
may be facilitated by the use of written information, advice of pharmacist and other
appropriate sources.

•

The natural course of the disease, the condition, the duration of symptoms and their
reoccurrence and consequences should be correctly self-assessable.

•

Contraindications, interactions, warnings and precautions should be those that can
be understood by the consumer.

Risk and consequences of incorrect use

•

Absence of a high incidence of conditions listed as contraindications, precautions or
warnings or a high rate of usage of interacting drugs in the population in case of
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patients likely to use the medicine that may increase the incidence and risk of
misuse.
•

Low danger to health if the patient uses the product where it is not indicated or uses
it for a longer period than recommended or exceeds the recommended dose or fails
to heed warnings or contraindications.

Patient information

•

Leaflet and label must contribute effectively to safe and effective use of medicine
and should be sufficient so that it substitutes for absence of medical supervision. All
information should be provided in layman's terms and prominently presented in the
leaflet. Leaflet and label should describe in equal prominence when and when not
the product should be used.

Known incorrect use
•

If known incorrect uses exist, then such a product may not be considered for

nonprescription medicine status. Similarly, products with low expenence, where
marketing authorization was only recently granted or when further investigation is
required should also be not considered for nonprescription medicine status. Further,
post-marketing information in an uncontrolled environment should be examined
while reclassification.
Recent authorization/limited experience

•

For reclassification at a new dose, m a new strength or usmg a new route of
administration further investigation is necessary. At a lower strength, efficacy
should be demonstrated. A re-evaluation of the risk to benefit ratio is necessary
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under the proposed conditions of nonprescription status. The same is true when a
combination of two or more active ingredients is considered.
Other considerations
•

No parenteral products or products classified as special or restricted prescription
products under Council Directive 92/26/EEC.

•

Pack size should be decided in relation to the intended length of the treatment.
Packages should be child resistant in nature and generally in restricted sizes as a
possible safeguard against misuse.
Part two of the EU guideline describes the data requirements and documentation

concerning safety and efficacy in support of an application for reclassification. This is
usually dependent on the nature of the active substance and the extent of changes to the
existing marketing authorization. In all cases, an expert report should be provided
taking a clear position and defending the proposal with scientific knowledge and
demonstrate why none of the criteria that lead to the prescription requirement should be
applicable. In addition to scientific data addressing all points related to determining the
suitability of the product for nonprescription status, other requirements summarized in
table 7 should also be included in the expert report.
The United Kingdom
In the United Kingdom, two types of reclassification are possible. The first type

of reclassification is from prescription only medicine to pharmacy medicine status
(POM to P) and the second type is from pharmacy medicine to general sales list (P to
GSL). The UK Medicines Control Agency (MCA) has specified a set of guidelines
related to each type of reclassification. The POM to P reclassification has been
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explained in Medicines Act Leaflet 77 (MAL 77) (13) and the P to GSL reclassification
is discussed in Medicines Act Leaflet 82 (MAL 82) (22).
For POM to P reclassification, MAL 77 describes the procedure for amendment
of the POM Order applying to products that are prescription medicines because they
contain one or more substances listed in Schedule 1 to the POM Order. Applications
under this procedure may be submitted as a variation or a new abridged application. The
variation route is appropriate if the marketing authorization (MA) holder has a product
suitable for reclassification, the proposal to amend the POM Order should be
accompanied by an application to vary the legal status of the product. Other product
particulars may also need to be varied in order for a product to be suitable for
reclassification. If reclassification is agreed, amendment to the POM Order will proceed
and the MA will be appropriately varied to take effect when the POM Order comes into
force. If an MA holder wishes to make a change, for example to introduce a new
strength, which requires a new application, a new abridged application should be made.
A new abridged application should also be made if the MA holder wishes to hold a
separate MA for the P product. Also, any interested party such as a professional body
that does not itself hold an MA may request the reclassification of a substance. The
content of the applications should be similar to that of applications from MA holders.
Since, Schedule 1 to the POM Order is substance based, amendment will usually affect
the legal classification of products containing that substance. If the MA is in line with
the amendment to the POM Order, the product becomes classified as pharmacy
medicine. However, MA holders should apply to vary their MAs in accordance with the
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amendment to the POM Order, and provide appropriately amended labeling and patient
information leaflets for approval.
Following assessment of the application, advice from the Committee on Safety
of Medicines (CSM) will usually be sought on the proposed reclassification. If the
reclassification proposal is supported, wider interests are then consulted. Responses to
the consultation are examined by the MCA whose advice is passed to Ministers. It is for
the Ministers to determine, in the light of the advice received, whether the POM Order
should be amended. If the CSM recommends that a request for reclassification be
refused, the originator of the proposal will be notified as to which POM criteria have
been considered to apply and the reasons for advising against the change, and will
receive a copy of the assessment report.
As stated earlier, the EC Directive on the classification of medicines
(92/26/EEC) has been implemented in the United Kingdom and incorporated into
section 58A of the Medicines Act, 1968. Although the prescription criteria of Council
Directive 92/26/EEC apply to all EC member states, the procedure for assigning
prescription classification remains the responsibility of each individual member state. In
the United Kingdom, the required documentation in support of a POM to P
reclassification request is substantially similar to that described in the EU guidance on
the same subject. Applications should contain the following key information that has
been discussed in detail in the earlier section in the European Union context. The key
elements to be addressed in the expert report must include:

•

Consideration of reclassification proposal in relation to the four criteria for
prescription control (reference to Article 3(1) of Council Directive 92/26/EEC)
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•

Summary of data relating to safety and where appropriate efficacy

•

Proposed patient information (labeling and patient information leaflet)

•

Clinical expert report .
MAL 82 provides guidance on pharmacy to general sale list (P to GSL)

reclassification procedures and requirements. As discussed earlier, similar procedures,
steps and possible routes as for POM to P reclassification also apply to P to GSL
reclassification. But, substantial differences exist in the criteria applied to evaluate
suitability for GSL and the contents of the supporting application. Criteria applied to
evaluate suitability of human medicines for GSL has been defined earlier. The
supporting application for a P to GSL reclassification must contain:
•

Expert report

o

Clear demonstration in light of scientific knowledge why the GSL criteria
must apply

o Discussion of maximum dose, maximum daily dose and the indications
suitable for use. Explanation of contra-indications, warnings, adverse
reactions, interactions and problems of overdose and other misuse under
GSL conditions.
o Justification for the need for special handling precautions as being very
small. Discussion of difficulties in the extrapolation of P to GSL use.
•

Data requirements

o

Experience m exposure to substance should be considerable. GSL use
suitable medicines should have been in P use for many years.
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0

Description of safety profile, to include, post-marketing surveillance/clinical
studies, adverse drug reports under GSL conditions in UK and foreign
nations. Comparison of safety with other approved GSL medicines for
similar indications.

0

New PK/PD or efficacy data are usually not required. Animal studies are
also not required except under special circumstances.

o Complete analysis of any experience of therapeutic misuse or abuse that may
be deliberate or accidental. Description of symptoms from overdose or
misuse along with recommended treatments.
o Proposed patient information leaflets, labeling, pack size and any other
changes in product presentation should be provided. Safety warnings such as
limited duration treatment or the need to consult a doctor or pharmacist
should be listed.
The guidance states that anthelmintics, parenteral products, drops/ointments for
ophthalmic use, enemas, products for irrigation of wounds or of the bladder, vagina or
rectum and products for administration to children that are preparations of aloxiprin or
aspirin are not included in the GSL.
Japan

The procedures, application format and data requirements for registration and
approval of nonprescription medicines, as discussed earlier, apply exactly and in same
measure to reclassification application dossiers in Japan (18). The future course of

MHw related to reclassification is presently under consideration and additional
guidance (15) in the interim may be summarized as:
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•

The active ingredients proposed for switching application should have undergone
complete re-examination or re-evaluation.

•

Review of switch applications should be conducted upon serious consideration of
the opinjons of Central Pharmaceutical Affairs Council to determine whether the
product is suitable for nonprescription medicines status. A rate of incidence of
adverse medicine reactions, administration and dosage, actual examples of use of
the medicine in foreign countries, results of either re-examination should be taken
into consideration.

•

To ensure appropriate use and safety of the medicine, conditions may be imposed at
the time of approval such as to conduct post-marketing surveillance (PMS),
directions on information provision and sales methods and advertising standards.

•

Upon approval of the switch application, the product may be sold only in a
pharmacy or a drugstore with a pharmacist.

•

PMS of the prescription product and actual use trials (AUT) should be conducted to
support switch applications. PMS should include two kinds of surveillance
emphasize actual use/administration of proposed OTC drugs by subjects and
adverse reactions documented after the product's launch.

•

New clinical trials are required and should be carried out in at least five locations in
Japan with not less than 150 cases even ifthe prescription product is considered for
switching without any changes.

World Health Organization perspective
The WHO finalized and published guidelines on the regulatory assessment of
medicinal products for use in self-medication in March-2000 (23). This guidance states
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that a medicinal product for self-medication should, at least, meet the following three
criteria:
J. Active ingredient: The active ingredient at the intended dose should have low

inherent toxicity (no reproductive toxicity, genotoxic or carcinogenic properties
relevant to human use, unless such hazard can be appropriately addressed by
labeling).
2. Intended use: The intended use should be appropriate for self-medication. Use of
the products should not unduly delay diagnosis and treatment of a condition
requiring medical attention.
3. Product properties: The product should not have properties that make it

undesirable. For example, it should not have an unfavorable adverse event profile,
require a physician's supervision for monitoring during drug therapy, represent a
significant risk of dependence or abuse or display other limiting characteristics
such as interaction with commonly used medicines or foods that may result in
serious adverse reactions.
If the product meets these criteria, the following additional requirements may be

applied:

•

The use of the product has been sufficiently extensive or in high enough volume.

•

The product has been marketed on prescription for at least five years .

•

Its adverse events give no cause for concern and their frequency has not increased
unduly during the marketing period.

A basic principle for the regulatory assessment, as per WHO guidance, is that
the pharmacokinetics, pharmacodynamics, indications, safety, efficacy, toxic or

66

allergenic potential of a medicinal product should have been reasonably well
established and documented in humans before its eligibility for use in self-medication
can be evaluated. The general regulatory assessment approach should, in detailed terms,
investigate the following five complementary aspects:
•

Active substance and rationality of its indications

•

Specific routes of administration, dosage forms and formulations

•

Specific safeguards

•

Suitability for self-medication status

•

Labeling and package inserts and other information forming a basis for advertising
and promotion
The guidance also provides details on the collection and regulatory assessment

of evidence for medicinal products intended for nonprescription status hitherto available
only on prescription. The objective of the regulatory assessment, while considering
reclassification should be to form an opinion on the basis of evidence that will generally
comprise:
•

The

original

regulatory

data

(chemistry,

manufacturing,

pharmaceutical,

pharmacological, toxicological, clinical pharmacological, clinical trial, therapeutic
efficacy and safety data)

This is relevant only if the product is being considered for reclassification
without any changes to the marketed prescription product. If the original animal
investigations suggested severe risks (like carcinogenicity) the risks should be
reassessed in light of subsequent experience in humans.

•

Clinical data obtained after the approval of the drug
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Trials performed according to current standards and relating closely to the
proposed use in self-medication should be accorded the greatest weight.

•

Drug utilization and consumption data

This is helpful in determining the way in which the product has hitherto been
employed by physicians (volume of use, major indications in practice,
precautions normally taken) and particularly in interpreting alleged risks.
•

Reported adverse events/reactions and interactions

This should be examined with respect to their profile, frequency and severity.
Sources in which the evidence is critically assessed (especially in well
controlled clinical studies or epidemiological studies) are preferable to those in
which unevaluated observations of possible adverse reactions are accumulated.
Data from sources that have collected adverse reactions information from
different countries for long periods of time may be useful, in particular, from
WHO's International Drug Monitoring Programme.
•

Current scientific data

The pharmaceutical form and packaging should be considered, any available
clinical studies, field data and market-related studies on consumer use of the
product for self-medication should be examined.
Comparative evaluation

An evaluation of the regulatory systems for nonprescription medicines in
comparable developed nations demonstrates the unequivocal recognition of their vital
role in public health care. The basic scientific rationale used to designate
nonprescription status to medicines is very similar within the considered models. But,
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there exists wide variation in the categories of nonprescription medicines available in
these markets. Some classification models (Australia, Canada, United Kingdom and
Japan) recognize an intermediate class of nonprescription medicines, controlled by the
pharmacist, whereas other models (the US and EU) do not. The issue of an
intermediate, pharmacist-controlled nonprescription category being included within the
US regulatory model has been quite controversial. The major proponent of an
intermediate class of medicines has been the American Pharmaceutical Association,
whereas the Consumer Health Products Association (CHP A, the trade association
representing the manufacturers and distributors of nonprescription medicines and dietary
supplements in the US OTC marketplace) has strongly opposed such a new class of
medicines (24,25,26). The US General Accounting Office (GAO) upon congressional
request in 1995 issued a report titled "Nonprescription Drugs: Usefulness of a Restricted
Sale Class has Not Been Demonstrated" (27). To date, this is the most comprehensive

study conducted in the US on this subject and performed a detailed investigation of drug
classification/distribution systems across ten countries. The US GAO reached the
conclusion that "reliable and valid studies that examine the effect of drug distribution
systems on overall health and healthcare system costs do not exist". This GAO conclusion

clearly demonstrates the need for reliable, objective and valid studies through which useful
information may be elicited to reach a definitive conclusion on this matter.
Although,

the

appropriate

scientific

principles

used

to

categorize

nonprescription medicines are remarkably similar across various regulatory systems, the
end results of each classification system are highly variable. There exist many examples
of the same drug substance being subject to conflicting status across the considered
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regulatory models. Also, there exists wide variation in classification of the same drug
substance based on dosage level. In Canada, UK and Australia, substance based lists of
drugs subject to prescription control are maintained whereas in the US , such is not the
case. The US approach of classification based only on the approved submissions,
without any substance based lists, offers greater clarity. The OTC monograph system in
the US that resulted from the OTC Drug Review benefits the pharmaceutical industry
by simplifying the approval process. A similar system as the OTC monographs, on a
global basis would benefit other regulatory systems also.
The scientific principles and the supporting data requirements based on which
reclassification applications are reviewed are also remarkably similar in the regulatory
systems studied here. As is the case with classification of drug substances, although the
process and principles used for evaluation of reclassification request are quite similar,
they have produced varying results for the same substance in different nations.
Regulatory bodies in the US, Australia, Japan have taken the position that they can,
themselves, initiate reclassification requests, whereas in Canada and the United
Kingdom such requests should be initiated only by the holders of marketing approval or
other interested bodies. All the regulatory models (Australia, Canada, UK, EU, Japan
and WHO guidance) elaborated here have well-defined and structured data
requirements that need to be submitted in support of reclassification requests. Such is
not the case with the US FDA. Although, 21 CFR 330.1 O does provide general insights
into the requirements and standards for safety, effectiveness and labeling in the OTC
context, the US FDA has not issued any specific guidance on the details of
structure/format of the justification and the types of data required to prove suitability for
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nonprescription use. An important lesson that would be very useful in the US context is
that US FDA should develop a guidance document for industry describing the nature of
data required for justification of a reclassification petition. Another major contrast
relates to the possibility of new chemical entities (NCE) being marketed as
nonprescription medicines (i.e. direct-to-OTC) if they meet all the necessary
requirements. There is no uniformity among the various regulatory models on the
duration for which a drug substance must be marketed as a prescription medicine before
it may be considered for reclassification to nonprescription status. That duration in,
Australia is two years, Canada is three years Japan is six years, and WHO regulations
require five years. The UK and EU regulations also state that any NCE must be
marketed as a prescription medicine for a substantial duration before reclassification
may be considered. The US position on this issue is unique as no such requirement is
explicitly stated, leaving open the possibility of an NCE being marketed directly on
OTC status. Reclassification requests in some markets (Australia, Canada and Japan)
require approval from regulatory bodies at both federal and state level. In the US and
UK such is not the case. Necessity to obtain approval from federal and state level
agencies (especially in Canada) is burdensome for the industry. Under the US and UK
models, approval is obtained primarily at the federal level which is efficient and
desirable.
Conclusion
Nonprescription medicines in major developed nations have been recognized as
crucial to efficient public health care. Accordingly, Australia, Canada, the United
Kingdom, the European Union and Japan have all established regulatory frameworks
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based on scientific principles for classifying drug substances under the nonprescription
status and reclassifying prescription medicines as nonprescription medicines. However,
there exists significant opportunity for improvement of current regulatory systems
within these nations to enhance efficiency of regulatory review, convenience to drug
manufacturers and consumer access to nonprescription medicines. In this regard, the US
OTC regulatory system should seriously consider issuing guidance to industry on
specific data requirements for reclassification petitions and investigating the merits of
an intermediate pharmacy-class of nonprescription medicines.
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Table 1: Summary of the schedules relevant to substances for human use as per the
Australian classification system

Description

Schedule
Schedule Two
(S2,
nonprescription
medicine)

•

Schedule Three
(S3,
nonprescription
medicine)

•

•

•
•

Schedule Four
(S4,
prescription
medicine)

•
•
•

Schedule Eight
(S8 ,
prescription
medicine)

•
•
•

Purpose

To allow effective
drugs for which
pharmacist advice on
use may be required
by the consumer to be
available without a
_l)fescription.
Substantially safe but require professional To allow effective
drugs which require
advice by a pharmacist
professional
advice on
Use of which requires pharmacist advice,
use by the consumer to
management or monitoring
be available from the
For ailments or symptoms which can be
identified by a consumer and verified by a pharmacist without a
prescription.
pharmacist and do not require medical
diagnosis or only require initial medical
diagnosis without need for close medical
management
To make available
Use of which requires professional
drugs the use, supply
medical, veterinary or dental
and prescribing of
management/monitoring
which should be by
For ailments or symptoms that require
registered medical,
professional medical, veterinary or dental
veterinary or dental
diagnosis or management
practitioners and
The safety or efficacy of which may
supply of which
require further evaluation
should be on
Which are new therapeutic substances
_Eescrigtion
To allow potent drugs
Which are dependence producing
to be available for
Which are likely to be abused or misused
medicinal use with
restrictions on
manufacturing, trade,
distribution,
possession and use to
prevent abuse,
addiction and
dependence
Substantially safe but counseling
available if necessary
For minor ailments that can be easily
recognized by the consumer and do not
require medical diagnosis
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Table 2: Summary of the assessment factors used in scheduling nonprescription
medicines for human use as per the Australian classification system

Assessment_fEctors

Schedule

S2Nonprescripti
on medicine
(regular OTC
products)

.
•

.
•
•
•
•
•

S3Nonprescripti
on medicine
(Pharmacist
only
medicine or
behind-thecounter
products)

•
•
•
•

.
.
•

Suitability for self treatment of a minor ailment or symptom
capable of being monitored by the consumer
Extremely low abuse potential, low potential for harm from
inappropriate use
Low adverse effects and contra-indications for which counseling is
available
Low interactions with commonly used substances or food for which
counseling is available
A wide therapeutic index and low risk of masking a serious disease
and compromising medical management of a disease
Not require ongoing or close medical diagnosis or management
Easy recognition of ailment by consumer
Amenable to short term treatment and monitoring and selfmanl!&_ement b_y_ consumer with counselin_g_
Low abuse potential, harm from inappropriate use, incidence of
side-effects or adverse events likely to require medical intervention
Only common drug/food interactions that may be managed by a
pharmacist
Medium to wide therapeutic index
Risk of masking a serious disease or compromising medical
management can be managed by a pharmacist
Not require close medical management or direct supervision by a
doctor
Ailment easily recognized with assistance of a pharmacist
Amenable to short term treatment and monitoring and selfmanl!&_ement b_y_ consumer with assistance of a__Q_harmacist
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Table 3: Summary of the factors used for listing drugs for human use in Schedule F
(subject to prescription control) as per the Canadian classification system
Drugs will be listed in Schedule F if:
individualized instructions and/or direct practitioner supervision, adjunctive therapy with
scheduled drugs or routine laboratory monitoring are required;
there is a narrow margin of safety between the therapeutic and toxic doses, especially in
populations such as geriatrics, children and pregnant or nursing mothers;

•

there are potential or known undesirable or severe side effects at normal therapeutic dosage
levels;

•

they are known by experimental data to induce toxicity in animals but have not been in
clinical use long enough to establish the pattern or frequency of long-term toxic effects in
humans;

•

they are used in treatment of a serious disease easily misdiagnosed by the public;

•

their use may mask other ailments;

•

they have contributed to, or are likely to contribute to, the development of resistant strains of
micro-organisms in humans;

•

they possess a dependence or abuse potential that is likely to lead to harmful non-medical
use;

•

they possess a high level of risk relative to expected benefits; or

•

they have a therapeutic effect based on recently elucidated pharmacological concepts, the
consequences of which have not been established.

Exceptions will be considered for drugs which:

•

are required to be readily available under emergency circumstances where it is not practical
to obtain a prescription (such as adrenalin in insect bite kits) ;

•

are rarely used without a practitioner's supervision, and where the need for free availability
outweighs the need for protection under Schedule F (such as insulin and nitroglycerin); or

•

have potential to produce dangerous interactions with other drugs or food constituents but
effective labeling can minimize the risk.
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Table 4: Description of factors that serve as the foundational basis for scheduling drugs
in Canada
Schedule I
Indications for use of the drug are identifiable only by the practitioner.
Use of the drug requires adjunctive therapy or evaluation .
Use of the drug may produce dependency .
Serious adverse reactions to the drug are known to occur or have a recognized potential to occur at normal
therapeutic dosage levels.
• There exists a narrow margin of safety between the therapeutic and toxic dosages of the drug, either in the
general population, or in identified subpopulations, or in patients with multiple medical problems.
• Serious interactions of the drug are known to occur.
• Use of the drug has contributed to, or is likely to contribute to, the development of resistant strains of
microorganisms.
• The mechanism of action of the drug is known but the consequences of widespread use are not adequately
establ ished.
• The therapeutic effects of a newly released drug are based on new or unknown mechanisms of action, but
the cons~uences ofwide~ead use are not a~u ate.!.Y. established.
Schedule II
• The initial need for a drug is normally identified by the practitioner, in addition chronic, recurrent, or
subseq uent therapy must be monitored by the pharmacist.
The
drug must be readily available under exceptional circumstances when a prescription is not practical.
•
• The drug is intended for administration in a health care setting or under direction of a health care
professional, or is in an injectable dosage form and is not otherwise included in Schedule I.
• Evidence of abuse of the drug has been reported, due to its inherent pharmacological action that has the
potentia l for abuse.
• The selection of the drug requires intervention by the pharmacist to confirm that an appropriate selfasse sment has been made by the patient.
• Use of the drug may delay recognition or mask the symptoms of serious disease.
• The drug may cause important adverse reactions, including allergies, or interacts with other drugs, foods,
or disease states that cannot be adequately addressed through product labeling.
• Use of the drug requires reinforcement or an expansion of the directions for use, through pharmacist patient dialogue.
• The drug is a new ingredient for self-medication and monitoring by the pharmacist is necessary to
faci li tate observation and reporting of any unexpected event.
• The max imum labeled dosage directions exceed the generally accepted or usual limits for Schedule Ill
status.
Schedule Ill
• The initial need for a drug is normally identified by the patient, physician, or pharmacist, but chronic,
recurrent, or subsequent therapy can be monitored by the pharmacist.
• The maximum recommended duration of use of the drug is limited and specified on the product label.
• The maximum recommended duration of use of the drug is not specified on the label, but continued use
may delay recognition or mask the symptoms of serious disease.
• The drug is used to treat a persistent, chronic or recurring condition and the availability of the pharmacist
to provide advice can promote appropriate use.
• The drug is used for self-treatment of self-limiting ailments; however, where product selection has been
identified as likely to cause patient confusion and the availability of the pharmacist to provide advice can
promote appropriate use.
• The drug demonstrates adverse effects, including allergies, or interacts with other drugs, foods, or disease
states that can be identified in product labeling, but appropriate product selection and explanation of risk
may require the advice of the pharmacist.
• The drug is a new ingredient for self-selected self-medication and the availability of the pharmacist to
provide advice can promote appropriate use.
• The drug has inherent pharmacologic action that has the potential for non-medical use that may result in
adverse patient outcomes.
• The maxim um labeled dosage directions exceed the generally accepted or usual limits for unscheduled
status.

•
•
•
•
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Table 5: Summary of suitable evidence required for justification of a rescheduling
application submitted to NDPSC review in Australia
Name of chemical/active constituent
•
Its approved name
• JUPAC name
• All proprietary, non-proprietary or other names
and code numbers

Toxicological database
• Toxicokinetics
• Acute studies
• Lethality or lower toxic dose
Skin & eye initancy
Skin sensitization
• Corrosivity
• Repeat dose studies
Short term
Sub chronic
Chronic
• Reproductive studies
Teratogenicity
Fertility
Peri/postnatal
• Carcinogenicity
• Genotoxicity
• Other
• Mechanistic
Specific organ toxicity
Immunotoxicity
• Neurotoxicity
• Toxicity of metabolites and
impurities
Human toxicological data
• Toxicity of mixtures
• In-vitro studies
Clinical data
Postmarketing reports
• Adverse drug reaction reports
• Additional clinical reports
• Epidemiology studies
• Poisoni'!S_ r~orts
Monitoring for public health impact of
rescheduling decision

..
..
.
..
.
..
.

End-use product details
• Distinguishing trade name
• Formulation type
• Active constituents and concentration
• Formulation composition
• Basic_ph_}'._sical and chemical _Q!"~erties
Physicochemical properties of the active ingredient
• Structure of the drug or chemical
• All relevant chemical and ~ical_Q_r~erties
Pharmacology
• Structural and pharmacological relationship to
other drugs
• Pharmacokinetic and pharmacodynamic
profiles
• Interactions, incompatibilities, side-effects or
adverse effects
Toxicology
• Summary of known toxicology of the drug
• Summary of known metabolism of the drug
• Summary of previous submissions, if applicable
• Relevant details of any published and
unpublished toxicological investigations of the
dl"I!&_
Statistical ana!J'sis
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.

Occupational health and safety details (if
applicable)

Regulatory status in Australia and overseas
Approved indications for drugs
Detailed information relating to the
classification or regulation of the
availability of drug in significant overseas
countries (Canada, Sweden, Netherlands,
New Zealand, UK & USA_l
Consumer education_Q_r~ams

•
•

Table 6: Steps in the regulatory amendment process to de-schedule drugs to
nonprescription status at the federal level in Canada

Step 1: Consultation
Draft of Regulatory Impact Assessment Statement (RIAS)
• Internal Consultation
• Review and analysis of internal comments
• External consultation_{stakeholders, other manufacturers etcl

•

Step 2: Pre-publication in Canada Gazette Part I
Review and analysis of external comments
• Preparation of full official Part I package for Canada Gazette. This package includes RIAS ,
approved copies of regulation, memos to the Director General (DG) and the Minister,
Communications Plan, letter to the Assistant Clerk of the Privy Council and a prepublication
notice
• Approval of the proposed regulatory amendment by the DG, Assistant Deputy Minister (ADM),
Deputy Minister (DM) and Minister
• Approval by SCC
• Pre-publication in Canada Gazette Part I
• Comment Period

•

Step 3: Publication in Canada Gazette Part Il
Review and analysis of stakeholders' comments from Part I
Preparation of a package for publication in Canada Gazette Part II. This package contains the
RIAS, stamped copies of the regulation and an order, memos to DG and Minister, letter to the
Assistant Clerk of the Privy Council, a recommendation and a communication plan.
• Approval by the DG, ADM, DM and Minister
• Approval by Special Committee of Council
• Registration
• Publication in Canada Gazette Part II

•
•
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Table 7: Summary of data requirements for a reclassification application in The
European Union

Safety

•
•
•
•

•
•
•
•

Summary of animal or human studies showing low general toxicity and no reproductive
toxicity, genotoxic, carcinogenic properties with the experience/exposure to the product.
Post-marketing experience in wide ranging patient population under prescription status for
preferably five years, or shorter period if active substance has been in use as a foodstuff or
as a metabolite of a known active substance.
Adverse reactions information, experience of use without medical supervision from foreign
sources, including numbers of patients treated, demographic details, indications for use and
dose.
Safety profile summarized as per EU guidelines, to include:
• Post-marketing surveillance study reports .
• Clinical trials and published literature related to safety .
• Discussion of reactions arising from misuse and unknown reasons .
• Data extrapolation from the prescription use population to nonprescription use
population.
Potential and consequences of drug interactions with commonly prescribed drugs .
Consequences of misuse, abuse or overdose .
Consequences of consumer using upon misdiagnosis of symptoms .
Consc::ciuences of incorrect or del!l}'ed di~osis of ~m.£!oms related to the..E_roduct.

Efficacy

•
•
•

When application includes changes in indications or posology, otherwise not needed .
Justification of a suitable time-period for treatment of the suggested indication(s) .
A..E_r~osed_£._ack size .

Product information
• Label and leaflet examined for comprehensive information and effectiveness in protecting
consumers from any safety hazards (very important)
• Description of use of the product and circumstances when referral for medical advice is
appropriate from the label.
• Compliance of labels with requirements as per Council Directive 92/27/EEC on the
readability of the label and package leaflet.
• Contraindications and warnings, such as advice limiting duration of treatment or the need
to consult a doctor in certain situations.
Package
Discussion of a chang_e of container when applicable to_g_ether with neces~ documentation .

•
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Table 8: Classification of proprietary drugs (nonprescription medicines) in Japan
Descrff!!ion

Cate_s!>f]I__

Class 1

Drugs which contain active ingredients which have been used neither in
_E!escription nor in OTCs _(referred to as "New active ingredients'1

Class 2

Drugs which contain active ingredients, other than "New active ingredients", which
have not been used as active ingredients in already approved OTCs (referred to as
"New non- p_rescrij)_tion i~edients'1

Class 3

Drugs which consist of active ingredients which have been used in already
approved OTCs but which have not been used in the therapeutic category in
question (referred to as "Newly combined ingredients"), and drugs which are
different from already approved OTCs in the therapeutic category in question in
terms of combinations of active ingredients, or indications and effects, or
administration and dosage. (However, drugs in either Classification 4 or 5 and
dru__g_s which com_£!.Y_ with Approval Standards shall be excluded.}_

Class 4

After completion of Post Marketing Surveillance on safety during use of drugs in
any one of Classifications, 1, 2, and 3 (collectively hereinafter referred to as "New
non-prescription medicines"), drugs which are applied for approval as drugs
containing either "New active ingredients" or "New non-prescription ingredients"
or "Newly combined ingredients" but which have differences in combination of
active ingredients used in already approved OTCs. The differences correspond to
the following two cases. However, these drugs shall be limited to those with the
same administration and dose, and indications and effects as already approved
OTCs, and with the same or slightly different dose forms from already approved
OTCs.
(1) When only active ingredients with pharmacological actions different from those
of "New active ingredients", "New non- prescription ingredients" or "Newly
combined ingredients" are different.
(2) Where ingredients with different pharmacological actions in the case(!) have
mild actions with no direct relations to ther'!£_eutic effica~

Class 5

Drugs which belong to the therapeutic categories with the Approval Standards and
only whose dose forms are different from those specified in the Approval
Standards, and drugs which belong to the therapeutic categories without the
Approval Standards and only whose dose forms are different from those of the
already approved OTCs in the therapeutic categories in question (Limited to those
with ~ecial dose forms}_.

Class 6

Drugs which conform to the Approval Standards, or drugs which do not fall into
an_x. one of the Classifications 1 throl!.&_h 5 above.
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Table 9: Data required for approval of nonprescription drugs in Japan
Class oj_Drip,_s

Jillj_s

Data required

I 2 3

A. Data on or!g!n and use in fore!g_n countries
I . Product ori_g_in and details of discov~
2. Use in foreig_n countries
3. Product_Eofile and com_E_arison with other dru_g_s
B. Data on j>_h_y_sical and chemicalj>_ro.I>_erties
1. Determination of chemical structure
2. P~sical and chemical_E_r~erties
3. ~ecifications and testi'!& methods
C. Data on stabili~
I . Long-term storag_e test
2. Severe test
3. Acceleration test
D. Data on toxici_ty
l . Acute toxic~
2. Subacute toxici!)'_
3. Chronic toxicity
4. Effects on r~oduction
5. Dei>_endence
6. Antigenici!)',
7. Mutag_enici_!Y
8. CarcinQg_enici!Y_
9. Local irritation
E. Data onj>_harmacol~ical action
l . Test supportirig effectiveness
2. Generalj>_harmacol~
F. Data on ADME
I . Abs()J"Qtion
2. Distribution
3. Metabolism
14. Excretion
5. Bioequivalence
G. Data on results of clinical trials

a b

0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0
0

x
x
x

x x x x x x
x x x x x x

0 0 0 0 0 0

0

0

x x x x x x
x x x x x x

x

0 0 0 0 0

0

#
#
x
x
x
#
x
x
#

0

0
0
0

#
#
#
#
#
0
0

0

x
x
x
x
x
x
x
x
x

x
x
x
x
x
x
x
x
x

x
x
x
x
x
x
x
x
x

0

x
x
x
x
x
x
x
x
x

x x x x x x
x x x x x x

#
x
0 x
0 #
x x
0

#
#
x
x
x
x
x
x
#

#
x
x
#
x

0 0 0

x
x
x
x
x
#

x
x
x
x
x
x

#
x
x
#
x
x

Key to symbols: o=Required #=Depending on the case x=Not required
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6

x
x
x
x
x
x

Table 1O: Description of clinical trial requirements for nonprescription medicines in
Japan
Class

Descri]J!ion

Clinical trials need to be conducted at more than five medical
Class 1 institutions with more than 150_£atients
Clinical trials need to be conducted at more than five medical
institutions with more than 150 patients
Note: Clinical data may be reduced to three medical institutions
Class 2 with 60 patients for those Rx-to-OTC switch drugs whose safety
and efficacy profile for general use has been well demonstrated by
clinical investigations or post-market surveillance previously
conducted.
Clinical trials need to be conducted at more than three medical
Class 3
institutions with more than 60_J>_atients
Clinical trials may need to be conducted at more than two medical
Class 4a
institutions with more than 40 _£atients
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MANUSCRIPT III
OTC SWITCH CASE HISTORY EVALUATION: NICORETTE®
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Abstract
As part of the FDA's current review of its regulatory approach to
nonprescription medicines, it is necessary for stakeholders to contribute to the ongoing
discourse. Reclassification of prescription medicines to over-the-counter status is an
important topic attracting the attention of many in the United States and elsewhere. This
article presents a detailed examination of FD A's application of switch regulatory policy,
the use of innovative consumer communication and education tools in the OTC
environment and overall public health impact of the switch using the Nicorette case as
an example. Post switch evidence shows that OTC reclassification of Nicorette achieved
the anticipated goal of balancing increased access with decreased control in the OTC
atmosphere resulting in a positive public health outcome in the area of smoking control.
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Introduction
The US Food and Drug Administration (FDA) is currently conducting a
comprehensive review of its regulation of nonprescription medicines and has asked for
public comment (1). Hence, interested professionals are closely scrutinizing the FDA's
application of regulatory policy for reclassification of prescription medicines to overthe-counter (OTC) status. Accordingly, to appraise a recent and successful OTC switch
from the perspectives of the regulatory basis and public health impact, the case of
Nicorette®is useful. The switch of Nicorette® chewing gum, a smoking cessation aid, to
OTC status by the FDA in 1996 is a unique and important example. This switch is very
important as it resulted in the availability of the first smoking cessation aid available
without a prescription for adults in battling nicotine addiction.
Within the context of studying the application of regulatory policy by the US
FDA in rendering switch decisions, this case is rather exclusive. The Federal Food,
Drug & Cosmetic Act requires that prescription control be applied to habit-forming
drugs as per Sec.503(b)(l). As the addictive properties of nicotine are widely
documented and acknowledged, the switch of Nicorette (that contains nicotine as active
ingredient) to OTC status is remarkable (2). Nicorette is distinctive among OTC
medicines, as it is part of a larger behavioral program that emphasizes individual
commitment to achieve smoking cessation. The concomitant tools used for effective
consumer communication employed by the sponsor in this case are also matchless
within the OTC medicines arena. For these reasons the OTC switch of Nicorette is
worthy of detailed examination.
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Background
Nicotine is a ganglionic cholinergic-receptor agonist (2,3). The pharmacologic
actions of nicotine are complex and include a variety of effects mediated by
stereospecific binding to receptors in autonomic ganglia, the adrenal medulla, the
neuromuscular junction, and the brain. Nicotine exhibits both stimulant and depressant
effects in the peripheral and central nervous systems. The principal pharmacologic
effect of small doses of nicotine is initial, transient stimulation of autonomic ganglia;
large doses or prolonged neuronal receptor exposure to nicotine results in subsequent
persistent depression of receptor activity. Nicotine produces marked CNS and
respiratory stimulation. The cardiovascular effects of nicotine generally are dose
dependent and are mediated principally via stimulation of sympathetic ganglia and the
adrenal medulla. Chronic use of nicotine may result in psychologic and physical
dependence, and tolerance to some of the pharmacologic effects may occur. As adjuncts
in the cessation of cigarette smoking, nicotine polacrilex and transdermal systems of
nicotine provide alternative sources of nicotine that help reduce the withdrawal
symptoms associated with nicotine dependence.
The FDA in January-1984 and June-1992 approved Nicorette 2mg and
Nicorette 4mg respectively. In December-1994, the sponsor submitted a supplement to
the new drug application (sNDA) to switch Nicorette from prescription to OTC status.
A summary of the proposed Nicorette OTC product is presented in table 1. The
proposed OTC doses and label indications were same as those for the approved
prescription product. At the time of switch application, Nicorette was available as a
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prescription product in over 50 countries and as a nonprescription product in over 30
countries.
On 28 September-1995, the Nonprescription Drug and Drug Abuse Advisory
Committees to the US FDA met jointly to consider the OTC switch application for
Nicorette®. Present on behalf of the Drug Abuse Advisory Committee (DAAC) were
four members and a consumer representative. The Nonprescription Drug Advisory
Committee (NDAC) consisted of seven members, one guest member and a
representative each from the industry and consumers. An analysis of the deliberations
that took place at this meeting (4) is presented in the subsequent sections. The
objectives are to expound the application of the OTC switch regulatory policy, evaluate
the regulatory options in rendering the switch decision by the Advisory Committees and
examine the public health consequences of this switch decision.
Open hearing
During the public comment section, Thomas Cooper, D.D.S., C. Everett Koop,
M.D., Alfred Munzer, M.D. and Rev. Herbert Watson Jr., stated their opinions on this
matter. Dr. Everett Koop, former Surgeon General speaking on his own as a physician
and private citizen supported the switch of nicotine gum from prescription to OTC use.
He said, "! believe one important answer is to make treatments that have been proven to
be safe and effective in the prescription setting more widely available by shifting them
to OTC availability. I believe nicotine gum is one of those treatments and I urge to
consider this switch application favorably. Smokers do want help. And everything that
we can do safely and prudently to get them that help will speed the day when we will
truly have a smoke-free society". Dr. Thomas Cooper, a dentist, retired professor,
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smoking-cessation researcher and a smoker for 36 years gave personal testimony on the
effectiveness of Nicorette in helping him quit nicotine addiction. He also endorsed the
safety of nicotine gum based on data observed from first hand experience as a
researcher in the area of smoking control. He urged that easily understood directions for
proper use are essential and that the benefits of OTC availability of nicotine gum are far
greater than the risks. Dr Munzer, Co-Director of the Department of Pulmonary
Medicine at the Washington Adventist Hospital and a past president of the American
Lung Association said that the reasons for making nicotine replacement therapy
available OTC are its safety, effectiveness and lack of significant interactions with other
medications. He added that the most important reason is, "because it answers a major
public health need".

Rev. Herbert Watson, Jr. , a pastor in East Baltimore and the board chairperson
for a program called Heart, Body, and Soul, a cooperative partnership between CURE, a
ministerial group in East Baltimore and the Johns Hopkins Center for Health
Promotion, who was instrumental in developing a church based smoking cessation
program stated his concern about the restrained access for nicotine gum within the
prescription setting. He emphasized the need for free and convenient access to nicotine
gum, not only in medically underserved communities, but also across the entire nation.
He encouraged the panel to make nicotine gum easily available to communities and
individuals who can use it safely and effectively.
.S..Oonsor presentation
The sponsor's presentation to assist the advisory committees in assessing the
risks and benefits and demonstrate the validity of Nicorette OTC switch can be broadly

90

di vided into five parts. An overview of the entire structure of the presentation was
followed by the epidemiology and treatment of smoking, results of prescription-to-OTC
switch development program for Nicorette and how they satisfy FDA's switch
requirements for safety and efficacy, risk-benefit analysis of Nicorette in terms of
dependence potential, abuse and misuse liability, and, marketing plan for Nicorette,
accompanying behavioral materials including development of the label for Nicorette
and how it satisfies the switch requirements for patients to self-select. The types of
studies conducted and results presented by the sponsor to elucidate each of the
aforementioned aspects have been tabulated in table 2. Information pertaining only to
the unique aspects of Nicorette in the context of OTC switches will be elaborated.
As the proposed OTC product was at the same doses and for the same
indication as the prescription product and as enormous post-marketing safety data in
prescription and OTC settings in a variety of regulatory environments was available,
proving the safety and efficacy for Nicorette 2mg and 4mg in the OTC setting was
relatively simple. The sponsor demonstrated the safety and efficacy by conducting
multi-center, simulated OTC actual use studies to replicate the absence of physician
intervention. The two most remarkable aspects of this OTC switch case are
demonstration of an acceptable risk in terms of dependence potential, abuse and misuse
liability and the development of labeling material and consumer communication tools
that facilitate effective self-selection in the uncontrolled OTC atmosphere.
The sponsor addressed the issue of long-term dependence by arguing that
mere long-term use of a medication does not indicate dependence. Additionally, longterm use must be characterized by compulsive use and impaired control, i.e. the drug
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comes to control your behavior. So long-term use in and of itself does not necessarily
mean dependence. Results from the meta-analysis of all the clinical trials that reported
long-term use showed that 18% of users still used the gum at the end of six months and
this statistic decreased to about one percent in two years. Among the special subgroup
of people who quit smoking by using the gum, the percentage using the gum at end of
six months was 35% and decreased to 3% in two years. Clearly, there was longer than
directed use observed in all the clinical trials. The reasons that the sponsor listed to
contend that these results do not represent long-term dependence were as follows:
(1) In the clinical trials, the nicotine gum was provided free of cost. A study where
people were randomly assigned to differently priced nicotine gum showed that
the simple intervention of having to pay for the gum decreased long-term use by
two thirds.
(2) Similar users of cocaine and cigarettes upon absence of any intervention showed
a very small decrease in the proportion of users over a two-year period, relative
to the fall to 3% with the nicotine gum.
(3) Further, there was no dose escalation observed among the long-term users with
the nicotine gum. Also, simple reassurance and education of long-term users
was adequate to wean them off the nicotine gum.
(4) The observed long-term use may be attributed to the fear of falling back into the
smoking habit having once quit smoking with the nicotine gum and residual
craving for nicotine upon smoking cessation that takes a long time to be weaned
off completely.
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The sponsor contended that the abuse liability associated with Nicorette was minimal
and acceptable. They asserted that in the context of abuse liability, more important than
the chemical effects of the drug is the drug delivery device. Upon cigarette smoking,
nicotine enters the arterial circulation from the pulmonary circulation and goes straight
to the brain without being diluted with the venous blood leading to high nicotine
concentrations. With the gum, nicotine is absorbed through the buccal membrane and is
diluted with the venous blood before entering the brain. Also, inhaling the drug is the
fastest way to get it to the brain. Hence, the addiction to nicotine via cigarettes is due to
the very rapid onset of the effect. The sponsor argued that the addiction to nicotine via
cigarettes is due to the high arterial concentrations, the rapid time to reach the brain, the
frequency of use and not due to the chemical per se. Also, when the dose of nicotine (as
cigarettes) was increased and the users were asked to rate their liking for nicotine, the
liking increased with the dose. With the gum, the response of the users was the opposite
as craving for nicotine decreased with higher dose. The differences in the responses
between cigarettes and gum were attributed to the different pharmacokinetic
characteristics. The potential for abuse by young adults was countered based on the
following:
(1) Nicotine chewing gum is difficult to chew and does not taste good (but is

palatable).
(2) Drug use among teenagers generally is initiated due to peer-pressure,
rebelliousness and anti-authoritarianism. Chewing gum is not considered "cool"
and does not conform to the badge behavior of being "cool" as is the case with
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alcohol or cigarettes. Also, increased doses with the nicotine chewing gum do
not lead to faster onset of action, but only increased nausea.
Based on this rationale of the benefits arising from increased access, especially for
young adults and medically underserved, and the minimal risks of long-term
dependence and abuse liability due to the benign pharmacokinetics of the nicotine
chewing gum, the sponsor urged the Advisory Committees to favorably consider their
OTC switch application.
The labeling for OTC Nicorette was developed based on labeling
comprehension studies and was suitable for sixth to seventh grade reading
comprehension levels. The marketing plan and associated consumer communication
methods proposed for OTC Nicorette were exceptional by any measure. The sponsor
claimed that its objective is to help Americans quit smoking and become Nicotine free.
Their two-fold strategy was to very carefully manage the expectations for the OTC
product and develop a marketing plan to balance control with the greater access of the
OTC product. The Nicorette target consumer was that smoker who has successfully
crossed the stages of thinking about quitting, firming up their determination to quit and
is ready to take action. The sponsor termed such smokers as "Committed Quitters" and
did not wish to speak to smokers in the evolutionary stages before the committed quitter
stage in their programs and marketing. The sponsor's advertising plan positioned OTC
Nicorette as an aid that can help quit smoking as opposed to a magic bullet. Further,
Nicorette OTC product was only one part of the complete package that would consist of
a user's guide, an audiotape and a number of program elements that are motivational
and can influence the individual's behavioral patterns and ability to successfully quit.
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The sponsor developed a program called the Committed Quitters (CQ)
program. The program becomes apparent immediately upon opening the package and
contains an 800 number encouraging the individual to call and enroll in a support
program. Upon calling the 800 number, the individual is interviewed to clarify the
reasons for their decision to quit and informed of the barriers they need to overcome to
successfully quit. Subsequently, a personalized user's guide calendar is put together for
the individual with the reasons driving their decision to quit and the barriers they could
not overcome in the past. Following initial enrollment in the CQ program, there are
about five interventions to help keep the individual from relapsing into smoking. If the
individual was chewing too many pieces of gum than recommended, there were also
programs that assisted them to wean off the gum, another 800 number is provided to
call and talk to a counselor who can assist the individual in weaning off the gum or who
has relapsed into smoking. The CQ program of which Nicorette OTC product was only
one part, was an active and interactive program for not only helping individuals as a
behavioral program but also assist those who have relapsed to smoking.
In terms of merchandising activities, the product would be priced above the

impulse level, it would not be sold in vending machines, no free samples would be
distributed even to physicians, it would be part of a theft deterrence program and would
be sold only to individuals above over 18 years of age. The sponsor also declared that
they were working with many insurance companies to urge them to cover this OTC
product and said that most insurers agreed to do so. In terms of cultural barriers, stores
in predominantly Spanish speaking communities would be provided with special 800
numbers and all the educational material would be in Spanish. As the proposed OTC
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product was relatively expensive, the sponsor had convened an independent advisory
panel to propose strategies for developing an outreach program for the medically
underserved areas and increasing their access to OTC Nicorette. The sponsor also
proposed the use of an exhaustive post-marketing surveillance program for OTC
Nicorette. As detailed here, the sponsor developed a comprehensive behavioral
program, pioneered the use of communication tools such as toll free numbers, audio
tapes and counselors to achieve effective consumer education, voluntarily committed to
numerous restrictions, clearly defined their target consumer and market positioning of
the OTC product, addressed the special needs of medically under served and ethnically
diverse communities and proposed a comprehensive post-marketing surveillance
program to balance control and increased access within the OTC setting. An
examination of the OTC medicines arena will clearly distinguish these aspects of OTC
Nicorette making it a unique and exclusive OTC switch.
FDA presentation
FDA focused on the methodology and results from labeling studies submitted
by the sponsor. The main concerns expressed in this area were:
(I) The sponsor conducted labeling studies based on the assumption that the intent
to heed (observing the directions) the label was a direct indicator of
comprehension (obeying the directions) when compared with the same for an
existing OTC product (as control). This assumption was not justified based on
results presented for self-selection of right dose (based on number of cigarettes
smoked), the decision not to use Nicorette by patients who had cardiovascular
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conditions or were pregnant, as subjects understood the label directions but did
not obey them.
(2) During the process of refining the label content, evaluative questions for the
subjects were phrased and iterated in such a manner to inevitably lead to the
desired response. Also, details of demographics were not presented to
understand the nature of the subject population. Questioning was leading and
did not delve into the attitudes and motivations that affect the actual behavior.
(3) Study methodology and design of questionnaire make it difficult to rely on the
results. They do not demonstrate with reasonable confidence that patients who
are directed to see a doctor first may do so at a high rate despite the warnings.
The following were comments on the results from two quit rate studies in the
prescription setting.
(1) Participants in clinical trials such as those for the NDA are different from
consumers in the general OTC population and quit rates may not be
representative of the actual results that may be expected in an OTC setting.
(2) The demographic distribution of the study samples also may not be as
representative of the smoking population who may elect to use the OTC
smoking cessation product.
Commenting on the issue of abuse and dependence, the FDA reviewer summarized that
most long-term use is seen in quitters than in non-quitters, who represent the positive
outcome. Continued use declines for Nicorette gum generally after six months to one
year and there are very few reports at two years.
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Regulatory options
FDA informed the committees and the sponsor that to approve an OTC switch,
it is essential that the following two conditions be met:
(1) The product is safe and effective under conditions of self-medication when used
as directed in the proposed label.
(2) The availability of the product in the OTC environment is of acceptable risk.
Additionally, the law states in this context that neither the toxicity of the drug,
the method of use, or any other potential harmful effect of the product
necessitate that the product remain prescription only.
These conditions offered the committees the criterion by which they were to
judge the suitability of Nicorette as an OTC medicine under the sponsor's plan. The
FDA officer stated that the Agency received numerous requests to address the issue of
pediatric access to therapeutic OTC nicotine upon publication of this meeting in the
Federal Register. The committees were requested to phrase their recommendations
solely in terms of what the Agency should accomplish. The committees were asked to
describe their recommendations in terms of the objective to be reached and not in terms
of specific means of accomplishment. Also, any recommendation to restrict the OTC
access to Nicorette will have to be subject to careful review and potential modification
by the Agency. The list of specific questions related to the proposed Nicorette OTC
switch, upon which the committees had to vote was also made available for discussion.
This list of questions is presented in table 3.
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Committee discussion
Over the topic of safety and efficacy, concern was expressed on adverse
effects related to Nicorette use in conjunction with smoking. The clinical data from
OTC use trials, original submission and post-marketing surveillance showed that
Nicorette was frequently used in combination with smoking, but there was no evidence
of any undue risk associated with this behavior. Also, it was suggested that the labeling
for both proposed OTC doses be indistinguishable and must reinforce the augmented
success with participation in a full behavioral/support program as opposed to just
chewing the gum. The sponsor was asked if there was a recommended time at which
users should restart the program, if they were not successful in quitting on first attempt.
The sponsor replied that there was no such recommendation being made. The issue of
the product being efficacious for adolescents (12 to 18 years) if purchased by a
responsible party and used under their supervision and pregnant women was raised. The
sponsor responded that while their clinical trials do not support any such conclusions,
there was empirical evidence that the product was effective in adolescents and a better
alternative than cigarettes for pregnant women. There was strong consensus that the
efficacy in the 12 to 18 year population needed to be studied. The committees' vote on
safety and efficacy ofNicorette in the OTC environment was unanimous in consent.
On question two (need for learned intermediary in special populations) posed
to the committees, it was concluded that adolescents, pregnant women and individuals
with coronary artery disease might require special physician intervention. During
discussion a committee member raised the consequences of making the product OTC in
terms of reimbursement. Specifically, the committees were concerned that the access to

99

the OTC product may be diminished due to lack of reimbursement if the prescription
product is eliminated. Under present law, it is not possible to classify the same product
for the same indications at the same dose simultaneously as OTC and prescription
products. Hence, the FDA was urged to retain both prescription and OTC
classifications. Also, the sponsor reassured that they would be working with managed
care organizations to make the coverage universal and they were in the process of
developing a pilot program to identify strategies that would help increase affordability
of the product especially to medically under served and poor section parts of our
population. The committees did not express any apprehension for misuse or abuse with
the exception of individuals chewing the gum longer than directed. However, that was
considered a positive cost benefit ratio provided the total tobacco consumption is cut
down. Also, the Canadian experience with the 2mg product, where it was OTC since
1993, reinforced the consensus that there was no serious risk of abuse.
Addressing the issue of special protection against abuse by children, the
committee strongly recommended the need for the Agency to take active steps in
examining the usefulness of nicotine replacement therapies in populations that are
beginning to use tobacco. The committees did not regard children as a potential source
of abuse for this product, but they were very concerned that the product was not
designed to assist children in smoking cessation due to lack of studies and urged the
FDA to devise solutions for this problem. The question related to efficacy claim based
on numerical quit rates is specific to the Nicorette case as the medication is part of a
larger behavioral program. Further, depending on the patients and the kind of
concomitant behavioral therapy they received, the quit rates vary form less than one

100

percent to over eighty percent. In order to manage the consumer expectations within a
clinically realistic domain and prevent a numbers war between sponsors based on
claims of effectiveness, this question was posed to the committees. The committees
strongly endorsed phraseology that would positively reinforce the consumer's
determination to quit without exaggerating the level of success. They urged that that
label refrain from any numerical characterization of quit rates and emphasize relief from
withdrawal symptoms (to assist in quitting) and participation in a concomitant
behavioral program.
An additional question that was also discussed by the committees was on the
subject of warnings related to concomitant medications. Specifically the question was,
is there a need to have specific warnings about theophylline and antidepressants or is a
general warning about prescriptive medications adequate? On this question the
committees arrived at the consensus that warnings on the label be general and broad in
nature against all prescription medicines and suggested that the label be subject for
review and change if evidence is found that such an action is necessary.
Post committee meeting
Based on the recommendations of the joint advisory panel, FDA approved
OTC status for Nicorette in both 2mg and 4mg strengths on 12 February-1996. In a
related talk paper, FDA stated that almost half of those who use Nicorette are able to
stop smoking for at least a few days, but many start smoking again. FDA also said that
most smokers must try to quit several times before they completely stop. Evidence also
suggests that the OTC availability of Nicorette led to an overall positive public health
impact by promoting cessation. A report published by the Center for Disease Control
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and Prevention in 1997 concluded that the OTC availability of nicotine medications
encouraged smoking cessation activity (5). Additionally, results of a study evaluating
the use of FDA approved pharmacologic treatments for tobacco dependence in the
United States between 1984 and 1998 published in 2000 indicated that the availability
of OTC products increased pharmacologically assisted quit attempts (6). The estimated
number of quit attempts ranging from 2 to 3 million during 1993-1995 increased to
approximately 6 million in 1996, coinciding with the availability of nicotine gum as an
OTC product. Also, the number of average monthly estimated quit attempts was
642,000 during May 1996-May 1997 when nicotine gum became available OTC,
compared with 259,000 during January 1993-April 1996.
Conclusion
This OTC switch demonstrates that the sponsor employed innovative
consumer education and communication tools, pioneered the development of
concomitant behavioral support programs and emphasized the enormous public health
benefit of OTC Nicorette in successfully obtaining OTC status for a habit forming drug
substance. Post switch evidence shows that OTC reclassification of Nicorette achieved
the anticipated goal of balancing increased access with decreased control in the OTC
atmosphere. It may be concluded that sponsors of OTC switch applications must devise
creative methods to balance the risk associated with increased access in an OTC
environment to maximize the overall public health benefit and effectively switch
prescription drugs to OTC status.
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Table 1: Description of proposed OTC Nicorette® product
Name

Nicorette~chewing gum formulation

Active

Nicotine from nicotine polacrilex

ingredient
Dose

2mg for smokers under 25 cigarettes a day and 4mg for smokers
over 24 cigarettes a day

Action

Stop smoking aid

Use

To reduce withdrawal symptoms, including nicotine craving,
associated with quitting smoking

Program

Committed Quitters program:
•

Six month duration

•

Toll free numbers for behavioral support and counseling

•

User's guide, audio tape and calendars

•

Starter kit of 108 pieces for 12 weeks, followed by refill pack
of 48 pieces

•

Emphasizes the importance of "individual commitment" in
successful quitting

Restrictions

•

Manages consumer expectations in a realistic manner

•

Not for sale to those under 18 years of age

•

Proof of age required

•

Not to be sold in vending machines
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Table 2: Summary of types of studies and information presented by the sponsor

Epidemiology, treatment and behavior associated with smoking

•

Mortality due to cigarette smoking and public health significance

•

Initiation of teenage smoking and difficulty in quitting without treatment

•

Rationale for nicotine replacement in smoking cessation

•

Effectiveness and success of nicotine replacement in conjunction with behavioral support in
smoking cessation

•

Evidence demonstrating smoker attitudes favoring "free access" in smoking cessation

Safety and efficacy ofNicorette in the OTC environment

•

Two 12 week long studies conducted to prove safety and efficacy in an OTC setting

•

One follow-up study to the above two studies was conducted at 6 and 12 month intervals
upon initiation of treatment to evaluate extensive treatment

•

Two studies were conducted to evaluate effectiveness in the prescription setting

•

Post-marketing safety data collected since the initial marketing ofNicorette

Risk-benefit assessment of making Nicorette available OTC

•

Higher cessation rates due to OTC availability ofNicorette

•

Prevention of tobacco related mortality due to OTC status

•

Dependence, abuse liability and misuse data from several sources

Development of labeling

•

Label comprehension studies

•

Additional components of marketing plan

•

Behavioral support and program
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Table 3: List of questions presented to the Advisory Committees for voting by the FDA
in relation to the proposed Nicorette OTC switch
Number

Question

1

Is there evidence to demonstrate that the product is safe and effective
through self-medication, when used as directed? This question was
posed for both the proposed 2mg and 4 mg OTC doses.

2

Are there some consumers who should use this product under the
direction of the physician or under the supervision of a physician?

3

Is there a risk of misuse or abuse of this product in the OTC
environment?

4

Should the Agency take appropriate measures to protect the misuse
or abuse of this product by children and adolescents?

5

Should the sponsor's efficacy claim be based on numerical quit rate
or a general statement indicating that the product is effective in
relieving withdrawal symptoms and of benefit in smoking cessation?
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MANUSCRIPT IV
OTC SWITCH CASE HISTORY EVALUATION: METAPROTERENOL
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Abstract
Globally, due to increasing use of nonprescription medicines, the associated
regulatory aspects are receiving close attention and scrutiny. The US Food and Drug
Administration (FDA) is presently conducting a comprehensive review of its regulatory
approach to nonprescription medicines. The FDA has asked if the Agency should itself
initiate prescription to over-the-counter switches. A response is presented through the
analysis of FDA's unsuccessful attempt, upon its own initiative, to switch
metaproterenol sulfate and the lessons derived from this unique switch case. Also,
certain important switch issues scheduled to be debated at an unprecedented joint
advisory committee meeting convened to consider a citizen switch petition in May
2001 , are addressed in this article. It is concluded that FDA is encouraged to initiate
switch proposals, but refrain from doing so unilaterally, and properly manage the
process of considering its switch proposals to ensure active participation of all
stakeholders.
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Introduction
Growing global interest in self-medication and related economic benefits
accentuate the importance of and necessity for a regulatory framework developed on the
basis of sound scientific principles. The US Food and Drug Administration (FDA)
recently announced a public hearing to evaluate the Agency's approach to regulating
over-the-counter (OTC) drug products (1). The purpose of the hearing was to solicit
information from, and the views of, interested persons, including scientists, professional
groups, and consumers. One specific question that the Agency posed in this context is:
should FDA be more active in initiating switches ofprescription products to OTC use?
In the development of an objective response to this question, it is helpful to

review and evaluate the well-known incident of the metaproterenol switch, when FDA
upon its own initiative allowed OTC marketing of metaproterenol and later had to
rescind on its decision. In the historical context of examining the application of FDA's
OTC switch policy, the metaproterenol case is unique and offers important lessons.
Hence, a detailed examination of the metaproterenol case history is of enormous
instructional value.
Background
In 1972, FDA initiated OTC drug review and rulemaking as to the classification

of OTC products as safe, effective and not misbranded. Initially, FDA established an
advisory panel for each of the twenty-six OTC therapeutic categories. After each
advisory panel completed its work, FDA published its Report and Proposed
Monograph, allowing a ninety-day comment period. After reviewing these comments

FDA published a tentative final monograph (TFM), allowing an additional thirty-day
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period for comments or request for oral hearing before the Commissioner, after which it
published a Final Monograph (FM) for the particular OTC product class.
Metaproterenol

was

first

approved

for

marketing

as

a

prescription

bronchodilator under an NDA in 1973 . As part of the OTC review, the Advisory Panel
on OTC cold, cough, allergy, bronchodilator and antiasthmatic drug products presented
its report to the FDA that was published in 1976 (2). This panel's report did not contain
any discussion pertaining to metaproterenol as no one presented any data or information
for its OTC use.
In October-1982 the FDA issued a notice of proposed rulemaking in the form of a TFM

for OTC bronchodilator drug products (3). In this TFM, FDA on its own initiative
included metaproterenol sulfate as eligible for OTC use although the advisory panel had
not examined its suitability for OTC use. As per the prevailing enforcement policy
mechanism, two pharmaceutical manufacturers began interim OTC marketing of
metaproterenol upon publication of the TFM and while awaiting the final monograph.
The controversy
Shortly after the OTC marketing of metaproterenol began, FDA started
receiving the first of many letters questioning the Agency's decision to allow
metaproterenol to be marketed OTC. The letters criticized, the decision to allow OTC
marketing, not notifying the professional community in advance and the Agency's
failure to await comment, or seek the advice of its Pulmonary-Allergy Drugs Advisory
Committee (P ADAC).
Specifically, some of the critical comments received by the FDA were:
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1. Recognized experts in the area of allergy treatment either disagreed or were
divided in opinion over the safety of metaproterenol under OTC conditions.
2. Pediatricians

expressed

concern

over

the

potential

misuse

of OTC

metaproterenol by children. Potential for misuse of OTC metaproterenol by
asthmatics seeking more relief by exceeding the dose instructions on the OTC
label.
3. As metaproterenol has a longer elimination half-life than epinephrine (another
drug used for similar conditions and was available OTC for a long time) the
drug could mask the symptoms of a serious asthma attack deterring persons in
need of immediate medical attention.
4. As metaproterenol had a longer onset of action, patients may overuse than the
recommended dosage under the mistaken belief that they are not obtaining the
expected relief at the suggested dosage.
5. There was unsatisfactory experience with OTC metaproterenol in other
countries. Although the drug remained OTC in some countries, Great Britain
had reverted the OTC status of metaproterenol sulfate inhalers and other similar
aerosol bronchodilators containing isoproterenol to prescription status on the
basis of misuse or improper use of such products that led to increased mortality
among asthmatics in the mid 1960s.
Resolution of controversy
In response to these criticisms, FDA arranged a meeting of its PADAC to

discuss the OTC status for metaproterenol. After the PADAC heard presentations from
the proponents, principal critics, FDA staff and the manufacturers who were marketing
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OTC metaproterenol on an interim basis, and based on its own deliberations, the
committee recommended to FDA that it rescind its decision to permit OTC marketing
of metaproterenol by a vote of 4 to 3.
FDA response
Following the recommendation of its PADAC, FDA published in the Federal
Register on 3 June-1983 that it has concluded that it should accept the advisory
committee's recommendation (4). FDA stated that it reached such conclusion based on:
1. Reservations within the medical community about whether metaproterenol
sulfate metered dose inhalers can be safely marketed without the safeguard of a
prescription limitation and professional supervision of the drug's use in
asthmatics. FDA intended to more fully consider such reservations before it
could allow metaproterenol to be marketed OTC.
2. The procedure by which metaproterenol was permitted to enter the marketplace
as an OTC product led to unintended confusion and controversy that, if allowed
to continue may, disrupt the relationship between physicians and their patients
and produce unnecessary anxiety among asthma sufferers seeking relief from
their symptoms through OTC therapy.
In order to further clarify the Agency's positions on this matter, FDA elaborated its

opinion on the safety of OTC metaproterenol and the regulatory mechanism by which it
was switched. FDA stated that the decision to switch metaproterenol to OTC status was
made in the context of an OTC bronchodilator market in which the only metered dose
inhaler products available were epinephrine preparations that the Agency believed to be
no safer or less effective than metaproterenol sulfate. FDA asserted that despite the
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advisory committee's recommendation to rescind, it continued to believe that a careful
weighing of the risks and benefits supports the proposal that metaproterenol sulfate
should be made available without prescription. On the concern that patients may not
follow carefully the label directions, FDA believed that asthmatic sufferers are capable
of understanding and heeding instructions for safe use of OTC metaproterenol. In
relation to potential for abuse by children, the Agency thought that essentially the same
potential existed for children using the product without parental supervision whether the
product was sold on prescription or OTC. Nevertheless, the Agency was committed to
respect the judgment of the specialists in the field who believed OTC metaproterenol
posed a public health risk and consequently decided to disallow the OTC marketing of
metaproterenol sulfate metered dose inhalers until the safety issues were resolved.
The Agency also explained its interpretation of the regulatory mechanism based on
which OTC sale of metaproterenol was allowed. The enforcement policy to include an
opportunity for FDA review for prescription to OTC switches before they occurred was
issued in 1975 and codified as 21 CFR 330.13 after allowing public comment. The
enforcement policy was later amended in 1982 (47 Federal Register, 17738, 23 April
1982) to permit a prescription drug to be marketed OTC if the drug is classified by an
OTC advisory panel in Category I (category of drugs that were found to be suitable for
OTC use as per the OTC Drug Review process). Also, a prescription drug may be
marketed OTC if FDA subsequently concludes that a drug not classified by an advisory
panel in Category I later tentatively qualifies for classification in Category I and so
states in a Federal Register announcement.
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FDA stated that the enforcement policy of 21 CFR 330.13 describes both a general
principle and a specific procedure. The specific procedure relates to drugs originally
considered by an advisory review panel. The general principle is that a prescription
product can be marketed OTC if it is included in the OTC Drug Review and FDA
tentatively concludes that it qualifies for Category I. The Agency reasoned that it
allowed interim marketing of OTC metaproterenol based on the general principle
underlying the enforcement policy of 21 CFR 330.13, although an advisory panel did
not consider this drug in its deliberation. In retrospect, due to the enormous public
criticism that this switch decision generated, the Agency conceded "the use of the
enforcement policy to allow interim marketing of metaproterenol sulfate metered dose
inhaler was inappropriate".

Discussion
Based on the metaproterenol expenence, it is possible to respond to FDA's
question stated at the outset of this article. This discussion of what FDA's regulatory
policy should be, on switching prescription products to OTC status, unilaterally, without
the support of sponsors is very timely, as FDA has decided to bring a citizen petition
seeking OTC status before a joint meeting of its advisory committees. The Agency's
PADAC and Nonprescription Drugs Advisory Committee (NDAC) met in an open
public hearing on 11 May, 2001 to consider a citizen petition submitted to request the
switch of fexofenadine hydrochloride, loratadine and cetirizine hydrochloride (three low
and non-sedating antihistamine drugs) to OTC status (5). This response also addresses
some important questions to be debated at this "unprecedented" joint advisory
committee meeting (6).
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Under the current regulatory framework the FDA can initiate a prescription to
OTC switch based on two separate mechanisms, 21 CFR 330.13 which is part of the
OTC monograph procedures or 21 CFR 310.200 known as the switch regulation.
Although, the metaproterenol case was not based on the switch regulation (21 CFR
310.200) the key instructional principles from this controversy may be applicable to
both circumstances.
From the metaproterenol case, it is abundantly clear that the primary cause for
controversy was the lack of adequate notice and opportunity for comment, to all
interested parties that would be affected by the switch proposal. It is informative to note
that although FDA published its proposal to switch metaproterenol to OTC status as a
TFM in the Federal Register, the Agency did not receive much comment on this matter
except for two manufacturers who stated their intention to market this OTC product.
However, the criticism against the switch proposal mounted rapidly once the interim
OTC marketing of the product began. This clearly demonstrates that the proposed
rulemaking published in the Federal Register as a TFM failed to reach to all
stakeholders interested in this switch proposal. It may be reasoned that a forum such as
a public advisory panel review meeting would have been more successful in facilitating
effective participation from all interested stakeholders. In fact, FDA's statements in
explaining its actions buttress this reasoning. The Agency stated that, "Not only would
the panel's deliberation afford notice that a "switch" of an ingredient was under
consideration but those who might object to the switch could convey their concerns to
the panel. Finally, any prescription drug converted to OTC status after initial
consideration by an advisory panel was necessarily reviewed by outside experts (i.e.,
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the panel members), in addition to medical staff, before any conversion was allowed to
take place".
Based on, the growing societal preferences for self-medication, the experiences
with medically safe and economically beneficial practice of responsible self-medication
since the OTC Drug Review and the learning from the metaproterenol case, the FDA is
encouraged to initiate switch proposals that it considers to be safe and effective in an
OTC environment and offer overall public health benefit. But, the Agency, in the
absence of support from the sponsor, must refrain from unilaterally switching
prescription medicines to OTC status except under the very rare circumstances of
overwhelmingly dire public health necessity. The Agency must switch medicines to
OTC status by ensuring active participation from all interested parties such as the
scientific, medical, pharmacist, industry, public and consumer interest communities in
the evaluation of its switch proposals and before reaching a decision to allow OTC
marketing. The metaproterenol case proves that the FDA could have enormously
benefited in its decision making, if it was aware of the rationale on which opposing
groups thought that metaproterenol was not suitable for OTC marketing and objected to
its switch. Regardless of the enforcement mechanism (OTC monograph or switch
regulation) the Agency must achieve effective participation of all stakeholders in an
open and transparent manner before reaching a final decision to allow OTC marketing.
Conclusion
The case of metaproterenol OTC switch by the FDA upon its own initiative
offers valuable information in the comprehension of FD A's application of OTC switch
regulatory policy. The FDA is encouraged to initiate switch proposals that it considers
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to be safe and effective in an OTC environment and offer overall public health benefit.
The learning from the failed metaproterenol switch demonstrates that a collaborative
effort with the sponsor and all interested parties is more likely to result in a
scientifically robust switch decision. Hence, the Agency must properly manage the
consideration of switch proposals that it has initiated by ensuring active participation of
all possible stakeholders that may be impacted by its rulemaking.
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EVALU A TI ON OF PROPOSED OTC SWITCH FOR LOVAST A TIN
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Abstract
Heart disease is a major cause of mortality among Americans, and the risk factor
of cholesterol elevation is well recognized. Making effective drug therapy more readily
available to consumers could facilitate improvements in managing this very costly
problem. Thus, it has been suggested that making antihyperlipidemic products available
over-the-counter (OTC) may contribute a solution. The goal of this article is to describe
and evaluate clinical data presented as evidence in determining the benefit to risk ratio
of lovastatin in the OTC setting and draw pertinent inferences from this switch case.
Based on the lovastatin switch experience, it may be reasoned that for drugs used for
chronic illnesses, that require the involvement of a learned intermediary, it may be
feasible to favorably balance the benefit to risk by classifying them under an
intermediate, pharmacist controlled class of drugs, where a physician's prescription is
not required.
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Introduction
Heart disease is a major cause of mortality among Americans, and the risk factor
of cholesterol elevation is well recognized. Hyperlipidemia affects 50 million
Americans and the first approach to lowering cholesterol levels is through lifestyle
changes. However, most patients are unable to sustain such lifestyle changes over the
long term. Making effective drug therapy more readily available to consumers could
facilitate improvements in managing this very costly problem. Thus, it has been
suggested that making antihyperlipidemic products available over-the-counter (OTC)
may contribute a solution.
Attempts to switch two antihyperlipidemic products from the "statins class" of
drugs to OTC status in the United States were made in 2000. One such product was
lovastatin (Mevacor®). The goal of this article is to describe and evaluate clinical data
presented as evidence in determining the benefit to risk ratio of lovastatin in the OTC
setting and draw pertinent inferences from this switch case. The Mevacor® switch case
is exceptional and offers key lessons related to application of US Food and Drug
Administration's (FDA) OTC switch policy. A detailed review of the Mevacor case
history is central to comprehending the current positions of interested parties and FDA's
opinion, on switching products to OTC status for chronic illnesses such as
hypercholesterolemia.
Background
Lovastatin (Mevacor®) has been marketed in the United States since 1987 as a
prescription drug, at doses of 1O mg a day to 80 mg a day. It is indicated for use as an
adjunct to diet for the reduction of elevated total and LDL cholesterol (TC and LDL-C)
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in patients with primary hypercholesterolemia, when the response to diet restricted in
saturated fats and cholesterol and, to other nonpharmacological measures alone has
been inadequate. It is also indicated to slow the progression of coronary atherosclerosis
in patients with coronary heart disease (CHD), as part of a treatment strategy to lower
TC and LDL-C to target levels.
The manufacturer of Mevacor presented to the FDA, a switch application
describing their rationale for OTC access to lovastatin at 10 mg a day (1 ). The sponsor's
target population consisted of individuals (men over the age of 40 and postmenopausal
women) without CHD. The issue of OTCness of cholesterol-lowering drugs was
addressed previously at two meetings of joint advisory committees to the FDA in 1995
and 1997, when an application for the OTC switch of Questran® (a prescription product
that contains cbolestyramine resin, which is a bile acid sequestrant antilipemic agent)
was discussed and refused. Following the 1997 meeting, FDA published a guidance
document indicating that hypercholesterolemia was not an OTC indication (2). The
guidance concluded that irrespective of the intrinsic safety and efficacy of the drugs
targeting this disease, hypercholesterolemia per se, was not an OTC disease. It also
stated

that

healthcare

practitioner

supervision

was

necessary

in

diagnosis,

individualization of treatment, and in follow-up, and that safe and effective use of drugs
in this area and the overall treatment of the disease could be assured only within the
context of prescription access.
Against this background, the Agency convened a joint meeting of its
Nonprescription Drug Advisory Committee (NDAC) and Endocrine and Metabolic
Advisory Committee (EMAC) on 13 July 2000 to consider this switch application and
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address the ''precedent-setting issues" raised by the OTC Mevacor petition (3).
Open hearing
Several interested parties strongly endorsed the proposed OTC status for
lovastatin during the open hearing (4). Dr. Ernest Madu, Cardiologist and Assistant
Professor at Vanderbilt University speaking on behalf of the Association of Black
Cardiologists, Dr. Rene Rodriguez, an orthopedic surgeon and President of an
organization of Hispanic physicians, Dr. Debra Judelson, an internist, cardiologist and a
past president of the American Medical Women's Association, Suzie Hughes, a nurse
clinician in the Department of Preventive Cardiology at the Cleveland Clinic
Foundation, representing the Board of Directors of the Preventive Cardiovascular
Nurses Association, Dr. John A. Gans, Vice President of the American Pharmaceutical
Association, Dr. Penny Kris Etherton, a distinguished professor of Nutrition at Penn
State University and a member of the second Adult Treatment Panel of the National
Cholesterol Education Program (NCEP-ATP 11), Brett Kay of the National Consumers
League, Dr. Bernie Kasten, Vice President and Chief Medical Officer of Quest
Diagnostics Ventures and a pathologist, Mr. Warren Pinckert of Cholestech
Corporation, a company that manufactures a point-of-care clinical instrument and has a
national testing service, Dr. Tom Pearson, Chair of the Department of Community and
Preventative Medicine at the University of Rochester, made statements supporting the
proposed OTC switch. In summary, these groups based their endorsement on, the
serious need to increase access to medicines to eliminate risk factors for cardiac
diseases, the established safety and efficacy profile of lovastatin, surging interest for
patient involvement in pharmacotherapy, the availability of technology to rapidly and
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easily obtain cholesterol levels by the public, to offer new pharmacological
interventions for minorities and medically underserved communities who are at greater
risk for cardiac diseases and to make available proven medicines beneficial to the
general public who are increasingly using unproven and untested products in the form
of dietary supplements and other traditional medicines for cholesterol lowering.
Dr. Sidney Wolfe of Public Citizen's Health Research Group strongly opposed the
proposed switch. The basis for this conflicting view was, serious questions about the
accuracy of several home diagnostic kits for cholesterol testing because of the
inexperience of the user; serious problems in self-selection which would not likely be
detected in the real world relative to experimental world where people screen
themselves, often without a cholesterol test and decide to use the drug; lack of evidence
of cholesterol reduction in any group with a 10-milligram dose and with a 20 to 40milligram dose the lack of clinical benefit for cases with HDL cholesterol (HDL-C)
over 40; diet and exercise may be thought to be less important if the primary strategy is
an OTC statin drug; excessive drug interactions associated with lovastatin and an
unacceptable benefit-to-risk ratio.
Sponsor presentation
The sponsor stated that OTC lovastatin targets use for primary prevention in a
population that was generally not recommended for treatment under NCEP-ATP II
guidelines. Specifically, the nonprescription lovastatin treatment population was defined
as being men aged 40 and older, and postrnenopausal women (at least 1 year past last
menses), without CHD and with TC of 200 to 240 mg/dL and LDL-C ~ 130 mg/dL (5).
On this basis, the sponsor estimated that there are approximately 15.5 million men and
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women potentially eligible to choose self-treatment with nonprescription lovastatin in
the United States.
The sponsor justified its request for OTC Mevacor based on: (1) existing
guidelines for cholesterol-lowering treatment conserved pharmacological treatment only
for those at highest risk for CHD (2) a substantial proportion of CHD events occur in
men and women with average TC who were generally not recommended by existing
guidelines for prescription cholesterol-lowering treatment, and (3) for motivated men
and women in the OTC-eligible population, access to the nonprescription lovastatin
treatment program of drug therapy and extensive education and support would provide
an effective new option for lowering cholesterol and maintaining cardiovascular health
(6).

Efficacy
The benefit of treatment with lovastatin 10 mg daily m the defined OTC
population was demonstrated using these approaches (7):
•

Observing the effect on lipid parameters associated with CHD risk (i.e., TC, LDLC, HDL-C and ratio of TC/HDL-C).

•

Observing the percentage of OTC eligible men and women who attain desirable
levels of TC and LDL-C as defined in NCEP ATP-II guidelines.

•

Estimating the effect on reduction of first acute CHD events (defined as fatal or
nonfatal myocardial infarction (Ml), unstable angina or sudden cardiac death) in the
OTC-eligible population.

Results were based on four studies that specifically measured the lipid-modifying
efficacy of the lovastatin 10-mg regimen; 2 double-blind, placebo-controlled trials and 2
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open-labeled trials. For reference, the efficacy of the 20-mg daily regimen oflovastatin,
the usual prescription starting dose, was used. The effects of the 20-mg regimen are
based upon data from 2 large, double-blind, placebo-controlled clinical trials: Air
Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) and
Expanded Clinical Evaluation of Lovastatin (EXCEL).
The sponsor stated that majority of individuals treated with 10-mg daily
regimens attained desirable levels of TC (<200 mg/dL). The vast majority treated with
10 mg achieved the NCEP-ATP II goal for primary prevention (68.8% to 75% had
LDL-C<130 mg/dL). Notably, 17.4 to 25.7% of individuals treated with 10 mg also
attained the goal targeted for secondary prevention (LDL-C< l 00 mg/dL), and this
percentage was similar to the 21.5% observed with lovastatin 20 mg in
AFCAPS/TexCAPS. Based on these results, the sponsor asserted that permitting the use
of lovastatin 10 mg daily in an OTC population would allow the majority of users to
achieve desirable levels of these atherogenic lipids, even without dose titration.
Lovastatin 10 mg/day was the lowest approved prescription dose. Studies in
OTC populations revealed that lovastatin favorably modifies lipids by reducing TC11 %, LDL-C-18% and TC/HDL-C-15% and increasing HDL-C-7%. As the OTCeligible population was defined as having TC<240 mg/dL, LDL-C is expected to be less
than 160 mg/dL for a majority of those who are OTC-eligible. With lovastatin 10 mg
daily, approximately 70% of OTC eligible men and women could attain levels of LDLC considered by NCEP-ATP II to be desirable for high risk primary prevention patients
(LDL-C <130 mg/dL). The risk of first CHD event was estimated to be reduced by 35%
based upon reductions observed in the TC/HDL-C ratio with lovastatin 10 mg daily.
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Given these data, the sponsor suggested that lovastatin 10 mg/day represents a
conservative but effective and appropriate dose for OTC therapy.
Pharmacology and pharmacokinetics
The sponsor reviewed the human pharmacology and pharmacokinetics of
lovastatin to show that, lovastatin is an inactive lactone that, upon hydrolysis, is
converted to the P-hydroxyacid (coded L-154819) that is an inhibitor of HMG-CoA
reductase (8). Lovastatin and its active metabolite P-hydroxyacid are highly (>95 %)
bound to human plasma proteins. Lovastatin is extensively metabolized to active and
inactive metabolites including, L-154819 and four other lactone: P-hydroxyacid pairs,
all of which account for about 80% of the total HMG-CoA reductase inhibitory activity
observed in plasma. Lovastatin at the 10-mg dose was not an inhibitor of CYP3A4 (Ki
= 7. 7 µM) in humans. Biliary excretion is an important route of elimination. L-154819
is rapidly cleared from the body (total body clearance and half-life averaged 639
mL/min and 1.5 hours, respectively). The systemic availability of L-154819 following
an oral dose of lovastatin is less than 9% of the dose because of first-pass hepatic
extraction. The plasma area under the curve (AUC) of active and total HMG-CoA
reductase activity increased 2-fold in patients with severe renal impairment (GFR=l 0 to
30 mL/min). Nonprescription lovastatin was not to be used in patients with renal
insufficiency without consultation with a physician. When lovastatin was administered
with food, as in clinical studies, the AUCs of active and total inhibitors are about 50%
higher compared to administration in the fasting state. For maximum benefit, lovastatin
should be given with meals. With lovastatin dosages of 10-, 40-, 60-, 90-, and 120-mg,
peak concentrations are achieved in 3 to 5 hours and the AUC and Cmax of both active
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and total HMG-CoA reductase inhibitory activity in plasma increase nearly
proportionally with dose. With once-a-day dosage regimens of lovastatin (10,40 or
80mg) there is modest steady-state accumulation of active and total inhibitors in plasma
(<10 to 50%). These data indicated that the pharmacokinetics of lovastatin are linear
throughout the therapeutic dosage range. Upon co-administration with a potent inhibitor
of CYP3A4 (such as itraconazole), the plasma exposure to active or total HMG-CoA
reductase inhibitory activity on the 10-mg dose of lovastatin was below the plasma
exposure observed following 80-mg of lovastatin, the maximum approved prescription
dose. No dose adjustment was required during co-administration of nonprescription
lovastatin with less potent inhibitors of CYP3A4, including calcium channel blockers
and moderate daily consumption of regular-strength grapefruit juice. Appropriate
labeling was proposed to reduce the likelihood that potent CYP3A4 inhibitors will be
used concomitantly with nonprescription lovastatin.
Safety
The proposed nonprescription dose of 10 mg has been available by prescription
and was estimated to account for approximately 720,000 patient-years of treatment (3%
of total use). Long-term, chronic use of lovastatin was generally well tolerated in both
EXCEL and AFCAPS/TexCAPS participants (9). The safety profile of lovastatin 20 to
40 mg/day was comparable to that of placebo. A review of the worldwide adverse event
data did not reveal a new association between lovastatin and any adverse experience not
currently included in the package circular. The spontaneous reports generally reflected
the known side effects of the drug (myopathy and aminotransferase elevations),
previous warnings within the product circular (lenticular disorders), or concomitant
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disease in the patient population (congestive heart failure, myocardial infarction). Doseproportional increases in hepatic transaminases (>3 x Upper limit of normal (ULN))
were observed with lovastatin; however, in studies of lovastatin 20 to 80 mg/day, the
incidence with 20 mg was no different than that observed with placebo. The
spontaneous reporting rate for serious hepatic adverse experiences of heterogeneous
pathology was extremely rare, on the order of 10 per million patient-treatment years of
lovastatin, did not appear to be dose related, and the relationship to lovastatin is unclear
in many of the reports. Routine monitoring of liver function tests (LFT) in users of
nonprescription lovastatin was expected to produce a high proportion of abnormal tests
which were not indicative of any hepatotoxicity associated with lovastatin. Routine
monitoring of LFT did not reduce the extremely low risk of serious liver disease in
people taking lovastatin 10 or 20 mg daily. The risk of myopathy or rhabdomyolysis
was low and dose related. In clinical trials, the incidence of myopathy in those receiving
lovastatin 20 mg daily was similar to that reported for those taking placebo. There were
no reported cases of rhabdomyolysis during marketed prescription use of lovastatin 10
mg daily. Myopathy is a rare symptomatic condition that can be recognized by patients
with warnings provided in the nonprescription lovastatin label. The condition usually
resolved after discontinuation of the drug. There was no apparent association between
exposure to lovastatin during pregnancy and the occurrence of any adverse pregnancy
outcomes. However, the number of reported cases with a known outcome was small. In
view of the limited benefit of this drug in premenopausal women, nonprescription
lovastatin was to be indicated only for postmenopausal women and would be
contraindicated m pregnancy. The lack of evidence for risk may provide some
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reassurance to women who are inadvertently exposed to lovastatin during pregnancy,
and to the health care professionals responsible for their care. Other lipid-lowering
agents (gemfibrozil and niacin) may increase the risk of myopathy through an unknown
mechanism in patients taking any of the HMG-CoA reductase inhibitors. Concomitant
treatment with potent CYP3A4 inhibitors may increase plasma HMG-CoA reductase
inhibitory activity levels, and therefore may increase an individual's risk of myopathy.
The risk of myopathy was very low with lovastatin 10 mg and 20 mg daily regimens,
and would be expected to remain low even with concomitant use of a potent CYP3A4
inhibitor. Use of these drugs concomitantly with lovastatin was contraindicated on the
nonprescription label.
Long term, chronic use of lovastatin at prescription doses of 10 to 80 mg daily
has been well tolerated. In controlled clinical trials, the safety profile of lovastatin 20
mg daily was comparable to that of placebo. Asymptomatic serum transaminase
elevations were dose-dependent, and were not proved to progress to clinical liver
disease even when drug therapy is continued; the incidence of confirmed ALT
elevations (>3 x ULN) was similar with lovastatin 20 mg daily and placebo. Clinically
apparent liver disease (hepatitis, hepatic failure) associated with lovastatin use at any
dose was very rare. Therefore, the sponsor argued that routine monitoring of LFT was
not of value in users of lovastatin 10 mg once daily. Although myopathy, and
rhabdomyolysis are considered the adverse experience of primary concern for the
HMG-CoA reductase inhibitors, both clinical study expenence and market-use
experience indicated that their occurrence is rare. The risk of lovastatin-associated
myopathy increased with increasing dose of lovastatin. In postmarketing experience
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collaboration with healthcare professionals. The ESP focused before purchase, on the
infonnation necessary for consumers to make an appropriate purchase decision and,
after purchase on the information needed to refine and extend the understanding of the
product and its use.

The importance of cholesterol testing and monitoring was

emphasized both before and after purchase. Before the purchase decision is made,
eligibility criteria for the initial selection of the product was introduced through
informative advertising which provides the basic information about who should and
should not use the product. The carton label then summarized all information necessary
for an appropriate purchase decision. After purchase, the consumer has access to several
label reinforcement tools contained within the package that refines the product selection
decision. More comprehensive information was available after purchase and educates
consumers on the importance of a healthy lifestyle and encourages long-term use in
order to maintain the benefit. The core elements of the labels specified the age and stage
of life when men and women are at increasing risk of CHD and therefore most likely to
obtain the benefit. Also listed were specific values for TC and LDL-C and those who
should not use the product reflect the warnings from the prescription labeling.
Additional materials called label reinforcement tools were also provided. These
included the package insert, a video-tape which introduces and reinforces the label
messages, an information booklet on cholesterol and the importance of maintaining a
healthy lifestyle and further communication links beyond the package for the purpose of
promoting appropriate use. A key feature of the ESP was the toll-free service which was
developed and tested in the sponsor's studies. Use of the toll-free service was
encouraged, not only for questions, but for reinforcement of key label messages after

131

purchase. By talking with the product specialists at the toll-free service, consumers
could learn more about their eligibility and appropriate use of the product. This service
recommends that consumers with higher risk of heart disease see their doctors and
provided an information card to enroll them in the compliance program. The
compliance promoting features were a key element of the product which requires longterm use to achieve the benefit. Once enrolled the consumer received a series of regular
newsletters with information, aids and the use of Mevacor OTC over the long term in
increasing and maintaining a healthy lifestyle. Further, it emphasized the importance of
reassessing ones risk profile over the long term. Also provided was a wallet-sized
reminder card for tracking lipid changes and avoiding potentially interacting drugs. The
product was contained in compliance-promoting calendar packaging. Cholesterol
testing and monitoring was encouraged throughout the process and a healthcare
professional could help guide the consumer at any time in the process. The first thing
consumers recognized upon opening the pack was the need to know their cholesterol
numbers. The ESP encouraged consumers to obtain a complete lipid profile and
provided guidance on where in the community to have a test conducted. Four
increasingly improved versions of the labeling materials were tested in a series of label
comprehension tests and in-home use studies. The final label was the one submitted in
the NDA. The first three labels were tested sequentially in three in-home use studies
conducted in community settings where consumers used the product under simulated
real-world conditions. One study was conducted from actual retail pharmacies and
allowed long-term use of Mevacor for up to 18 months. Two studies were conducted in
rented store space in local shopping centers and tested the toll-free service. Follow-up
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surveys were conducted in subsets of study participants in order to supplement the
information collected from the clinical studies A fourth study, was ended early due to
poor enrollment. The sponsor also conducted three label comprehension tests finishing
with one round of improvements to create the NDA label. These studies showed that
effective labeling guided most consumers to make an appropriate selection decision and
that the ESP further improves the correctness of that decision to use the product.
The sponsor asserted that consumer behavior testing showed that, (a) most
consumers made an appropriate product selection decision (b) accuracy of the product
selection decision was further improved when consumers reviewed the label
reinforcement tools contained in the package (c) toll-free telephone label reinforcement
service was highly effective as a label reinforcement tool (d) results support the
conclusion that the nonprescription lovastatin 10 mg labeling system of communication,
education and support effectively guides consumer product selection (e) comprehension
testing showed that strong scores were achieved on key messages in the general
population and the safety subgroup, and that low literacy subgroup scores were also
acceptable.
The sponsor stated that even though excellent label comprehension was
achieved, additional minor refinements were made to further enhance the final label
submitted in the NDA. These minor refinements included: reformatted liver disease and
pregnancy warnings for increased prominence; strengthened drug interaction warning
text; doctors and pharmacists added as individuals the consumer can contact to
detennine if they are taking a "Do Not Use" medication; and a caution to consumers
with continuing medical conditions that they may need further medical care.
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The sponsor concluded that, (a) consumers maintain or improve eating and
exercise habits while taking nonprescription lovastatin 10 mg in a nonprescription
setting (b) a substantial segment of interested consumers comply well with long-term
daily dosing with nonprescription lovastatin 10 mg to achieve clinically meaningful
lipid changes, and (c) nonprescription lovastatin labeling system encourages
collaboration with health care professionals.
FDA PRESENTATION
OTC population and efficacy
AFCAPS/TexCAPS was a randomized, double-blind, placebo-controlled clinical
trial designed to demonstrate that treatment with lovastatin 20 to 40 mg every day in
6,605 patients without clinical evidence of CHD and moderately elevated TC and LDLC and low HDL-C levels would reduce the incidence of a first acute coronary event
(composite endpoint consisting of: fatal CHD; nonfatal MI; and unstable angina). After
a mean follow-up duration of 5 years, treatment with lovastatin 20 to 40 mg daily in
conjunction with a low saturated fat diet resulted in a 37% risk reduction in
experiencing an acute coronary event compared to placebo.
The selection of study subjects in the OTC Mevacor development program was
based on the sponsor's definition of the target OTC population. A review of the OTC
efficacy data by the FDA found that HDL-C level was never specified as a criterion for
selecting these individuals from the primary prevention population who would be
eligible for treatment with lovastatin (11). AFCAPS specifically enrolled individuals
with below average HDL-C levels based on an exclusion criterion specifying that HDLC levels be <45 mg/dL in males and <47 mg/dL in females. When the estimates of CHD
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risk and treatment benefit were summarized in the OTC-eligible subgroup of AFCAPS
based on baseline HDL-C levels; of <35, 35 to < 40, and 2': 40 mg/dL, the risk reductions
were greatest in those with HDL-C levels <40 mg/dL. There was no treatment
difference seen in those individuals with HDL-C levels 2':40 mg/dL who otherwise met
the sponsor's definition of being eligible for nonprescription lovastatin treatment.
A subgroup (n=4,092) of the AFCAPS/TexCAPS cohort was selected for
baseline lipid levels which matched those of the OTC-eligible population. After
excluding for the presence of diabetes and/or use of multiple antihypertensive
medications, there were 3,805 patients (57.6%) remaining in the AFCAPS/TexCAPS
cohort meeting the eligibility criteria for treatment with nonprescription lovastatin. Of
these, 1,884 (49.5%) were treated with lovastatin 20-40 mg daily and 1,921 (50.5%)
were treated with placebo. Based on analyses of the AFCAPS OTC-eligible subgroup,
treatment with lovastatin 20-40 mg per day for an average of 5 years resulted in a 44%
reduction in risk of experiencing an MI, unstable angina, or sudden cardiac death
compared to placebo. From these results, the sponsor concluded that treatment with
nonprescription lovastatin in the targeted OTC-population could reduce the risk of
CHD. FDA asserted that this conclusion may not be valid based on the following:
•

The lovastatin dose for which a clinical benefit was demonstrated is 2 to 4 times
higher than the proposed nonprescription dose. The LDL-C lowering results
associated with the 20 to 40 mg per day dose are not comparable to the
nonprescription dose.

•

The average duration of treatment in AFCAPS/TexCAPS exceeds the treatment
duration observed in any trial conducted in the OTC clinical development program
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•

The benefit of lovastatin treatment in the AFCAPS/TexCAPS OTC-eligible
subgroup was greatest in those with HDL-C levels

~40

mg/dL. In the targeted OTC

population, the majority of individuals had HDL-C levels exceeding this value,
suggesting that any potential benefit will apply to a much smaller proportion of the
target OTC population than estimated by the sponsor.
Based on the data reviewed from studies in the OTC development program and
the OTC-eligible AFCAPS cohort, the FDA medical review concluded that the
sponsor's proposal cannot be justified for the following reasons (12):
•

The clinical benefit of lovastatin treatment observed in AFCAPS was associated
with the 20 to 40 mg dose whereas the proposed nonprescription dose is 10 mg. The
LDL-C lowering effect of 20 mg in AFCAPS exceeds that of the 10 mg dose
observed in the efficacy study.

•

The risk reductions associated with lovastatin therapy in AFCAPS was over an
average 5-year treatment duration with approximately 70% of those randomized to
lovastatin treatment remaining on therapy for this duration. In contrast, the actualuse studies suggest that any potential benefit associated with nonprescription
lovastatin use will be limited by the high number of individuals discontinuing
treatment after a few months of treatment.

•

The potential clinical benefit of nonprescription lovastatin relies on the ability of the
consumer to appropriately initiate treatment based on his/her CHD risk profile. The
individuals in the primary prevention population most likely to benefit from drug
treatment are those with low HDL-C levels. The sponsor did not evaluate whether a
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consumer could appropriately initiate drug treatment based on his/her HDL-C level
since this criterion was not on the proposed package label.
Hence, the FDA medical review concluded that, "the aforementioned reasons add
significant uncertainty to any estimates of benefit associated with lovastatin 10 mg use
in the nonprescription setting. Given the unknown clinical cardiovascular benefits of
treating the primary prevention population with the unrestricted availability of
lovastatin 10 mg, the benefit-to-risk relationship of this drug in this population cannot
be adequately assessed. "

Safety
FDA argued that safety evaluation of OTC lovastatin should not be limited to
the I 0 mg dose because in the OTC setting due to unrestricted access some individuals
will self-titrate. At the I 0-milligram dose FDA found that the safety and tolerability of
the I 0 mg dose of lovastatin to be comparable to that of placebo. And the incidence of
myalgias was low and similar across the studies.

There were no cases of

rhabdomyolysis, myoglobinuria, or liver toxicity reported. At the higher dose of
lovastatin, FDA found that consecutive elevations in liver enzymes to more than
3xULN was dose related and at the highest approved dose, the instance was about 1.5
percent, but there were no cases of liver toxicity associated with this enzyme elevation.
FDA contended that the sponsor acknowledged this safety concern, and
proposed that this concern can be adequately conveyed to consumers through proper
labeling. The sponsors proposal was to warn/advise consumers not to take
nonprescription lovastatin if they were on any medications such as erythromycin,
clarithromycin, ketoconazole itraconazole, nefazodone, cyclosporin, protease inhibitor,
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niacin, gemfibrozil, or any other prescription statin drugs. FDA asserted that this was an
extensive list and likely to increase as more drugs are approved. So FDA felt that this
method of risk communication was challenging to the consumer. This method of risk
communication in the prescription setting was apparently not effective enough to avoid
some of the drug-related toxicities. So it raised concern that the proposed method of risk
communication for OTC lovastatin may also be ineffective.
A comprehensive review of post marketing safety surveillance of all currently
available statins in the United States by the FDA led to the conclusion that a significant
concern exists over liver failure associated with HMG-CoA reductase inhibitors given
that liver transplants, irreversible and fatal hepatic damage, have occurred. Of the liver
failure cases, more than 50% of the patients expired while on lipid-lowering therapy
consisting of an HMG-CoA reductase inhibitor. Despite this fatal consequence, the
labeling in OTC package inserts did not mention liver failure as an adverse reaction to
HMG-CoA reductase inhibitor administration. Additionally epidemiological analysis
indicated that the reporting rate of liver failure for the HMG-CoA reductase inhibitors
exceeds the background rate for liver failure. Based on the severity of liver failure they
recommended that liver failure be included as an adverse event in the labeling of
package inserts for OTC lovastatin.
FDA's safety review concluded that, "Given the fact that there is very little
compliance with liver function test monitoring and this class of drugs have been
associated with other potentially serious adverse events (including rhabdomyolysis),
and have the potential to cause dangerous drug and drug-food (grapefruit) interactions,
it is prudent to defer any decision on the OTC switch of these drugs (13)." FDA opined
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that for safety, there are rare, but serious adverse events associated with lovastatin use,
particularly that of muscle toxicity which can be potentiated by certain drugs or
substances which impair lovastatin's metabolism through the 3A4 isoenzyme. This
safety concern was further amplified by the use of lovastatin as a nonprescription drug.
As an OTC drug it would be in an unsupervised setting such that the safety of OTC
lovastatin is dependent upon the consumer's comprehension of the label, its use
according to label instructions, such that there would be no self-titration to higher doses,
and no use by individuals at risk for drug-related toxicities.
In evaluating the prescription to OTC switch of lovastatin 10 milligrams, FDA

asked the question: What is the balance of benefit versus risk of nonprescription
lovastatin? On the benefit side they found LDL-C reduction and agreed that lovastatin
does reduce LDL-C. But stated that the effectiveness of this treatment approach in the
OTC population will likely be diminished by poor adherence to drug therapy. Another
part of the benefit side was that of clinical cardiovascular benefit. FDA asked if drug
treatment, in the OTC target population resulted in reductions in cardiovascular
mortality and morbidity? And asserted that there is no evidence from controlled clinical
trials to demonstrate that. On the risk side, FDA found the safety concerns to be rare,
but believed the seriousness of muscle toxicity potentiated by certain drugs and
compounded by the unrestricted, unsupervised use of this product in the OTC
environment to be excessive and unacceptable.
Consumer behavior and labeling

An FDA review of the actual use studies conducted by the sponsor led to these
observations (14). The sponsor proposed drug treatment for cholesterol in an OTC
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population without CHD. The target population is designed to include healthy subjects
who have fewer than 2 risk factors for CHD in addition to subjects who have

~2

risk

factors and the protocols use the cholesterol level as a surrogate marker for clinical
benefit. The FDA reviewer argued that this population did not meet the NCEP-ATP II
guidelines for drug therapy. The AFCAPS/TexCAPS trial, did not demonstrate
significant clinical benefit for the < 2 CHD risk factor population who took Jovastatin
20 mg or 40 mg. There was no proof that lowering cholesterol with Jovastatin 10 mg in
the proposed population would decrease the incidence of myocardial infarctions or
strokes. In the OTC marketplace, subjects with minimal risk of developing CHD, could
choose to take lovastatin 10 mg and thereby place themselves at risk of side effects. The
mean HDL in one study was higher than for AFCAPS/TexCAPS. An HDL-C level
below 35 mg/dl justifies more intense efforts to lower the LDL-C level. It has been
recommended that tailoring therapy to the individual patient be accomplished.
In AFCAPS/TexCAPS, the compliance at approximately 6 months was close to

90%, but there was a steady decline to approximately 71 % at the end of the study. It has
been demonstrated that a 15% 1-year probability of lovastatin discontinuation was
observed for patients in a health maintenance organization setting. In the OTC
lovastatin actual use trials, compliance was, 27.6% of subjects discontinued during the
first 24 weeks, 31.3% of subjects discontinued the 8 week study and 25.6% of subjects
discontinued the 4 week study for three study protocols. This Jed to the conclusion that
subjects who self-prescribe lovastatin 1O mg are not as compliant as subjects who
receive their medication from and are followed by a physician.
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FDA found that many subjects did not self-select properly with regard to
whether they could take lovastatin. This was attributed to not having an accurate
knowledge of their cholesterol values or of their concomitant medications. None of the
labels were in the FDA required "Drug Facts" format for OTC labeling. The laboratory
measurements in the actual use trials were performed on a desktop analyzer, and
presumably, this is the way consumers would check their lipid values in a pharmacy
when deciding whether to purchase lovastatin. FDA opined that desktop analyzers are
fairly accurate on average, but measurements tend to be more variable than those
obtained with laboratory methods.
The NCEP-ATP II guidelines recommended a 9-12 hour fast as opposed to a 2-hour
fast. Because of variability in measurements, as per NCEP-ATP II guidelines, and as
was done in AFCAPS/TexCAPS, subjects should have had at least, two blood samples
analyzed for lipids to determine drug eligibility. As OTC consumers would not comply
with enough, properly fasted, cholesterol measurements to provide an accurate
determination of their baseline cholesterol profiles, this would argue against the
appropriateness of OTC self-diagnosis and treatment.
The FDA review found the design and results of the actual use trials to be
inadequate in the following ways:
1. Since the HDL value is an important determinant of risk for CHD, it should be
included as a factor to determine who can take lovastatin 10 mg. Consumers should
be tested to determine if they understand the meaning of their HDL level and can
appropriately use this information as a factor in self-selection.
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2. A single cholesterol test performed without a proper fast is a poor way to decide
whether someone should take lovastatin 10 mg. The sponsor should demonstrate
that proper screening methods and compliance can be achieved in the OTC setting.
3. The labels did not provide sufficient information to use the product effectively. Selfselection errors were too frequent. The safety information was incomplete because
laboratory data (especially LFT and creatinine phosphokinase (CPK)) was not
provided.
4. The compliance rate in the OTC setting was poor. This would probably impact on

any long-term benefit to be derived from taking lovastatin 10 mg in this population.
5. A long-term clinical benefit of taking lovastatin 10 mg in the population at low risk
for CHD (especially those with< 2 risk factors) has not been demonstrated.
FDA review of the label comprehension studies observed that the studies
covered the communication objectives with questions that, in most cases, do not require
participants to do more than repeat or identify the presence of information on the label.
Hence, FDA opined that it is not possible to determine how well consumers can use the
information and interpret it correctly. In particular, there were no questions to determine
if participants understood that they must meet all three criteria to use the product: TC of
200-240, LDL-C ~130, males > 40 years and females at least 1 year past menopause.
The reviewer stated that it was likely that questions requiring participants to apply the
information on the label to hypothetical situations would have produced lower scores,

but would have given a better assessment of how well the label is understood. The
results indicate that there may not be good understanding of who cannot take the
product, including men under 40 and pre-menopausal women.
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As the phrasing of the question on this issue permitted responses that the
information was not on the label it was difficult to know if participants understood well
who could not use the product if the information was not on the label. Results about
who should not use the product, coupled with the incomplete information on
participants' understanding about who can take the product, raised concerns about
appropriate self-selection. FDA found although a few scores improved substantially
after participants read the materials inside the package, correct responses remained in
the 74-77% range for questions about pre-menopausal women and men under 40, and
improved scores after reading all the materials may have been due to the study
methodology rather than the effect of the additional materials.
Further, the questionnaire collected information about the personal health status
of participants, participants were never asked if they could use the product themselves.
This information would have been useful in determining how well consumers could
self-select and might have overcome some of the shortcomings of the other questions
about who could and could not use the product. The low literate participants had
problems understanding some of the important messages. They had particular problems
understanding if Mevacor OTC can be used by persons with various total TC and LDLC levels and by women before menopause. The reviewer concluded that this study does
not provide sufficient information to state confidently that consumers can self-select to
use the product appropriately; or, whether they understand key information such as they
must check cholesterol after beginning use.
COMMITTEE DISCUSSION
Based on the presentations made by the sponsor and the Agency, FDA posed a
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list of questions to the committees that have been presented in table 1 (15). The
committees deliberated each question and voted a yes or no response to each question.
The first question related to the "clinical benefit" of lovastatin 10 mg was split by the
committee into two parts for clarity. When clinical benefit was defined, merely, as the
lowering of LDL-C, the committee unanimously voted in agreement (13-yes; 0-no; 0abstained). But, when clinical benefit was defined as reducing cardiovascular events,
the committee voted strongly in dissent (1-yes; 12-no; 0-abstained). This split vote
showed that the committee did not endorse the sponsor's rationale of using lowering of
LDL-C as a surrogate marker for reduction in cardiac events to demonstrate the clinical
benefit of OTC lovastatin. Further, the committee stated that a placebo-controlled
clinical trial in the target population with cardiovascular endpoints should be conducted
to demonstrate clinical benefit.
The second question was on the global safety, not merely the OTC population,
of I 0 mg dose of lovastatin. On this question, the committee was unanimous in
endorsing the safety of 10 mg lovastatin (13-yes; 0-no ; 0-abstained). Question three was
on the balance of benefit and risk of OTC lovastatin, and due its close similarity to the
earlier two questions, the committee decided not to vote on this question. On question
four the committee unanimously voted (0-yes; 13-no; 0-abstained) that the sponsor
failed to demonstrate that consumers could achieve a clinical benefit in an OTC setting.
The major reasons for this dissent were inability to self-select and understand the need
for lifelong therapy by the consumers. Question five was on the demonstration of safety
of lovastatin in the OTC setting and seven members thought it was safe, whereas six
others thought it was not safe (7-yes; 6-no; 0-abstained). Some reasons for the
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dissenting vote were possible self-titration leading to overdose, lack of evidence
showing effective communication to ineligible population, potentially numerous
interacting drugs and the inability of consumers to see a physician when required.
The committee modified question 6 to, has the sponsor provided sufficient
evidence that lovastatin 10 milligrams can be used safely and effectively in an OTC
setting? This question was answered in strong dissent by the committee (1-yes; 11-no;
I-abstained). In terms of additional studies to demonstrate approvability of OTC
lovastatin, the committee made these suggestions:
•

Demonstrate efficacy using better defined eligibility criterion and using LDL-C as
a surrogate marker relative to prescription lovastatin use.

•

Study actual use in a wholly unrestricted manner to demonstrate ability of
consumers (to cover minorities, ethnic and low literacy populations) to self-select,
self-deselect safely and effectively the proposed OTC medicine.

•

Survey large groups to determine their interest in lipid-lowering agents, the
obstacles involved with using such drugs and if inadequate medical care is
considered an obstacle.

•

Study the ability of consumers to self-titrate to larger doses in a safe and effective
manner.

Conclusion

Elevated cholesterol is an important risk factor for cardiac disease in the United

145

States. The public health significance of cholesterol-lowering drugs is intensifying and
NCEP recently issued major new clinical practice guidelines on the prevention and
management of high cholesterol in adults (16). One of the key changes in the new
guidelines is the emphasis on aggressive cholesterol-lowering treatment. Despite the
renewed accent on pharmacological intervention in cholesterol management, growing
public support for OTC antihyperlipidemics, and, free and widespread availability of
some cholesterol lowering agents in the form of virtually unregulated dietary
supplement products, the Agency's current position is that hypercholesterolemia is
intrinsically a non-OTC indication. Along with the lovastatin switch petition, FDA
advisory committees also refused to approve a similar OTC switch petition for
pravastatin (another prescription cholesterol lowering drug from the statins class). FDA
maintains that safe and effective use of drugs in this area and the overall treatment of
the disease could be assured only within the prescription setting where access to a
learned intermediary is readily available.
It is possible to reason that for drugs such as these, used for chronic illnesses,

where FDA maintains that the involvement of a learned intermediary is necessary, it
may be feasible to favorably balance the benefit to risk by classifying them under an
intermediate, pharmacist controlled class of drugs, where a physician's prescription is
not required, but pharmacists may dispense medication based upon patient consultation
and their professional judgment. Such an intermediate class of drugs presently does not
exist as per the current United States classification system, but other developed nations
such as Canada, United Kingdom and Australia allow for this class of nonprescription
medicines. However, the creation of such a pharmacist class of nonprescription
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medicines in the United States would require legislative action to amend the Food, Drug
& Cosmetic Act. Also, as more potent molecules become candidates for reclassification

to OTC status, the intermediate class of drugs may facilitate the achievement of an
acceptable benefit to risk ratio in the nonprescription setting.
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Table 1: List of questions posed by FDA to its advisory committees on the proposed
OTC status for lovastatin 10 mg
Ejjjfa<]'_ and Scif!!!2'__in the PrqJ!_osed Tal]S!!t P<!E}Jlation
I. The sponsor proposes an indication, based upon an expectation of cardiovascular benefit, for the use of
lovastatin IO mg in individuals with TC 200-240 mg/dL and LOL-C > 130 mg/dL, regardless of HOL-C level,
and without CHO or diabetes, Current guidelines for the treatment of hypercholesterolemia do not target such
indi viduals for drug treatment. Based on the data submitted in the NOA, has the sponsor adequately
demonstrated a clinical benefit of lovastatin I 0 mg in the target population?
a. lfyes, what is the nature and magnitude of the benefit?
b. lfno, what additional data are needed to demonstrate a clinical benefit in the target population?

2. Statins have been associated with myopathy, including rare cases of rhabdomyolysis, as well as with
elevations in hepatic transaminases (although the association between use of these drugs and serious hepatic
disease is less clear). lntercurrent illness, undefined individual susceptibility factors, and interactions with other
drugs and/or foods may increase the risk for rhabdomyolysis with statins.
Taking into account these and other safety issues, has the sponsor presented adequate data to support the safety
of lovastatin 10 mg in the target population?
a. lfno, what additional data are needed to demonstrate safety?
3. Taking into consideration the balance of risk and benefit, has the sponsor presented data that are adequate to
support the use of lovastatin 10 mg in the low-risk population with TC 200-240 mg/dL, LOL-C > 130 mg/dL,
regardless of HOL-C level, without CHO or diabetes?
a. If no, what additional data are needed to su_0)_ort such an indication?
OTC Considerations
4. Assuming an indication for the use of lovastatin I 0 mg in the proposed target population can be justified
based upon an expectation of clinical benefit, has the sponsor adequately demonstrated that consumers can
achieve such a clinical benefit in an OTC setting? In responding to this question, please consider the following:
a. The abi li ty of consumers to appropriately self-select (and de-select) based upon cholesterol levels and other
risk factors.
b. The ability of consumers to evaluate response to treatment and to monitor cholesterol levels (including
understanding of how to undertake a fast and the frequency of re-testing).
c. The ability of consumers to adhere to chronic therapy with lovastatin I 0 mg.
d. The need for the physician or other healthcare professional in the effective treatment and follow up of
dyslipidemia.
e. The capacity of the proposed label to direct consumers in the effective use of lovastatin I 0 mg OTC.
5. Assuming that lovastatin 10 mg is deemed adequately safe when used for the proposed indication in the
target population, has the sponsor presented adequate evidence that consumers will be able to use lovastatin I 0
mg safely in an OTC setting? In responding to this question, please consider the following:
a. The ability of the consumer to identify adverse reactions to lovastatin and to act appropriately.
b. The ability of the consumer to monitor hepatic safety including the need for monitoring of hepatic
transami nases and the abi lity of the consumer to perform such monitoring if needed.
c. The need for and ability of the consumer to identify and avoid interacting drugs and other substances.
d. The likelihood of use of lovastatin 1O mg at higher than recommended doses (I tablet per day).
e. The ability of women who are pregnant or likely to become so to appropriately avoid use of lovastatin I 0
mg.

f. The need for the physician or other healthcare professional in the safe treatment and follow up of
dyslipidemia .
...&.: The Cl!I>_ac~ of the...e.r~osed label to direct consumers in the safe use of lovastatin 10 mg_ OTC.
Approvabi/i!X._
6. Assuming that the answer to Question 3 is yes (i.e., the sponsor has provided sufficient information to
support the safety and effectiveness of lovastatin IO mg for the proposed indication in the target population),
has _the sponsor provided sufficient evidence that lovastatin 10 mg can be used safely and effectively in an OTC
setting?
a. If yes, are any additional studies needed post-approval? What are the key messages that need to be conveyed
tlo the c~nsumer in the product label (carton and package insert) to provide for the safe and effective use of
ovastatm 1O mg
OTC?
b. If no, what additional studies are necessl!!}'._ to

s~ort ~oval for OTC marketil_!g_?
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Abstract
Loratadine, fexofenadine and cetirizine are orally active H 1-receptor antagonists
that do not have the sedating side

effects of earlier antihistamines like

chlorpheniramine. In 1998, Wellpoint Health Networks filed a citizen petition with the
FDA to request the reclassification of certain marketed products containing these
second generation antihistamines to over-the-counter status in the United States.
Contrary to common practice, this switch request did not originate from the
manufacturers of these drugs. This remarkable departure from conventional practice
related to the switch process makes this citizen switch petition unprecedented in nature.
The unparalleled nature of this case raises many significant regulatory, safety and legal
issues related to OTC switch process in the United States. This article aims to present an
objective and detailed examination of the regulatory and safety issues related to this
OTC switch petition.
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Introduction
Loratadine (LR), fexofenadine (FX) and cetirizine (CZ) are orally active H 1receptor antagonists that do not have the sedating side effects of earlier antihistamines
like chlorpheniramine (1 ). They are commonly referred to as "second generation
antihistamines" and are currently available, only by prescription, in the United States.

LR is indicated for the relief of nasal and non-nasal symptoms of seasonal allergic
rhinitis (SAR) and treatment of chronic idiopathic urticaria (CIU). FX is indicated for
the relief of symptoms associated with SAR and treatment of CIU. CZ is indicated for
symptomatic relief from seasonal and perennial allergic rhinitis (SAR and PAR), m
addition to CIU treatment.
In 1998, Wellpoint Health Networks filed a citizen petition with the FDA to
request the reclassification of certain marketed products containing LR, FX and CZ to
over-the-counter (OTC) status in the United States (2). This article aims to present an
objective and detailed examination of the regulatory and safety issues related to this
OTC switch petition.
Background
To elucidate the unprecedented nature of this OTC switch petition, it is
beneficial to describe the underlying rationale for the prescription requirement and the
general OTC switch process in the United States. The principles based on which
medicines are classified into, OTC or prescription status, in the United States originate
from the Durham-Humphrey amendment to the Food, Drug and Cosmetic Act (FDCA)
in 1951 . This amendment clarified the dispensing obligations of the pharmacist by
defining the kinds of drugs that cannot be safely used without medical supervision and
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restricting their sale to prescription by a licensed practitioner (3). An implication of
section 503(b )(1) of FDCA, which needs emphasis, is that drug products are inherently
presumed to be nonprescription unless otherwise required. This assertion is generally
stated as, "if it can be OTC, it must be OTC" to illustrate the inherent bias for
"nonprescriptionness" arising from the law and is critical in the context of the current
discussion (4).
Traditionally, prescription drugs have been reclassified to OTC status via, either
the OTC monograph process or an OTC switch petition in the form of an NDA. When
FDA initiated the OTC Drug Review in 1972, the monograph process resulted in many
drugs being recl assified to OTC status. More recently, drugs have been switched to
OTC status upon approval of manufacturer initiated switch petitions (NDA). However,
the current request to reclassify certain products of LR, FX and CZ to OTC status did
not originate from the manufacturers of these drugs. An independent party, other than
the drug manufacturers, requested the FDA to approve the proposed OTC status for
these nonsedating antihistamines. This remarkable deviation from conventional practice
related to the switch process makes this citizen petition for OTC status of LR, FX and
CZ unprecedented in nature. The unparalleled nature of this case raises many significant
regulatory, safety and legal issues related to OTC switch process in the United States.
Rationale and basis of citizen petition
The regulatory basis for this citizen petition to request OTC status was
21CFR§l0.30 and 21CFR§310.200, wherein, any interested person may petition the
FDA for regulatory action, and, drugs limited to prescription use under an NDA can be
exempted from that limitation if the FDA-Commissioner determines the prescription
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requirements to be unnecessary for the protection of public health. Additionally, the
petitioner provided the following medical and pharmacoeconomic rationale to justify
the request (2):
•

Of the 3.5 billion health problems treated annually, almost 2 billion (or 57%) are
treated with OTC drugs as primary or major adjunctive therapy. The current
restrictions limiting OTC access to antihistamine and antihistamine/decongestant
medications with a higher incidence of sedation and anticholinergic side effects is
dangerous and costly.

•

Americans are 4 times as likely to purchase an OTC medication as they are to
consulting a physician. Many patients cannot afford the office visit associated with a
physician. The current restrictions precluding OTC access to antihistamine and
antihistamine/decongestant medications with a lower incidence of side effects
predisposes

many

patients

to

dangerous

antihistamine

and

antihistamine/decongestant treatment options.
Almost 60% of all dosage units consumed by patients are for OTC medications.
Over 500 medical conditions are treatable with one or more OTC medications as the
primary therapy or major adjunctive therapy. These conditions occur millions of
times each year (e.g. cold, allergy, and nasal congestion). The current restrictions
precluding OTC access limits many patients to dangerous antihistamine and
antihistamine/decongestant treatment options.
•

Requiring that a patient schedule an office visit to obtain safe medications is an
undue time and financial burden to the patient. Additionally, requiring a prescription
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for these safe antihistamine and antihistamine/decongestant combinations trivializes
the patient-physician relationship.

•

Based on recent historical precedent, the cost of the OTC versions of the drugs
listed above will be 50% of the prescription drug cost.

Advisory committee meeting
To decide upon this citizen petition and seek advice on the suitability of LR, FX
and CZ for OTC status, the FDA convened an open meeting of its Nonprescription and
Pulmonary-Allergy Drugs Advisory Committees on 11 May, 2001 (5). FDA informed
the advisory committees that the intent of this meeting was to seek advice on whether
LR, FX and CZ, given their marketing history, safety profiles, and that they are in a
class of drugs already accepted for OTC availability, could be used appropriately and
safely by consumers without the intervention of a learned intermediary. FDA clarified
that it is not, seeking advice on the economic considerations of this switch (as this is not
within the purview of the FDA), or, seeking debate on the regulatory and statutory basis
for a FDA-initiated switch to OTC status, from its advisory committees. Hence, the
FDA presented questions only on the safety of LR, FX and CZ in the OTC setting to its
advisory committees for voting. These questions are tabulated in table 1.
Sponsor's position
The manufacturers of LR and FX participated in the public hearing, whereas the
manufacture of CZ declined the invitation to join the meeting. The manufacturer of LR
asserted that OTC status is inappropriate for these drugs and submitted the following as
major reasons to justify their position (6):
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•

The citizen petition did not provide data of the type or rigor that is required to
support an OTC switch. The petition relied solely on anecdotal safety evidence from
a Canadian adverse drug reaction database and a meta-analysis that inappropriately
combined data from clinical trials with differing methodologies. Further, data
pertinent to actual OTC use would have to be generated and additional analyses
conducted for proper assessment of safe and effective use without a physician's
supervision. This would include prospective studies to investigate the expected
therapeutic index for drug use in an OTC setting, as well as estimates and evaluation
of the probability of various adverse outcomes.

•

The complexity of proper diagnosis and treatment of allergic diseases, as well as
associated comorbid conditions, suggests that self-care may often be inappropriate
and that labeling to ensure safe and effective OTC use cannot be developed without
further study. Prescription status may well be necessary to protect and optimize
public health. As compared to when earlier antihistamines were made available
OTC, there is a dramatically different understanding today of the seriousness of
allergies, their pervasive effects on health and quality of life, and most notably, their
very high association with other serious comorbidities. In particular, a strong
relationship with asthma has now been documented, as well as an association with
sinusitis and otitis. A thorough medical evaluation with identification of
environmental allergens and clinical or subclinical comorbid conditions is essential
for optimal treatment outcomes.

•

The safety profile of second-generation antihistamines in an OTC setting is not fully
known. Although safety is well established for prescription use, significant issues
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require further study to ensure that equivalent safety would exist without a
physician's care. The absence of a physician or pharmacist as an intermediary who
would be aware of a patient's concomitant medications is a concern. The
pharmacokinetic interaction and safety profile for each of the second-generation
antihistamines is different and each of the antihistamines must be considered and
evaluated independently. Other aspects of the pharmacologic profile of these drugs
also warrant more specific evaluation, particularly were the drugs to be used without
physician oversight. The history of this class of drugs is one in which unexpected
interactions have been discovered many years after use by millions of patients.
The manufacturer of FX, in contrast to LR's sponsor, did not argue that OTC
status was completely inappropriate for FX. Instead, they took the position that it was
premature to make an objective assessment of its OTC suitability, as FX was approved
only in July-1996 for U.S. marketing. To justify their cautious approach, they cited the
example of an earlier non-sedating antihistamine terfenadine (TF is the parent drug that
is metabolized to FX). TF was initially approved in the U.S. as a prescription drug and
was later considered for OTC status. However, within the first several years of
marketing, a serious safety concern related to cardiac arrhythmias eventually resulted in
TF being withdrawn from the U.S. market.
Medical community's position
The American Academy of Allergy, Asthma and Immunology and the American
College of Allergy, Asthma and Immunology were strongly opposed to the nonsedating antihistamines being moved to OTC status. The rationale for their position was
as follows (7):

157

•

Contrary to the purpose of this switch petition, if approved, the placement of these
compounds on the OTC market will result in a reduced availability of these valuable
medications to patients. The cost of these drugs will likely make them unavailable to
those patients who received them through insurance covered formularies.

•

OTC availability will eliminate the physician from the care process of patients
taking antihistamines. The appropriate use of these medications needs the
reinforcement of health care providers with expertise about allergic disorders.
Overuse or misuse of this class of drugs for disorders in which they have no proven
efficacy will increase health care costs. Conversely, underuse in appropriate allergic
disorders will negatively impact their effectiveness and result in poorer outcomes.
Furthermore, the drugs being considered are not necessarily equivalent in their
efficacy or their capacity to induce sedation, or cognitive and performance
impairments depending on the dose.

•

Allergies are not necessarily a self-diagnosable condition. Although 20-30% of the
U.S. population suffers from allergic disorders, public surveys indicate that up to
75% of people feel they have allergies. This leads to the overuse of antihistamines
for disorders where they have no proven efficacy. By placing these agents in an
OTC status this problem will be compounded.

•

Subjects with allergic diseases often fail to adequately appreciate the degree of
impairment they have from their disease as well as whether treatment impacts upon
this impairment. By placing these agents in an OTC status, physicians will not play
as active a role as they should in assessing disease status and response to therapy.
By placing these agents in an OTC status, in some cases there may be a resultant
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trivialization of the disorders for which they should be utilized. Reduced availability
or utilization of these drugs without physician evaluation may mask or delay
appropriate diagnosis of underlying disorders such as sinusitis, otitis, or asthma. As
well, urticaria can be a manifestation of a serious underlying condition, which if left
undiagnosed, could lead to substantial morbidity and mortality.
The American Academy of Otolaryngology-Head and Neck Surgery (AAOHNS) stated that a physician and pharmacist is necessary in the responsible use of nonsedating antihistamines and did not support the proposed OTC status (8). Further, they
opined that allergic rhinitis (AR) may not be self-diagnosed as nasal polyps or tumors
could be the problem.
FDA's position
The Agency asserted that AR and related conditions are generally considered
amenable to self-diagnosis and self-treatment (9). Antihistamines as a class have a long
history of OTC availability and are used in these indications, with correct usage guided
by OTC monograph labeling. Hence, FDA reasoned that neither an actual use study nor
a label comprehension study was required to support the proposed OTC switch petition
for LR, FX and CZ. Further, FDA opined that it is not appropriate that these drugs be
switched to OTC status for all age ranges, formulations and/or indications for which
they are approved for prescription use. For instance, CIU, an approved prescription
indication for all three drugs was not considered to be an appropriate OTC indication.
Also, FDA stated that the efficacy of this class of drug products and the appropriateness
of antihistamines in general for OTC marketing is not in question. The Agency took the
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position that efficacy of these drugs is not in question as there is a long history of OTC
marketing of antihistamines.
Hence, FDA's OTC switch review team conducted an extensive review of
worldwide safety information related to LR, FX and CZ to determine whether there are
safety concerns that might preclude their appropriate use in the OTC marketplace. The
safety data for all three drugs were derived from the NDA safety databases, the
spontaneous reporting system (AERS) database, and the published literature (10). FDA
concluded that a thorough review of all available data, from its own safety information
and from countries where LR was available without a prescription, failed to identify
conclusive evidence of a causal relationship between use of LR and serious adverse
events. It must be clarified that countries where LR is available without a prescription
allow for a third class of drugs, which require dispensing, only in a pharmacy under the
supervision of a registered pharmacist. Under the current US classification system, there
does not exist a comparable class of medicines. Hence, it must be emphasized that even
in countries where LR is available without a prescription, the involvement of a learned
intermediary is not completely eliminated. Potential safety signals were noted for
ventricular arrhythmias and liver failure; however, the data were deemed as
inconclusive and suggested that if such events were causally related to LR, they are
extremely unusual. A potential association between LR use and seizures was observed,
consistent with information contained in the current package insert, and likely
consistent with a class effect.
FX is the active metabolite of TF, but lacks the pro-drug's ability to inhibit the
main subunit of the potassium channel in vitro, which is felt to be the primary
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mechanism responsible for cardiac arrhythmias associated with TF use. As the sole
active metabolite, FX is predicted to have a non-cardiac adverse events profile
reflective of TF, and to be safe from a cardiac perspective. A full safety review of TF,
excluding cardiac events, was also conducted by the Agency to supplement the
available post-marketing data available for FX. For FX, the Agency concluded that a
detailed review of all available safety data did not reveal evidence of a causal
association between FX use and serious and/or life threatening adverse events. A
possible association between FX use and seizures was noted that is not currently
reflected in the package insert. A potential signal of ventricular arrhythmias in
association with FX use was detected, however, the data was thought to be inconclusive
and the known pharmacologic properties of FX argue against a causal link.
CZ is an active metabolite of hydroxyzine, a currently marketed prescription
antihistamine. Upon an extensive review of adverse event reports associated with use of
CZ, FDA found possible associations between CZ and sedation, neuropsychiactric
events, including seizures, cardiac arrhythmias, and thrombocytopenia. The Agency
thought that there is a preponderance of neuropsychiatric adverse events, particularly
sedation, which may exceed the rate of reporting of similar events for LR and FX. The
Agency reviewers felt that the data were inconclusive with regard to a causal
relationship between CZ and arrhythmias and thromobcytopenia.
FDA also reviewed the post-marketing surveillance data related to first
generation antihistamines and compared the observations with those of the drugs in
question. Overall, the Agency made the inference that although generally accepted as
appropriate OTC drugs, the first generation antihistamines agents possess a number of
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safety concerns, some of which are serious, m addition to their widely recognized
sedative and cognition-impairing properties. Although the occurrence rates of adverse
events attributable to the OTC antihistamines cannot be directly compared to those of
LR, FX or CZ due to many potential confounders, the Agency suggested that these three
products might offer certain safety advantages over the currently available first
generation antihistamines, primarily with regard to sedation and cognition.
Advisory committees' recommendation
Based on the above-described positions, testimony from other interested parties
and their own deliberation; the advisory committees voted 19-4 endorsing acceptable
safety profile in an OTC setting for LR and CZ. For FX, the panel voted 18-5 in favor
of an acceptable OTC safety profile. Members of the advisory panel that voted in
dissent reasoned that the lack of data from actual-use studies does not allow an accurate
assessment of the benefit-to-risk ratio for these drugs in an OTC setting. The
committees deliberated upon the nature of labeling that may be required to facilitate
effective consumer communication. The consensus agreement was to use the existing
labeling from the final antihistamine monograph, with some modifications. The
committees suggested that a warning statement on sedation be included for CZ.
Additionally, several committee members also recommended contraindications for
consumers with renal and hepatic disorders; in particular, elder patients were suggested
to see the physician before use.
Discussion
As stated earlier in the article, this unprecedented switch petition and FDA's
consequent action lead to significant questions pertaining to the OTC switch process in
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the United States. Two such questions relevant in the present context are, (a) Under
what circumstances should FDA actively propose OTC marketing for a drug in the
absence of support from a sponsor? and (b) Should FDA be more active in initiating
switches ofprescription products to OTC use? In fact, as part of an ongoing review of
the Agency's approach to regulating OTC drug products that began in June 2000, FDA
has solicited public comment on these two questions (11). In responding to these
questions, it is necessary to ascertain if FDA has the statutory right to propose OTC
marketing of a drug product. This author opines that FDA has the statutory authority to
propose OTC marketing of a drug product. The basis for this opinion is
21CFR§310.200(b) also known as the "switch regulation" and section 503(b)(3) of
FDCA. As per 21CFR§310.200(b),
"A ny drug limited to prescription use under section 503(b)(J)(c) of the act shall
be exempted from prescription-dispensing requirements when the Commissioner finds
such requirements are not necessary for the protection of the public health by reason of
the drug 's toxicity or other potentiality for harmful effect, or method of its use, or the
collateral measures necessary to its use, and he finds that the drug is safe and effective
for use in self-medication as directed in proposed labeling. "
Section 503(b)(3) ofFDCA states,
"The Secretary may by regulation remove drugs subject to sections 502(d) and
505 from the requirements ofparagraph (I) of this subsection when such requirements
are not necessary for the protection of the public health. "
As stated earlier, Section 503(b)(l) of FDCA states the prescription-dispensing
requirements and Section 505 of FDCA describes the pre-marketing approval
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requirements and process for drugs. Additional evidence in favor of this opinion is
found in the Agency's response to metaproterenol controversy (12). In 1983, as part of
the OTC Drug Review the Agency allowed OTC marketing of metaproterenol sulfate,
but later, due to the advisory panel's recommendation against the OTC status for
metaproterenol, rescinded upon its earlier decision to allow OTC status for
metaproterenol. In explaining that action, FDA wrote that although it agreed with the
advisory committee's recommendation on that occasion, it did not believe that all drug
decisions require the prior involvement of an advisory panel or notice-and-comment
procedures. The Agency asserted that Congress has given the duty of approving drugs
to FDA and argued that it has the statutory responsibility to make a broad range of
decisions (related to safety, efficacy, prescription or OTC status, indications for use and
labeling of drugs) involving the suitability of drugs for use by the American public.
Also, according to FDCA all medicines are inherently assumed to be
nonprescription in nature and the prescription restriction is applied only when necessary
to safeguard public health. Extending this rationale to the current situation, wherein
both the Agency and its advisory committees have endorsed the safety of these drugs in
an OTC setting, it is possible to reason that FDA may remove the prescription
requirement for LR, FX and CZ. One implication of applying the "if it can be OTC, it
must be OTC" rationale to this situation is as follows and deserves explanation. It is

well known that descarboethoxyloratidine (DCLR) is a major active metabolite of LR.
If an interested party requests marketing approval for DCLR in a separate NDA to the

Agency under prescription category, FDA will then be compelled to grant OTC status
for DCLR also. As DCLR and LR have the same pharmacological safety and toxicity
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profi les, it would be inconsistent if FDA granted OTC status for LR and approved a
prescription NDA for marketing DCLR, LR's active metabolite. Based on this
reasoning, it may be inferred that FDA has the authority to reclassify drugs to OTC
status. But, it remains unclear as to what regulatory mechanism the Agency may
employ, should it decide to allow OTC status for these drugs.
In relation to nonsedating antihistamines FDA has taken the position that neither
an actual-use study nor a label comprehension study is required as AR is a known selfdiagnosable condition and an OTC antihistamine monograph exists. In the absence of
data from an actual-use trial it remains unclear how the target OTC population for these
medicines can be determined. Also, the duration of use after which consultation with a
physician is required is unknown for these drugs. The use of second-generation
antihistamines tends to be chronic in nature and a warning of short duration of use may
be inappropriate (9). In this regard, FDA's position presents a dramatic departure from
its rigorous data and evidence based decision-making approach that was employed in
evaluating recent switch petitions.
The position of this author is that FDA should initiate switch proposals that it
considers to be safe and effective in an OTC environment and offer overall public
health benefit. Also, the Agency must switch medicines to OTC status by ensuring
active participation of all interested parties such as scientific, medical, pharmacist,
industry, public and consumer communities in the evaluation of its switch proposals and
before reaching a decision to allow OTC marketing. The author believes that the drastic
regulatory action of FDA switching a product to OTC status despite the sponsor's
objection should be carried out only under very limited and highly unusual
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circumstances. Such a situation may be an enormous and overwhelming support among
the general public and other stakeholders for OTC availability of a certain product,
assuming it meets all the safety, effectiveness and labeling standards required of any
OTC products.
Conclusion
The citizen petition for OTC status of these nonsedating antihistamines
demonstrates a remarkable deviation from common practice related to the switch
process in the United States and makes this citizen petition unprecedented in nature.
The unparalleled nature of this case raises many significant regulatory, safety and legal
issues related to OTC switch process in the United States.
Based on overall review of the safety profile of LR, FX and CZ, the Agency
concluded that these drug products, in the OTC setting, might offer certain safety
advantages over the currently available first generation antihistamines, primarily with
regard to sedation and cognition. FDA also took the position that no actual use trials or
label comprehension trials are needed to support this switch request as they fall under
an existing OTC monograph for antihistamine products. The Nonprescription and
Pulmonary-Allergy Drugs Advisory Committees to the FDA voted strongly in favor of
these drugs meeting the safety profiles required for unsupervised use in an OTC
environment.

It may be inferred that FDA has the authority to reclassify drugs to OTC status.
However, it remains unclear as to what regulatory mechanism the Agency may employ,
should it decide to allow OTC status for these drugs. This author believes that the
drastic regulatory action of FDA switching a product to OTC status despite the
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sponsor's objection should be carried out only under very limited and highly unusual
circumstances.
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Abstract
The objective of this study was to examine the attitudes of stakeholders on
issues related to regulation of nonprescription medicines. The study was designed as an
internet based electronic survey questionnaire. The attitudes of 473 participants in the
United States, Australia, the United Kingdom and Canada were measured using their
stated responses on issues related to regulatory aspects of nonprescription medicines
using a five-point Likert scale. A majority (65%) of responses came from the United
States whereas other responses were roughly equally distributed between Australia
(10%), United Kingdom (12%) and Canada (13%). Response rates of 17% and 7% were
observed for the two respondent cohorts from the United States and outside United
States respectively. Responses from all four countries show ambivalence towards the
role of regulatory agencies in initiating switches or unilaterally switching medicines to
nonprescription status without the sponsor's support. Respondents unanimously stated
that risks and benefits to individuals and public health must be the paramount criterion
in rendering decisions on availability of new OTC medicines. A substantial majority of
all respondents believed that chronic illnesses (such as asthma), diseases that require
initial diagnosis by a physician (such as hypercholesterolemia) and diseases such as
hypertension are unsuitable for self-treatment. Respondents also firmly believed that
diuretics, antihypertensive drugs, oral antidiabetic drugs, antimicrobials, cholesterollowering drugs, osteoporosis medications and oral contraceptives are not appropriate for
self-medication. Respondents believed that the consumers do not possess the knowledge
or ability to ensure responsible use of potent nonprescription medicines without the help
of a learned intermediary.

170

Introduction
The growing global interest in self-medication and the potential economic
benefits accentuate the necessity for a regulatory framework developed on the basis of
sound scientific principles. Hence, this area is beginning to receive much attention from
global regulatory authorities. The US Food and Drug Administration (FDA) is currently
examining its overall approach to regulating over-the-counter (OTC) drug products and
has conducted a public hearing to solicit information from interested persons including
scientists, professional groups, and consumers (1). The FDA listed specific questions
related to regulatory aspects of OTC drug products upon which it requested comments
of all interested groups (such as pharmacists, academicians, physicians, consumers and
pharmaceutical industry).
The primary objective of this investigation is to develop answers to questions
that FDA has posed (on issues such as the OTC regulatory environment, role of
regulatory agency in Rx-to-OTC switches, criteria for OTC classification, suitability of
drugs for OTC status and disease conditions for self-medication, consumer behavior and
understanding of OTC medicines and the approval of new OTC medicines) using the
responses of some stakeholders in the United States, Canada, the United Kingdom and
Australia. A second aim was to use the data collected to gain insight into the opinions of
a subsection of stakeholders interested in the regulation of OTC drug products.
Methodology
Study participants: Requests for participation in the study and the web address of the

questionnaire were forwarded by email to all listed faculty members in pharmacy
practice and pharmacy administration departments in the United States, United
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Kingdom, Canada and Australia. Upon accessing the web page the respondents were
provided an introduction to the study and were asked to review the informed consent
document. The University of Rhode Island Institutional Review Board (URI-IRB)
reviewed and approved the two questionnaires and the informed consent document
before start of the study. The questionnaires were also pre-tested in a small group of
individuals and appropriate modifications were made before start of the study. Upon
giving their consent, the respondents completed the electronic survey questionnaire and
their responses were stored in a Microsoft Access database. To preserve the anonymity
of the respondents, no information related to the respondent except the date of
completion of the questionnaire was captured in the database.
Measures: An internet based electronic survey questionnaire instrument was the

primary data collection method used in this study. The statements for the questionnaire
were adapted from the public hearing notice published by the FDA with a few
modifications made to the phraseology as presented by the FDA. Selected questions
posed by the FDA were presented as statements and respondents were asked to state
their attitude using a five-point Likert scale, ranging from strongly disagree (SDA
coded as 1), disagree (DA coded as 2), undecided (UD coded as 3), agree (AG coded as
4) to strongly agree (SAG coded as 5). Respondents were also asked to state their
knowledge (poor, moderate, good and very good) of nonprescription regulations,
location (Japan, Australia, United Kingdom, United States, Canada and Other) and
profession (registered pharmacist, pharmaceutical industry professional, government
regulatory agency professional, academic professional and other). Respondents were
offered the opportunity to make any additional comments. The respondents were
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allowed to choose only one response for each statement. Two questionnaires were
developed: one for the United States and a second for all other countries. These
questionnaires differed minimally and the great majority of the questions were identical.
The sets of statements used in the two questionnaires are presented as an appendix to
this article.
The questionnaires were developed as an electronic form for completion by the
respondents

and

were

made

available

over

the

internet

at

a

website

(www.npmsurvey.org) from March to October, 2001 to facilitate unrestricted and
convenient global access.
Statistical analyses : Descriptive statistics such as the mean response, the standard error

of the mean, the mode response, standard deviation, the sample size and the 95%
confidence level of the mean were computed. In addition to descriptive statistics, Chisquare test of independence was performed to understand the relationship between the
country of the respondent and variability in their responses. For statistical testing, the
five point Likert scale was abridged to a three-point scale resulting in agree, undecided
and disagree categories on the response scale.
Using the contingency table constructed for each statement, the value of the Chisquare test statistic was computed. The rejection rule was to reject the null hypothesis
(the responses are independent of the respondent's country) if the computed test statistic
was greater than 12.59 (standard chi-square value for 5% level of significance and six
degrees of freedom).
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Results
A total of 473 responses were received from United States, Australia, United
Kingdom and Canada. Table 1 provides a detailed summary of the composition and
distribution of the responses received based on the profession, country and knowledge
of nonprescription regulations of the survey respondents. A substantial majority of all
responses (65%) were received from United States whereas the reminder of responses
was approximately equally distributed between Australia (10%), UK (12%) and Canada
(13%). Response rates of about 17% and 7% were observed for the two cohorts of
respondents in the United States and outside United States respectively. Tables 2A to
2C present an overall summary of the responses on each statement and associated
descriptive statistics. Results are summarized below according to question content:
Regulatory environment

49% of Americans thought that the current regulatory environment for
marketing OTC medicines in the US was inadequate and 41 % took the contrary view.
Unlike American respondents, a majority of Australians (86%), Britains (59%) and
Canadians (70%) stated that the current regulatory environment for marketing OTC
medicines in their respective countries was adequate. When asked if the US FDA can
learn from different OTC regulatory environments and marketing systems within
developed nations, 64% respondents answered in the affirmative. On the same issue,
60% of Australians, 79% of Britains and 89% of Canadians believed their respective
regulatory authority could learn from other countries.
An overwhelming majority (80%) of American respondents believed that the US

should adopt a regulatory framework that includes an intermediate, pharmacist-
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controlled class of nonprescription medicines. Similarly, 85% of Americans opined that

us

FDA should issue a "guidance for industry" document on the reclassification of

prescription products to OTC status describing the nature of the evidence required to
substantiate such applications. An implication of this result is that although the OTC
standards for safety, effectiveness and labeling are described in 21CFR §330.10(a)(4), it
may be useful to delineate such data requirements in a guidance document especially to
support an Rx-to-OTC switch petition.
A substantial majority of all respondents (75% of Americans, 78% of
Australians, 82% of Britains and 85% of Canadians) endorsed the development of
globally acceptable monographs for OTC drug products within the developed world.
Contrarily, there was no clearly inferable opinion from the American respondents on the
issue of direct-to-consumer marketing of prescription drug products adversely
influencing reclassification to OTC status and availability of new OTC drug products as
approximately, 31 % disagreed, 34% were undecided and 35% agreed.
Role of regulatory agency

When asked if their regulatory agency should actively propose OTC marketing
of a drug in the absence of support from the sponsor, the response was varied. American
opinion was evenly split with 40% disagreeing, 39% agreeing and 21 % being
undecided. Roughly two-thirds of the Australian respondents disagreed with this
statement, whereas 42% of British respondents agreed and half the Canadians disagreed
with this proposal. About 19% Canadians, 21 % Americans and 22% Britains remained
undecided. Responses were found to be statistically independent of the participant's
location in this case. On the related question of their regulatory agency unilaterally
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initiating switches of prescription medicines to OTC use, American opinion was unclear
with 43% agreeing, 42% disagreeing and 15% being undecided. Roughly 70% of
Australians disagreed and 52% of Britains agreed with this idea. A majority of
Canadians (45%) rejected this notion.
Criteria for OTC classification
In the US , 33% of respondents thought that the current criteria used by the US

FDA in rendering decisions on OTC availability of OTC drug products was adequate,
whereas 35% disagreed with this view and 32% remained undecided. This ambivalence
reinforces the dissatisfaction of Americans observed earlier with their OTC regulatory
framework. On the same issue, 58% of Australians, 46% of Britains and 60% of
Canadians believed their respective criterion for decisions on OTC availability to be
adequate, but, 13% of Australians, 28% of Britains and 25% of Canadians said they
were undecided. These responses were found not to be statistically independent of the
participant's location.
The respondents almost unanimously (95% of Americans, 93% of Australians,
98% of Britains and 95% of Canadians) stated that the risks and benefits to individuals
and public health should be assessed and weighed in any decision on OTC marketing of
drug products. 90% of Americans stated that initiatives to market at least some
nontraditional medicines (dietary supplements and nutraceuticals) as regular OTC
products by subjecting them to the same rigorous premarketing scientific evaluation and
clinical review criteria should be promoted. Also, most respondents added that this is
perhaps the most important public health issue in the area of OTC medicines regulation
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Suitability of drugs for OTC status and disease conditions for self-medication

The majority of Americans (65%), Britains (70%) and Canadians (68%) stated
that chronic illnesses (such as asthma) are not suitable for treatment with OTC products.
But, 56% of Australian respondents agreed to the contrary. In Australia, P-agonist
inhalation products for asthma are available without a prescription under the pharmacist
class of medicines due to which a majority of Australians believed that asthma is
suitable for self-medication. A consistent majority across all countries, 59% Americans,
71 % Australians, 70% of Britains and 73% of Canadians stated that diseases that
require initial diagnosis by a physician (such as hypercholesterolernia) are unsuitable
for self-medication. This attitude is in unison with FDA's position that irrespective of
the safety profile of the drug molecule, OTC indications for cholesterol-lowering drugs
are not appropriate as high cholesterol is a condition that is inherently unsuitable for
self-diagnosis and self-medication. Based on this rationale, FDA recently refused to
approve OTC status for lovastatin and pravastatin, two cholesterol-lowering
medications (2,3). Similarly, a substantial majority of about 75% of respondents from
all four countries believed that diseases (such as hypertension) that, if left untreated or
are inadequately treated can lead to serious morbidity or mortality are also unsuitable
for self-medication.
More than three-quarters of all respondents from each country believed that
diuretics should not be made available without a prescription. At least 83% of all
respondents from each country disagreed that antihypertensive drugs should be
available OTC. Similarly, more than three-quarters (78%) of all respondents from each
country believed that oral antidiabetic drugs, and, at least 85% of all respondents from
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each country stated that antimicrobials, should not be granted OTC status. The majority
of all respondents, 59% Americans, 78% Australians, 61 % Britains and 68% of
Canadians, did not believe that cholesterol lowering drugs should become
nonprescription medicines. 69% of Australians, 46% of Britains and 54% of Canadians
disagreed with granting OTC status for treatments for osteoporosis (including its
prevention), whereas, a majority of Americans (48%) agreed with this proposal.
Opinion was diverse on the idea of removing the prescription requirement for oral
contraceptives. More Americans disagreed (45%) than that agreed (42%) with this
proposal. 46% Australians disagreed versus 40% Australians that agreed with OTC
status for oral contraceptives. 57% of British respondents agreed, whereas, 49% of
Canadians disagreed with oral contraceptives being given OTC status.
Consumer understanding and behavior

A majority of respondents from all countries, 55% Americans, 55% Australians,
63% Britains and 54% Canadians, rejected the idea that rational selection of treatment
regimens by consumers may be ensured when prescription and OTC therapies coexist
for a certain disease. Similarly, more than 80% of respondents from all countries
thought that patients do not know the best ways to treat their illnesses in an environment
with coexisting prescription and OTC therapies for a certain disease. At least 63% of
respondents from all countries thought that prevention claims for OTC medicines would
encourage ill-advised behavior (such as ignoring smoking cessation and dietary
discretion while using an OTC cholesterol-lowering drug, if it were available) among
consumers.
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Approval of new OTC medicines
When asked if the first drug to enter the OTC market should be the "best" drug
in terms of benefit-to-risk ratio within a therapeutic class, a majority of respondents
concurred. Almost half (49%) of Americans, about 56% Australians, about two-thirds
(67%) of Britains and 58% of Canadians were in agreement with the above statement.
In United States, this is not true as the order of availability of new OTC medicines to
the general public is decided by the sponsor's willingness to switch and the FDA has no
role in this decision. As discussed earlier, the issue of regulatory agencies initiating and
pursuing switch proposals in the absence of support from the sponsor is critical in this
context. A majority of the respondents from all countries (46% Americans, 60%
Australians, 63% Britains and 50% Canadians) agreed that the availability of a ''better"
OTC product in terms of efficacy or safety should affect the status of products already
in the OTC market for treatment of the same condition within a therapeutic class.
Additionally, about two-thirds of the respondents (66% Americans, 67% Australians,
69% Britains and 65% Canadians) believed that when newer nonprescription products
become available within a therapeutic class, older therapies that may provide less
benefit or more risk should be either removed from the market or their labeling should
be revised. These observations must be interpreted cautiously as the decision to remove
older OTC medicines upon availability of newer OTC medicines must be considered on
a case specific basis. In some cases removal of an OTC medicine (as in the case of
phenylpropanolamine in the United States) may be the right course due to public health
reasons. However, attempts to extend such a policy universally may be imprudent as
individuals do not show a uniform pharmacological response to any medicine and it is
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necessary to allow for a choice of pharmacological therapies being available to
individuals.
There was variability among responses on the issue of direct-to-OTC marketing
(a new chemical entity (NCE) is directly granted OTC status without being first
marketed as a prescription product for some duration of time). 46% of Americans, 51 %
of Australians, 78% of Britains and 36% of Canadians agreed with the principle of
direct-to-OTC marketing, whereas, 37% of Americans, 33% of Australians, 20% of
Britains and 49% of Canadians disagreed. The responses on this statement were found
not to be statistically independent of the country as each regulatory agency has taken a
different position on this matter. Also, an opinion held by most health professionals is
that a drug's safety profile cannot be understood based solely on controlled clinical
trails during development and surveillance during real-world clinical practice is
necessary.
Discussion
Literature m this scientific discipline does not widely document the use of
internet, despite its obvious and well-known advantages, for administering a survey.
This study demonstrates the utility of electronic communication in the rapid and
effective completion of a global survey. Also, the electronic survey instrument is
presented as an efficient alternative to traditional questionnaire-by-mail survey
technique.
As with any study, this study is also subject to limitations and the results must
only be interpreted within the context of any such limitations. Some noteworthy
limitations are: (a) the phraseology of the questionnaire may not ensure consistent
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comprehension by all respondents, (b) responses are influenced by the inherent biases
of the respondents (c) respondents were forced to choose only one response on the fivepoint Likert scale that is closest to, but not necessarily, their true opinion (d) the
participants did not have the opportunity to qualify their responses (e) the study sample
population may not accurately represent the overall population (f) normal distribution of
responses that is not fully accurate was assumed in the estimation of descriptive
statistics. Additionally some respondents commented that their opinion could not be
completely captured using only a five-point scale. Despite the limitations, these results
are useful to discern the attitudes of certain stakeholders on regulation of
nonprescription medicines. This assertion is reinforced, as the study is exploratory in
nature and was not designed to test any specific hypotheses. Moreover, the absence of
any information in the global context related to these important issues accentuates the
significance of these results.
Foreign respondents out numbered American participants in stating that their
regulatory agency can learn from other nations, despite the observation that their level
of satisfaction with their regulatory systems was greater than that for Americans. On
statement 1 (current regulatory environment for marketing nonprescription medicines
(NPM) in the US is adequate) and statement 2 (the US FDA can learn from different
nonprescription medicine regulatory environments and marketing systems within other
developed nations), statistical analysis showed that nature of the responses was not
independent of the country of the participant. This dependence of responses on the
country may be attributed to the differences in regulatory frameworks within the four
countries. The endorsement of an intermediate, pharmacist-controlled class of
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nonprescription medicines by the American respondents is very significant and this
contentious matter has been debated for a long time (4,5,6). Although the respondent
population does not include all stakeholders, it can be inferred that there is strong
support for such a proposal amongst an important subsection of stakeholders. However,
it is necessary to evaluate the support for an intermediate-class of OTC drugs amongst a
broader population of stakeholders as this study focussed only on pharmacists and
academicians. Also, it may be reasoned that this is a potential improvement to the US
regulatory system on which American respondents may have based their earlier
response.
Presently, the US OTC monograph system is unique among the four countries
wherein an OTC product may be marketed without pre-market approval if compliance
with an approved OTC monograph is ensured. Such an initiative when expanded to
other countries would benefit the general public and the pharmaceutical industry as best
practices related to OTC regulation from across the developed world can be integrated
resulting in an efficient OTC product development and approval system. Statistical
analysis showed that the responses on statement 5 (on the US questionnaire, ''the US
FDA should be more active in unilaterally initiating switches of prescription medicines
to nonprescription use") were found not to be independent of the participant's location.
Although, the inferential The Chi-square test statistics for statements 4 and 5 in the US
questionnaire (11.39 and 14.81 respectively) although minimally different from the
critical value for rejection (12.59) led to differing statistical inferences. Overall, there is
ambivalence on the issue of regulatory agencies initiating and pursuing switch
proposals in the absence of support from the sponsor. This observation is timely and
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important in the context of proposed OTC status for second-generation, non-sedating
antihistamines in the United States (7 ,8). Although, this topic has substantial legal
complexity and experts in drug law did not participate in this study, it is important for
the FDA to consider the opinion of pharmacists and academicians in formulating its
regulatory policy on OTC status for non-sedating antihistamines.
It is important to note that responses on statements related to suitability of
disease conditions and drugs for self-medication were found to be statistically
independent of the country in all but, two cases. The United States has only one class of
nonprescription medicines whereas Australia, United Kingdom and Canada have two
classes of nonprescription medicines (one that requires consultation with a pharmacist
in a pharmacy before purchase and the other that may be purchased anywhere). It has
been argued that the existence of the pharmacist-controlled class of nonprescription
medicines offers a more efficient approach to manage the risk/benefit ratio associated
with potent nonprescription medicines and ensures their safe use. If this hypothesis
were true, it is reasonable to expect that the responses of participants from countries
with a pharmacist-controlled class of nonprescription medicines might possibly be
different from those in United States. However, the results show this trend only in two
of the ten statements. Also, a proportion of all respondents stated that their responses on
above statements might have been different if a pharmacist-class of nonprescription
medicines was available and pharmacist intervention can be frequently exercised.
Hence, it is unclear if a majority of all respondents believe that most of the diseases or
drug classes discussed above are unsuitable for self-medication even if a pharmacistcontrolled class of nonprescription medicines were available. Two limitations of this
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study, the phraseology of the questionnaire not possibly ensunng consistent
comprehension by all respondents and the participants not having the opportunity to
qualify their responses, are particularly important in this context. It is necessary that
subsequent studies designed to specifically test hypotheses such as these must be
conducted for an accurate assessment.
Recently, dietary supplements have witnessed a rapid growth in usage
(9,10,11,12) and there has been a vocal expression of concern among the professional
community over the safety and efficacy of these products and this overall opinion is
aligned with the views of the majority of the scientific and medical community
(13, 14, 15, 16, 17). The responses observed on regulation of dietary supplements imply
that such products presently regulated as per the Dietary Supplement Health and
Education Act (DSHEA) of 1994 need to be comprehensively reviewed and
fundamental changes must be made to the regulatory framework. Observations on the
subject of consumer understanding and behavior related to nonprescription medicines
indicate that the respondents believe that consumers posses neither the knowledge nor
the commitment to correctly select and safely use OTC medicines without being
assisted by a learned intermediary. It is vitally important for consumers to responsibly
use OTC medicines and effective education of the general public must be accomplished.
The significance of these observations is augmented as it is expected that attempts to
make potent prescription medicines available without a prescription will increase in the
future.
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Conclusion
This study demonstrates the rapid and effective administration of an electronic
survey questionnaire to a global audience with the objective of developing answers to
questions that the US FDA posed on the subject of nonprescription medicine
regulations. It can be inferred that relative to Australian, British and Canadian
participants more American respondents regard their regulatory framework for OTC
medicines as inadequate. Results suggest that potential improvements to the US
regulatory framework can include creation of an intermediate, pharmacist-controlled
class of OTC medicines, delineation of data requirements in a guidance document to
support a switch petition, regulation of nontraditional medicines (dietary supplements
and nutraceuticals) based also on current OTC standards of pre-market demonstration of
safety and efficacy, and, the development of global OTC monographs.
Responses from all four countries show ambivalence towards the role of
regulatory agencies in initiating switches or unilaterally switching medicines to
nonprescription status without the sponsor' s support. Respondents unanimously stated
that risks and benefits to individuals and public health must be the paramount criterion
in rendering decisions on availability of new OTC medicines. A substantial majority of
all respondents believed that chronic illnesses (such as asthma), diseases that require
initial diagnosis by a physician (such as hypercholesterolemia) and diseases such as
hypertension are unsuitable for self-diagnosis and self-medication. Respondents also
firmly believed that diuretics, antihypertensive drugs, oral antidiabetic drugs,
antimicrobials,

cholesterol-lowering drugs,

osteoporosis

medications

and

oral

contraceptives are not appropriate for self-medication. However, the study results do
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not help in understanding if these attitudes might change if a pharmacist-class of
nonprescription medicines were available. Respondents also thought that the consumers
do not possess the knowledge or ability to ensure responsible use of potent
nonprescription medicines without the help of a learned intermediary.
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Appendix
List of statements in the questionnaire for US respondents
1. Current regulatory environment for marketing nonprescription medicines (NPM)
in the US is adequate.
2. The US FDA can learn from different nonprescription medicine regulatory
environments and marketing systems within other developed nations.
3. US should adopt a regulatory framework that includes an intermediate,
pharmacist-controlled class of nonprescription medicines (i.e. behind-thecounter medicines).
4. The US FDA should actively propose nonprescription marketing of a
prescription drug in the absence of support from the drug manufacturer
(sponsor).
5. The US FDA should be more active in unilaterally initiating switches of
prescription medicines to nonprescription use.
6. Current criteria used by the US FDA in rendering decisions on availability of
nonprescription drug products is adequate.
7. The following types of diseases/illnesses are suitable for treatment with
nonprescription drug products:
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a. Chronic illnesses (such as asthma)
b. Diseases

that

require

initial

diagnosis

by

a

physician

(such

as

hypercholesterolemia, i.e. high cholesterol)
c. Diseases (such as hypertension) that, if left untreated or are inadequately
treated can lead to serious morbidity or mortality
8. The following are specific classes of medicines that are not currently marketed
as nonprescription medicines that should be available without a prescription:
a. Diuretics
b. Antihypertensive drugs
c. Cholesterol lowering drugs
d. Oral antidiabetic drugs
e. Treatments for osteoporosis (including its prevention)
f.

Antimicrobials

g. Oral contraceptives
9. Rational selection of treatment regimens by consumers may be ensured when
there are coexisting prescription and nonprescription therapies for a certain
disease.
10. Patients know the best ways to treat their illnesses in an environment with
coexisting prescription and nonprescription therapies for a certain disease.
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11. The risks and benefits to individuals and public health should be assessed and
weighed in any decision on nonprescription marketing of drug products (for
example, the potential benefits of nonprescription antimicrobial agents with the
potential risks to society at large of the development of resistant organisms).
12. Prevention claims for nonprescription medicines encourage ill-advised behavior
(for example, use of an nonprescription cholesterol lowering drug would allow
patients to ignore other needed interventions such as smoking cessation, dietary
discretion and management of other risk factors).
13. Within a therapeutic class, the first drug to enter the nonprescription market
should be the "best" drug in terms of the benefit-to-risk ratio.
14. Within a therapeutic class, the availability of a "better'' nonprescription product
in terms of efficacy or safety should affect the status of products already on the
nonprescription market for treatment of the same condition.
15. When newer nonprescription products become available within a therapeutic
class, older therapies that may provide less benefit or more risk should be either
removed from the market or their labeling should be revised.
16. Initiatives to

market at least some nontraditional

medicines

(dietary

supplements, vitamins, nutraceuticals and other traditional medicines) as regular
OTC drug products by subjecting them to the same rigorous premarketing
scientific evaluation and clinical review criteria should be promoted.
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17. Direct-to-consumer marketing

of prescription

drug

products

adversely

influences reclassification to OTC status and availability of new OTC drug
products.
18. Initiatives to develop and establish globally acceptable monographs for
nonprescription drug products, at least, within the developed world should be
promoted.
19. The US FDA should issue a "Guidance for Industry" document on the
reclassification of prescription products to OTC status describing the nature of
evidence required to substantiate such applications.
20. Assuming a new chemical entity meets all regulatory requirements necessary for
nonprescription classification, it should still be marketed as prescription
medicine for a specified duration before reclassification to nonprescription
status may be considered.
List of statements in the questionnaire for outside US respondents
1. Current regulatory environment for marketing nonprescription medicines (NPM)
in your country is adequate.
2. Your country can learn from different nonprescription medicine regulatory
environments and marketing systems within other developed nations.
3. The relevant regulatory Agency in your country should actively propose
nonprescription marketing of a prescription drug in the absence of support from
the drug manufacturer (sponsor).

191

4. The relevant regulatory Agency in your country should be more active in
unilaterally initiating switches of prescription medicines to nonprescription use.
5. Current criteria used by the relevant regulatory Agency in your country in
rendering decisions on availability of nonprescription drug products is adequate.
6. The following types of diseases/illnesses are suitable for treatment with
nonprescription drug products:
a. Chronic illnesses (such as asthma)
b. Diseases that require initial diagnosis by a physician (such as
hypercholesterolemia, i.e. high cholesterol)
c. Diseases (such as hypertension) that, ifleft untreated or are inadequately
treated can lead to serious morbidity or mortality
7. The following are specific classes of medicines that are not currently marketed
as nonprescription medicines that should be available without a prescription:
a. Diuretics
b. Antihypertensive drugs
c. Cholesterol lowering drugs
d. Oral antidiabetic drugs
e. Treatments for osteoporosis (including its prevention)
f.

Antimicrobials
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g. Oral contraceptives
8. Rational selection of treatment regimens by consumers may be ensured when
there are coexisting prescription and nonprescription therapies for a certain
disease.
9. Patients know the best ways to treat their illnesses in an environment with
coexisting prescription and nonprescription therapies for a certain disease.
10. The risks and benefits to individuals and public health should be assessed and
weighed in any decision on nonprescription marketing of drug products (for
example, the potential benefits of nonprescription antimicrobial agents with the
potential risks to society at large of the development ofresistant organisms).
11. Prevention claims for nonprescription medicines encourage ill-advised behavior
(for example, use of an nonprescription cholesterol lowering drug would allow
patients to ignore other needed interventions such as smoking cessation, dietary
discretion and management of other risk factors).
12. Within a therapeutic class, the first drug to enter the nonprescription market
should be the ''best" drug in terms of the benefit-to-risk ratio.
13. Within a therapeutic class, the availability of a "better" nonprescription product
in terms of efficacy or safety should affect the status of products already on the
nonprescription market for treatment of the same condition.
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14. When newer nonprescription products become available within a therapeutic
class, older therapies that may provide less benefit or more risk should be either
removed from the market or their labeling should be revised.
15. Initiatives to develop and establish globally acceptable monographs for
nonprescription drug products, at least, within the developed world should be
promoted.
16. Assuming a new chemical entity meets all regulatory requirements necessary for
nonprescription classification, it should still be marketed as prescription
medicine for a specified duration before reclassification to nonprescription
status may be considered.
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Table 1: Distribution of survey respondents classified by profession, country and knowledge of nonprescription regulations
~ofession

us

~eg_Phann
j!>harm Ind Prof
Q_ovt RA Prof
!.icad Prof
IQ_th er

N
140
4
0
155
11

[otal

310

45.16
1.29
0.00
50.00
3.55

N
32
4
1
7
1

100.00

45

i_o/<tl_

54 .55
1.82
0.00
41.82
1.82

N
22
5
3
30
3

34.92
7.94
4.76
47.62
4.76

All countries
N
i_o/<tl_
224
47 .36
14
2.96
4
0.85
215
45.45
16
3.38

100.00

63

100.00

473

UK

Australia

ffo)

71.11
8.89
2.22
15.56
2.22

N
30
1
0
23
1

100.00

55

Canada

i_o/tl_

__{_%)

100.00

% of Respondents per
65.54

~ount12

9.51

11.63

13.32

100.00

Australia

UK

Canada

!Knowled_g_e of non_.e.rescri~tion r~lations

us
!Poor
!Moderate
IQ_ood
IY_e!}'__g_OOd

N
45
133
106
26

14.52
42.90
34.19
8.39

N
2
4
14
25

4.44
8.89
31.11
55.56

N
10
19
14
12

18.18
34.55
25.45
21.82

N
4
13
22
24

6.35
20.63
34.92
38 .10

All countries
N
(o/<tl_
61
12.90
169
35.73
156
32.98
18.39
87

\rota!

310

100.00

45

100.00

55

100.00

63

100.00

473

i_o/<tl_

i_o/<tl_
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i_o/<tl_

i_o/tl_

100.00

Table 2A: Summary of responses to survey statements and descriptive statistics
Res_l)_onse _{_o/tl_
~tatem

ent

Countiy

SDA

DA

UD

AG

SAG

Mean

I

us

6.82

42.21

9.42

40.26

1.30

2.87

Aus.

0.00

8.89

4.44

71.11

15.56

UK

9.26

22.22

9.26

53 .70

5.56

Can.

3.17

19.05

7.94

65 .08

4.76

2

3

'!Ql

llil

fill

f7A(6A

J_

[~68

[Gi_6C

Descri_£!ive statistics
¥'.:1(95.0
SE Mode SD
o/tl_ ~hi-~ Sign.
N
0.06

2

1.07

308

0.12

3.93

0. 11

4

0.75

45

0.23

3. 18

0.16

4

1.22

55

0.33

3.49

0. 12

4

0.97

63

0.24

45.90

.:t._es

us

1.30

10.06

24.03

53.57

10.71

3.63

0.05

4

0.86

307

0.10

Aus.

8.89

24.44

6.67

51.11

8.89

3.27

0.18

4

1.19

45

0.36

UK

0.00

9.26

12.96

62.96

16.67

3.85

0.10

4

0.80

55

0.22

Can.

1.59

4.76

4.76

73 .02

15 .87

3.97

0.09

4

0.74

63

0.19

us

3.57

6.17

10.06

38.96

41.23

4.08

0.06

5

1.04

308

0.12

none none

11 .39

us

10.71

29.22

21.10

30.84

7.79

2.96

0.07

4

1.16

307

0.13

Aus.

24.44

40.00

11.11

20.00

4.44

2.40

0.18

2

1.19

45

0.36

UK

7.41

29.63

22.22

37.04

5.56

3.04

0.14

4

1.09

55

0.29

Can.

15 .87

31.75

19.05

23 .81

7.94

2.71

0.15

2

1.26

63

0.32

us

8.44

33.44

14.94

36.69

6.49

2.99

0.07

4

1.14

308

0.13

Aus.

15.56

S3 .33

4.44

22.22

4.44

2.47

0. 17

2

1.14

4S

0.34

UK

S.S6

29.63

14.81

48 . IS

3.70

3.14

0.14

4

1.06

SS

0.29

Can.

7.94

36.SI

IS.87

28.S7

11.11

2.98

0.15

2

1.20

63

0.30

us

3.2S

32. 14

30.84

31 .82

1.62

2.96

O.OS

2

0.92

307

0.10

Aus.

4.44

24.44

13 .33

S7.78

0.00

3.24

0.14

4

0.98

4S

0.29

UK

3.70

24.07

27.78

44.44

l.8S

3. 16

0.12

4

0.94

SS

0.2S

Can.

3. 17

11.11

2S.40

SS .56

4.76

3.48

0.11

4

0.88

63

0.22

us

2S.6S

39.29

S.84

26.30

l.9S

2.39

0.07

2

1.19

30S

0. 13

Aus .

8.89

31.11

4.44

48 .89

6.67

3.13

0.17

4

1.20

4S

0.36

UK

24.07

46.30

3.70

20.37

S.S6

2.33

0.16

2

l.2S

SS

0.34

Can.

20.63

47.62

7.94

17.46

4.76

2.33

0.14

2

1.18

63

0.30

us

20.13

38.96

8.77

27.92

2.92

2.S4

0.07

2

1.19

304

0.13

Aus.

20.00

SI.I I

8.89

20.00

0.00

2.29

O. IS

2

1.01

4S

0.30

UK

14.81

S l.8S

l.8S

20.37

9.26

2.47

0.17

2

1.32

SS

0.36

Can.

20.63

S2.38

4.76

20.63

0.00

2.22

0.13

2

I.OS

63

0.27

13 .31

3.90

2.15

0.06

2

1.12

303

0.13

us

30.52

44. 16

6.49

Aus .

24.44

57.78

8.89

4.44

4.44

2.07

0.14

2

0.96

45

0.29

UK

20.37

57.41

1.85

16.67

1.85

2.13

0.14

2

1.09

55

0.29

Can.

26.98

46.03

7.94

12.70

4.76

2.18

0.14

2

1.16

63

0.29

196

40.01 .:t._es

no

14.81 .:t._es

2S.83

.:t._es

17 .32

.:t._es

9.20

no

4.60

no

Table 2B: Summary ofresponses to survey statements and descriptive statistics
Res...£_onse_{_o/tl_

~tatem
ent
i8A(7A

i

~8(78~

~g_1c~

~0(70

J_

8E(7E

8F(71J

i8G(7G
)

9(~

Coun!!Y_

SDA

DA

UD

AG

SAG

Mean

us

26.30

49.03

5.84

15 .9 1

1.62

2.16

Descri_Eti ve statistics
jCl(95.0
N
SE Mode SD
o/tl_ ~hi-~ S!g_n.
0.06

2

1.05

304

0.12

Aus.

35.56

51.11

8.89

2.22

2.22

1.84

0.12

2

0.85

45

0.26

UK

35 .1 9

48.15

7.41

11.11

0.00

1.94

0.12

2

0.93

55

0.25

Can.

28.57

49.2 1

9.52

12.70

0.00

2.06

0.11

2

0.95

63

0.24

us

35 .39

48 .05

4.55

9.74

0.97

1.91

0.05

2

0.94

304

0.11

Aus.

37.78

51.11

4.44

6.67

0.00

1.8

0.12

2

0.81

45

0.24

UK

33.33

50.00

9.26

9.26

0.00

1.95

0.12

2

0.89

55

0.24

Can.

33.33

52.38

6.35

7.94

0.00

1.89

0.10

2

0.84

63

0.21

us

20.78

38 .64

8.44

27.60

3.57

2.54

O.Q7

2

1.20

305

0.14

Aus.

20.00

57.78

4.44

15 .56

2.22

2.22

0.15

2

1.02

45

0.31

UK

24.07

37.04

9.26

25.93

5.56

2.52

0.17

2

1.26

55

0.34

Can.

19.05

49.2 1

9.52

17.46

4.76

2.39

0.14

2

1.13

63

0.28

us

38.96

44.8 1

6.49

7.47

0.97

1.85

0.05

2

0.91

304

0.10

Aus.

31.11

55.56

2.22

8.89

2.22

1.96

0.14

2

0.95

45

0.29

UK

35. 19

55.56

1.85

9.26

0.00

1.85

0.11

2

0.85

55

0.23

Can.

33.33

44.44

11.11

11.11

0.00

2.00

0.12

2

0.95

63

0.24

us

7.14

30. 19

13 .31

44.48

3.90

3.08

0.06

4

1.09

305

0.12

Aus.

15.56

53 .33

11.11

17.78

2.22

2.38

0.15

2

1.03

45

0.31

UK

9.26

37.04

12.96

38.89

3.70

2.90

0.15

4

1.13

55

0.30

Can.

19.05

34.92

6.35

36.51

3.17

2.69

0.15

4

1.24

63

0.31

us

58.44

28.25

7.14

3.57

1.30

1.59

0.05

I

0.87

304

0.10

Aus.

46.67

37.78

4.44

8.89

0.00

1.75

0.13

I

0.92

44

0.28

UK

40.74

44.44

3.70

12.96

0.00

1.89

0.13

2

0.98

55

0.26

Can.

57.14

33.33

3.17

6.35

0.00

1.58

0.10

I

0.84

63

0.2 1

us

14.61

30.52

12.01

33.44

8.44

2.90

O.Q7

4

1.25

305

0.14

Aus.

8.89

37.78

13 .33

33.33

6.67

2.91

0.17

2

1.16

45

0.35

UK

5.56

25.93

11.11

44.44

12.96

3.27

0.16

4

1.24

55

0.33

Can.

19.05

30.16

11.11

33.33

6.35

2.78

0.16

4

1.28

63

0.32

us

12.34

42.53

19.81

20.13

2.60

2.57

0.06

2

1.04

300

0.12

Aus.

15.56

40.00

15 .56

26.67

2.22

2.6

0.16

2

1.12

45

0.34

UK

16.67

46.30

24.07

11.11

0.00

2.21

0.13

2

0 .98

55

0.26

Can.

14.29

39.68

19.05

23.81

3. 17

2.6 1

0.13

2

I. IO

63

0.28
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7.70

no

3.14

no

7.01

no

6.43

no

20.63 ies

7.37

no

5.49

no

5.91

no

Table 2C: Summary of responses to survey statements and descriptive statistics
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48.70

10.71

4.87

0.65

1.91

0.05

Aus.

33 .33

48.89

11.11

4.44

0.00

1.86
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18 .52

66.67

9.26

3.70

0.00

Can.

28.57

53.97

9.52

7.94
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0.65

0.32

2.27

36.04
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4.44

0.00

2.22

44.44

48.89

SD

N

o/~

2

0.83

297

0.10

0.12

2

0.80

44

0.24

1.90

0.10

2

0.75

55

0.20

0.00

1.96

0.10

2

0.84

63

0.21

59.09

4.55

0.04

5

0.63

303

O.Q7

4.33

0.13

5

0.90

45

0.27

SE Mode

UK

0.00

0.00

1.85

51 .85

46.30

4.36

0. 10

4

0.80

55

0.22

Can.

1.59

0.00

1.59

30. 16

65.08

4.52

0.11

5

0.90

63

0.23

us

2.60

21.10

10.06

50.97

13 .96

3.53

0.06

4

1.06

304

0.12

Aus.

4.44

17.78

8.89

40.00

28.89

3.71

0.17

4

1.20

45

0.36

UK

1.85

18.52

16.67

44.44

18 .52

3.52

0.15

4

1.15

55

0.31

Can.

3.17

17.46

12 .70

47.62

19.05

3.61

0. 13

4

1.08

63

0.27

us

6.82

27.27

15.26

40.58

8.77

3.17

0.07

4

1.14

304

0.13

Aus.

6.67

22.22

15.56

42.22

13.33

3.33

0. 17

4

1.17

45

0.35

UK

5.56

9.26

18.52

48 . 15

18.52

3.58

0. 15

4

1.17

55

0.32

Can.

3.17

17.46

20.63

46.03

12.70

3.47

0.13

4

1.03

63

0.26

us

3.57

31.17

17.21

39.94

6.49

3.15

0.06

4

1.06

303

0.12

Aus.

2.22

31.11

6.67

53 .33

6.67

3.31

0.15

4

1.06

45

0.32

UK

0.00

18.52

18.52

57.41

5.56

3.43

0.13

4

0.98

55

0.26

Can.

4.76

22.22

22.22

44.44

6.35

3.25

0.13

4

1.03

63

0.26

us

4.22

19. 16

9.42

53 .90

12.01

3.51

0.06

4

1.07

304

0.12

Aus.

6.67

22.22

4.44

55.56

11.11

3.42

0.17

4

1.16

45

0.35

Qi-~ Sj_g_n.
1.31

no

4.62

no

2.66

no

11.94

no

11 .62

no

11 .25

no

UK

0.00

14.8 1

16.67

61.11

7.41

3.55

0.12

4

0.96

55

0.26

Can.

3.17

12.70

19.05

55.56

9.52

3.56

0. 11

4

0.95

63

0.24

16

us

1.30

3.25

4 .22

38 .64

51 .30

4.37

0.05

5

0.82

304

0.09

none none

17

us

3.25

27.92

32.79

27.60

7.47

3.08

0.06

3

0.99

305

0.11

none none

us

12.99

61 .36

14.29

3.79

0.05

4

0.85

304

0.10

4.53

l l!.(I ~

19

2Q{_l6)

1.62

8.44

Aus.

2.22

4.44

15 .56

42 .22

35.56

4.04

0.14

4

0.95

45

0.29

UK

0.00

5.56

12.96

53.70

27.78

3.96

0.13

4

0.96

55

0.26

Can.

6.35

1.59

6.35

53.97

31.75

4.03

0.12

4

1.02

63

0.26

us

0.65

0.32

12 .34

62.66

22.08

4.07

0.04

4

0.65

302

O.Q7

12.01

3.18

O.Q7

4

1.13

303

0.13

us

3.25

33.77

14.94

34.42

Aus.

11.11

22.22

15 .56

31.11

20.00

3.27

0.19

4

1.32

45

0.40

UK

3.70

16.67

1.85

53 .70

24.07

3.70

0.16

4

1.21

55

0.33

Can.

12.70

36.51

14.29

30.16

6.35

2.81

0.15

2

1.19

63

0.30
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no

none none
24. 19 _y_es

Table 2D: Description of legends for Tables 2A through 2C
Response(%)

Indicates the % of all study respondents with that view

SDA

Strongly disagree

DA

Disagree

UD

Undecided

AG

Agree

SAG

Strongly agree

Descriptive statistics
Mean

The mean response

SE

Standard error associated with the mean reponse

Mode

The response with the highest frequency

SD

Standard deviation associated with the responses

N

Sample size or total number of respondents

CI(95.0%)

95% confidence interval around the mean response

Chi-sq.

Value of the chi-square test statistic computed as
described in the text of the article

Sign.

Results of the chi-square test describing the statistical
significance or lack thereof
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Abstract
The first part of this investigation developed and described quantitative answers
to questions that FDA has posed through the administration of an electronic survey
questionnaire. The goal of this part was to qualitatively probe these issues further by
conducting telephone interviews with key opinion leaders in the United States, Canada,
the United Kingdom and Australia. This study aimed to extend the earlier effort and
gain additional insight into issues described above and explored the opinions of thirty
six key opinion leaders and stakeholders in the area of OTC medicines regulation from
the United States, United Kingdom, Australia and Canada. Results suggest that potential
improvements to the US regulatory framework can include creation of an intermediate,
pharmacist-controlled class of OTC medicines, delineation of data requirements in a
guidance document to support a switch petition, regulation of nontraditional medicines
(dietary supplements and nutraceuticals) also as per current OTC standards of premarket demonstration of safety and efficacy, and, the development of global OTC
monographs. Responses showed support for regulatory agencies to unilaterally switch
drug products and such decisions to be based only on the overall public health benefit
considerations.
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Introduction
As part of examining its overall approach to regulating over-the-counter (OTC)
drug products the US Food and Drug Administration (FDA) has conducted a public
hearing to solicit information from interested persons such as scientists, professional
groups and consumers (1). The FDA listed specific questions related to regulatory
aspects of OTC drug products upon which it requested comments of all interested
groups

(such

as

pharmacists, academicians, physicians, consumers

and

the

pharmaceutical industry).
Part one of this investigation developed and described quantitative answers to
questions that FDA has posed (on issues such as the OTC regulatory environment, role
of regulatory agency in Rx-to-OTC switches, criteria for OTC classification, suitability
of drugs for OTC status and disease conditions for self-medication, consumer behavior
and understanding of OTC medicines and the approval of new OTC medicines)
developed through the administration of an electronic survey questionnaire. The goal of
this part was to qualitatively probe these issues further by conducting telephone
interviews with key opinion leaders in the United States, Canada, the United Kingdom
and Australia. This study aimed to extend the earlier effort and gain additional insight
into issues described above.
Methodology
Measures: A telephone interview survey questionnaire instrument was the primary data

collection method used in this study. Also, to obtain a broad spectrum of views, data
collected from the public statements of some key opinion leaders in the area of OTC
regulation have been used.
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Study participants: Requests for participation in the study were forwarded by email or

telephone to individuals or organizations with established expertise or interest in the
area of nonprescription medicines in the United States, United Kingdom, Canada and
Australia. The group of individuals or organizations requested to participate was
carefully selected to obtain a broad spectrum of views on OTC medicines and their
regulation.
Survey interview: Participants who agreed for the telephone interviews were provided

an introduction to the study and explained the informed consent document. The
University of Rhode Island Institutional Review Board (URI-IRB) reviewed and
approved the questions and the informed consent document before start of the study.
Upon giving their consent, all the participants were interviewed by the author.
Participants were also requested to grant permission for recording the interview for
review and transcription purposes by the author only. Participants were assured that
their identity and individual responses will be kept anonymous and that only collective
data from the interviews will be publicly discussed. Hence, table 1 describes the nature
of the participants only in general terms without specific information. The statements
for the interview survey questionnaire were adapted from the public hearing notice
published by the FDA with a few modifications made to the phraseology as presented
by the FDA. Selected questions posed by the FDA were presented as statements during
the interview and respondents were asked to state their opinion. The format of the
interview was free flowing and the participants were allowed to respond without any
restrictions. The set of statements used in the interviews is appended to this article.
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Data analysis: Data collected through the interviews and the public statements was
pooled and qualitatively examined to discern prominent observations and trends. An
attempt to make inferences helpful towards formulation of rational regulatory policy
was also made.
Results
The opinions of thirty-six stakeholders from United States, Australia, United
Kingdom and Canada have been collected. The nature and composition of the
participants interviewed for this study is presented in table 1. Additionally, table 2
presents a description of the participants whose publicly stated positions on OTC
medicines have been used in this study. Some important stakeholders like American
Association of Health Plans, National Association of Chain Drug Stores in the US,
National Organization for Women and American Association of Retired Persons
(AARP) did not respond to the authors interview requests. The Canadian Association of
Chain Drug Stores (CACDS) stated that they do not have an official position on this
matter. Also, attempts to interview key members of the US House of Representatives
and US Senate in the area of healthcare delivery were not fruitful. A majority of the
participants (72%) were from United States, representation from UK (11 %) and Canada
(11 %) was equal and the reminder of participants was from Australia (6%). Results
have been summarized below according to the nature of the question content.
Regulatory environment
When asked if the regulatory environment for nonprescription medicines was
adequate and if learning from other regulatory models can be gained, responses of the
participants varied widely. Respondents who thought the regulatory systems were
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adequate cited public health and safety as being the underlying criterion for OTC status,
the multi-tier scheduling system in Australia allowed better balance between access and
safety and the OTC monograph model of product approval in the US was built on
strong scientific foundation as reasons. Others disagreed saying that, there was an
aggressive thrust towards deregulation by the industry at the risk of public health, the
growing demand for counseling and education for nonprescription medicines was
unmet, over-regulation was observed where self-regulation could have been adequate,
the US Food, Drug & Cosmetic Act does not clearly define an OTC product and FDA
does not have adequate resources to regulate OTC medicines.
The American Medical Association (AMA represents physicians), Consumer
Health Products Association (CHPA represents manufacturers of nonprescription
medicines in the USA) and the Pharmaceutical Research and Manufacturers of America
(PhRMA represents research-based pharmaceutical and biotechnology companies in the
USA) stated that the existing regulatory model for nonprescription medicines in the
United States was adequate and satisfactory due to the success observed since the
implementation of OTC Drug Review in the early seventies. Mr. Peter Hutt, a food and
drug lawyer who led the FDA's OTC review in the seventies opined that the current
priority attached to regulating OTC medicines within the Agency is inadequate and
greater importance needs to be placed on this matter. He stated that the present OTC
division must be elevated to an office within FDA's organizational hierarchy. He also
stated that the unfinished monographs in certain therapeutic areas must be finalized. Mr.
Pineo and Mr. Steinberg, two food and drug lawyers also agreed with this view of
bringing incomplete monographs to final status.
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The views of the participants on the utility of a pharmacist-controlled class of
nonprescription medicines were wide-ranging. Almost all respondents interviewed said
that the US would benefit from an intermediate class of OTC medicines, but, there were
differences in how such an intermediate class was envisioned. However, most
respondents said that the creation of such a class of drugs in the US is unlikely due to
political reasons. Respondents from Australia, Canada and United Kingdom where such
a class of OTC medicines already exists stated that this class facilitates better
management of risk and benefit in case of nonprescription medicines. National
Community Pharmacist's Association (NCP A) and American Pharmacist's Association
(APhA) strongly supported an intermediate class of medicines. Specifically, the NCPA
supported a transitional class of medicines that can serve as a bridge between
prescription and OTC medicines. The NCP A also stated that the Controlled Substances
Act allows for a C-5 category that is sold only under a pharmacist's supervision or by
prescription. The APhA also suggested that in some states there are collaborative
practice agreements between states and manufacturers allowing limited prescriptive
authority for pharmacists. Dr. Wolfe, a physician and consumer advocate and the
Women's Health Network also supported the utility of a third class of pharmacist
dispensed OTC medicines.
The CHP A and AMA opposed the establishment of a behind-the-counter class
of medicines. They cited the study "Nonprescription Drugs: Value of a pharmacist
controlled class has yet to be demonstrated" conducted by the US Congress' General
Accounting Office as evidence for their position. They asserted that this concept
restricts access and has been rejected by the FDA.
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A substantial majority of the respondents interviewed stated that direct-toconsumer advertising of prescription pharmaceuticals does not affect the reclassification
of those products to OTC status. Also, they strongly endorsed a proposal to create
global OTC monographs so that the scientific basis and knowledge used in approval of
OTC products may be efficiently shared across nations. Respondents also supported the
issuance of a guidance document prepared by the FDA for sponsors describing the
nature and kind of evidence required in switch petitions.
Role of regulatory agency

When asked if their regulatory agency should actively and unilaterally propose
OTC marketing of a drug in the absence of support from the sponsor, the responses
were assorted. Most of the respondents said that it would be appropriate for a regulatory
authority to force a switch against the willingness of a manufacturer if such a move
meets public health needs. However, respondents also stated that the most productive
and efficient approach to switches would be a collaborative one between the
manufacturer and the regulatory authority. The reasons provided to justify a unilateral
switch by the regulatory authority were; (a) public health benefit must be the paramount
criterion for driving such actions (b) in some therapeutic areas the safest treatment
options are available by prescription only and not OTC, and (c) sponsors should not be
allowed to wait until the economically opportune time for them to initiate switch
proposals.
Some participants said that while they agree with unilateral switching by the
regulatory authority in principle, they envisioned legal and intellectual property
problems, if the US FDA takes such an action. The legal and intellectual property
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difficulties were also the rationale on which the CHP A and PhRMA vigorously opposed
the authority of FDA to unilaterally switch drugs to OTC status. Dr. Woodcock,
Director, Center for Drug Evaluation & Research (CDER), FDA stated that FDA has
the legal authority to unilaterally switch drugs to OTC status during a recent
Congressional hearing on this subject. Kaiser Permanante, the largest nonprofit health
maintenance organization in America took the position that OTC status must be
determined only on the basis of the pharmacological profile of the drug and safe use by
consumers irrespective of manufacturers willingness to switch. Well Point Health
Networks, a managed care company also agreed with the Kaiser's position and
suggested that FDA must take an activist role to reclassify prescription drugs deemed
safe for OTC use regardless of sponsor's willingness.
Criteria for OTC classification

A substantial majority of the participants opined that the current OTCness
criterion of safety/efficacy of drug, self-treatment of condition and overall public health
benefit of a medicinal product in the absence of a learned intermediary as adequate for
making decisions on OTC suitability. However, a reasonable portion of the respondents
also stated there were inconsistencies in the implementation of these criterion in the
decision making process and evaluating OTC suitability. One participant stated that
there should not be any limitations on who can petition for reclassification to OTC
status in the US. Also, some respondents requested clarifications in the regulatory
process for OTC evaluation of prescription medicines.
CHPA, PhRMA, Kaiser Permanante and Well Point Health Networks agreed
that the existing regulatory criteria applicable in the estimation of risk-to-benefit ratio
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for OTC availability were adequate. The APhA recommended that the FDA must
additionally consider the environments surrounding the use of the drug and the disease
or symptom for which it is used . Dr. Wolfe suggested that ease of self-diagnosis, selflimited or chronic condition, benefit-to-risk ratio and its evaluation, low potential for
abuse, adverse reactions and drug interactions, and long-term prescription use data as
six principles that must be used to evaluate potential Rx-to-OTC switch candidates.
A significant theme that was repeatedly observed among the participants was
serious concern over the unscientific approval process for non-traditional OTC
medicines under the Dietary Supplement Health and Enhancement Act (DSHEA).
Almost all respondents felt that the robust scientific and data-driven decision making
process followed for most pharmaceutical OTC products as per the OTC Drug Review
was completely eliminated for DSHEA products and such was medically unjustifiable.
Suitability of disease conditions for self-medication and drugs for OTC status

The opinion of participants interviewed on the suitability of disease conditions
and drug classes for OTC use was diverse. Almost all the participants strongly opposed
the OTC use of medicines such as diuretics, antihypertensives, cholesterol-lowering
drugs, oral antidiabetic drugs, osteoporosis treatments, antimicrobials and oral
contraceptives. But, a reasonable subsection of the participants said that they would be
more amenable to OTC status for some of these drug classes (such as cholesterollowering drugs, some types of osteoporosis treatments, diuretics and antihypertensives)
if pharmacist intervention and prescription are made mandatory in the purchasing
process. The Preventive Cardiovascular Nurses Association strongly recommended that
FDA consider OTC status for some cholesterol lowering statin medications. Dr. Wolfe
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strongly opposed consideration of OTC status for statins. None of the participants
thought that antimicrobials should be made OTC and very few groups supported OTC
status for oral contraceptives. The National Women's Health Network and the American
Life League opposed OTC status for oral contraceptives. But, the National Women's
Health Network joined the American Society for Emergency Contraception in strongly
supporting OTC status for emergency contraceptives.
The views of respondents were similar on the suitability of conditions such as
chronic illnesses (such as asthma), diseases that require an initial diagnosis by a
physician (such as a hypercholesterolemia) and hypertension for self-treatment.
Respondents were more favorable to certain classes of asthma medications being OTC,
if pharmacist involvement were mandatory. Mr. Hutt stated that at the time of the OTC
Drug Review, the committees were asked to approach the evaluation of OTC suitability
with a very open mind, with no conditions or classes presumed to be unsuitable as the
philosophy was to have all drugs available for consideration and deliberation before the
committees. The CHP A also advocated a similar approach of open-mindedness without
presuming unsuitability and arriving at decisions based on a data-driven and casespecific basis.
The AMA was concerned at a number of prescription drugs used to treat various
chronic diseases being considered for switch to OTC status. The AMA recommended
that the FDA move with extreme caution in this area. AMA argued that the benefits of
physician diagnosis (including other pre-exisiting conditions), prescription of the right
drug at the right dosage, counseling, and monitoring for compliance, therapeutic
response and adverse effects for these chronic diseases are very important. In the
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AMA's view, to potentially lose the benefit of physician supervision by switching drug
products to OTC status would be detrimental to the public health.
Overall, the participants felt that complete elimination of a learned intermediary
(physician or pharmacist) would be imprudent and supported a collaborative system
where a close relationship between the physician and the pharmacist is preserved with
the responsibility for maintenance and monitoring of the treatment placed largely on the
pharmacist.
Consumer understanding and behavior

A reasonable proportion of the study participants believed that consumers could
neither make a rational selection of treatment regimens nor choose the best way to cure
their illness, when there are coexisting prescription and OTC therapies for a certain
disease. Further, they also thought that prevention claims for OTC medicines might
encourage ill-advised behavior among consumers. Respondents reasoned that
consumers are neither trained nor qualified to make such decisions and most often do
not have the appropriate information to use medicines properly in an OTC environment.
CHP A asserted that its research showed that 95% of consumers read the labels
before using OTC medicines and that there is a very high level of label comprehension.
Also, they stated that OTC does not necessarily eliminate the physician from the selftreatment process. National Consumer's League's behavioral research data showed that
consumers were willing to learn and had good understanding in some areas of OTC use,
but in other aspects they needed professional counseling. APhA and NCPA stated
support for methods that assess consumer understanding of proposed labeling that
involves the pharmacy and the pharmacist. Dr. Bradford, a researcher in the area of
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OTC clinical trials, suggested active surveillance as a tool to estimate how consumers
interface with the labeling and use the OTC medicine. One respondent representing a
women's health group stated that FDA must ensure that consumers receive unbiased
information and not rely solely on manufacturer's advertisements. Mr. Hutt who
oversaw the OTC Drug review commented that the review was conducted on the
premise that consumers are intelligent, can be educated, interested in their own health
and want a share of their healthcare decisions.
App roval of new OTC medicines

When asked if the first drug to enter the OTC market should be the "best" drug
in terms of benefit-to-risk ratio within a therapeutic class, a majority of respondents
concurred. A majority of the respondents agreed that the availability of a "better" OTC
product in terms of efficacy or safety should not affect the status of products already in
the OTC market for treatment of the same condition within a therapeutic class.
Additionally, participants stated that when newer nonprescription products become
available within a therapeutic class, older therapies that may provide less benefit or
more risk should not be removed from the market or their labeling should not be
revised. On the issue of direct-to-OTC marketing (a new chemical entity directly
marketed as an OTC product without being a prescription medicine for some duration),
there was universal agreement that products must be marketed as a prescription
medicine under the supervision of a learned intermediary for some duration before
reclassification to OTC status may be considered. Respondents stated that a drug's
safety profile cannot be understood based solely on controlled clinical trials during
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development and surveillance during real-world clinical practice is necessary before
OTC status may be considered.
Discussion
As with any study, this study is subject to limitations and the results must only
be interpreted within the context of any such limitations. An important limitation of this
study is that the study sample population may not accurately represent the overall
population of stakeholders. Although attempts were made to interview all stakeholders,
it is rarely feasible to fully realize this objective. Also, responses are influenced by the
inherent biases of the respondents and must be accounted in analyzing the data. Despite
the limitations, these results are useful to discern the attitudes of important stakeholders
on regulation of nonprescription medicines. This assertion is reinforced, as the study is
exploratory in nature and was not designed to test any specific hypotheses. Moreover,
the absence of any information in the global context related to these important issues
accentuates the significance of these results.
Study results demonstrate that opinions of respondents over most issues were
wide-ranging in nature. This observation is reasonable as all stakeholders do not share
the same interests and their positions are correspondingly influenced. It is evident from
the results that stakeholders' positions are developed to be favorable to their underlying
interests.

However, optimal regulatory policy must be formulated to maximize the

public health benefit. Thus, unhindered access to potent drug products and their safe use
by consumers must be cautiously balanced to acheive effective self-medication.
Results suggest that proposals to improve US regulatory structure for OTC
medicines may include finalizing the pending OTC monographs and increasing
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pharmacist intervention and/or prescriptive authority for OTC medicines. The latter
proposal has been a controversial one for sometime and as discussed earlier has been
vigorously opposed by the CHPA and the AMA. However, views from respondents in
countries that have a pharmacist class of OTC medicines show that such a class can be
enormously beneficial in ensuring safe and effective use of OTC drug products. Results
from the earlier part of this study also evidenced very strong support for a pharmacist
class of OTC medicines. Additionally, as the OTC arena in the US evolves and more
potent prescription drug products are considered for OTC status, the pharmacist
intervention can be employed as an effective tool in increasing the public health benefit
and decreasing the public health risk.
Evidence shows support for regulatory agencies to be able to unilaterally switch
drug products and that such decisions must be based only on the overall public health
benefit considerations. Study observations indicate that regulatory agencies must pursue
a collaborative approach with manufacturers in switching drug products to OTC status.
Based on the Australian system, it may be helpful to include "judicious use of
medicines" to the current OTCness criterion as applied by the FDA in evaluating drug
products for OTC status. Judicious use is defined as "the use of medicines only when
appropriate with non-medicinal alternatives considered as needed" as per the Australian
system. The urgency to correct the current non data-driven regulatory process for
marketing of dietary supplements as per DSHEA is strongly supported by the study
results. The importance of addressing safety of products marketed through DSHEA
process cannot be overemphasized, as dietary supplements are rapidly becoming a
substantial part of the OTC armamentarium.
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Observations suggest that the suitability of disease conditions for self-treatment
and drugs for OTC use must be evaluated without any presumption or bias in a case
specific manner based on a data-driven approach with overall public health benefit as
the paramount objective. Respondents stated that consumers are inherently intelligent
and if educated adequately can make the decisions resulting in the responsible use of
OTC medicines.

In this regard, the onus of consumer education must be shared

between the manufacturer and the regulatory authority to ensure that consumers have
complete and truthful information that will enable them to use OTC medicines safely
and effectively. Again, the utility of a pharmacist as a learned intermediary is invaluable
in this regard and efforts to bridge the gap between the physician and the pharmacist to
enhance the quality of healthcare delivery must be seriously considered. Results also
suggest that marketing status of medicines should not be affected by the availability of
newer or better medicines as it would be desirable to have a variety of treatment options
as individuals do not respond to pharmacological agents in a uniform manner.
Conclusions
This study explored the opinions of thirty six key opm10n leaders and
stakeholders in the area of OTC medicines regulation from the United States, United
Kingdom, Australia and Canada on issues such as the OTC regulatory environment, role
of regulatory agency in Rx-to-OTC switches, criteria for OTC classification, suitability
of drugs for OTC status and disease conditions for self-medication, consumer behavior
and understanding of OTC medicines and the approval of new OTC medicines. Results
suggest that potential improvements to the US regulatory framework can include
creation of an intermediate, pharmacist-controlled class of OTC medicines, delineation
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of data requirements in a guidance document to support a switch petition, regulation of
nontraditional medicines (dietary supplements and nutraceuticals) also as per current
OTC standards of pre-market demonstration of safety and efficacy, and, the
development of global OTC monographs.
Responses showed support for regulatory agencies to unilaterally switch drug
products and such decisions to be based only on the overall public health benefit
considerations. A substantial majority of all respondents believed that consumers are
inherently intelligent and if educated adequately can make the decisions resulting in the
responsible use of OTC medicines.
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Appendix
List of statements in the interview questionnaire

1. Current regulatory environment for marketing nonprescription medicines (NPM) in
your country is adequate.
2. Your country can learn from different nonprescription medicine regulatory
environments and marketing systems within other developed nations.
3. US should adopt a regulatory framework that includes an intermediate, pharmacistcontrolled class of nonprescription medicines (i.e. behind-the-counter medicines).
(US ONLY)
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4. The relevant regulatory Agency in your country should actively propose
nonprescription marketing of a prescription drug in the absence of support from the
drug manufacturer (sponsor).
5. The relevant regulatory Agency in your country should be more active m
unilaterally initiating switches of prescription medicines to nonprescription use.
6. Current criteria used by the relevant regulatory Agency in your country in rendering
decisions on availability of nonprescription drug products is adequate.
7. The following types of diseases/illnesses are suitable for treatment with
nonprescription drug products:
a. Chronic illnesses (such as asthma)
b. Diseases that require initial diagnosis by a physician (such as
hypercholesterolemia, i.e. high cholesterol)
c. Diseases (such as hypertension) that, if left untreated or are
inadequately treated can lead to serious morbidity or mortality
8. The following are specific classes of medicines that are not currently marketed as
nonprescription medicines that should be available without a prescription:
a. Diuretics
b. Antihypertensive drugs
c. Cholesterol lowering drugs
d. Oral antidiabetic drugs
e. Treatments for osteoporosis (including its prevention)
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f.

Antimicrobials

g. Oral contraceptives
9. Rational selection of treatment regimens by consumers may be ensured when there
are coexisting prescription and nonprescription therapies for a certain disease.
10. Patients know the best ways to treat their illnesses in an environment with
coexisting prescription and nonprescription therapies for a certain disease.
11. The risks and benefits to individuals and public health should be assessed and
weighed in any decision on nonprescription marketing of drug products (for
example, the potential benefits of nonprescription antimicrobial agents with the
potential risks to society at large of the development of resistant organisms).
12. Prevention claims for nonprescription medicines encourage ill-advised behavior (for
example, use of an nonprescription cholesterol lowering drug would allow patients
to ignore other needed interventions such as smoking cessation, dietary discretion
and management of other risk factors).
13. Within a therapeutic class, the first drug to enter the nonprescription market should
be the "best" drug in terms of the benefit-to-risk ratio.
14. Within a therapeutic class, the availability of a "better" nonprescription product in
terms of efficacy or safety should affect the status of products already on the
nonprescription market for treatment of the same condition.
15. When newer nonprescription products become available within a therapeutic class,
older therapies that may provide less benefit or more risk should be either removed
from the market or their labeling should be revised.
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16. Initiatives to market at least some nontraditional medicines (dietary supplements,
vitamins, nutraceuticals and other traditional medicines) as regular OTC drug
products by subjecting them to the same rigorous premarketing scientific evaluation
and clinical review criteria should be promoted. (US ONLY)
17. Direct-to-consumer marketing of prescription drug products adversely influences
reclassification to OTC status and availability of new OTC drug products. (US
ONLY)
18. Initiatives to

develop

and

establish globally acceptable monographs

for

nonprescription drug products, at least, within the developed world should be
promoted.
19. The US FDA should issue a "Guidance for Industry" document on the
reclassification of prescription products to OTC status describing the nature of
evidence required to substantiate such applications. (US ONLY)
20. Assuming a new chemical entity meets all regulatory requirements necessary for
nonprescription classification, it should still be marketed as prescription medicine
for a specified duration before reclassification to nonprescription status may be
considered.
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Table 1: Description of participants interviewed for this study

Participant

Description

Australia
Participant # 1

Community pharmacist affiliated with the group of independent retail
pharmacists

Participant #2

Community pharmacist and Self-care specialist affiliated with the group
of practicing pharmacists
United Kingdom

Participant #3

Community pharmacist, lawyer and professor affiliated with the
University of Nottingham

Participant #4

Health care economist and professor affiliated with the University of
London

Participant #5

Regulatory specialist affiliated with the industry group of manufacturers
of nonprescription medicines
Canada

Participant #6

Regulatory specialist affiliated with the industry group of manufacturers
of nonprescription medicines

Participant #7

Community pharmacist affiliated with the group of practicing
pharmacists

Participant #8

Pharmacy regulatory professional affiliated with the group of
pharmaceutical regulatory authorities

Participant #9

Professor and researcher in OTC medicines affiliated with University of
Saskatchewan
United States of America

Participant # 10

Physician, professor and researcher in OTC medicines affiliated with
Northwestern University

Participant #11

Community pharmacist and lawyer affiliated with the group of
practicing pharmacists

Participant # 12

Community pharmacist, clinical researcher and professor affiliated with
Drake University

Participant #13

Physician, professor and expert advisor to US FDA on OTC medicines
affiliated with University of Pennsylvania
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Table I: Description of participants interviewed for this study

Participant

Description

Participant #14

Community pharmacist, self-care researcher and professor affiliated
with University of Florida

Participant # 15

Pharmacist, Ex-FDA and Ex-Industry leader affiliated with a food and
drug law think tank

Participant # 16

Community pharmacist, self-care researcher, author and professor
affiliated with Southwest Oklahoma State University

Participant #17

Representative of a women's health consumer activist group

Participant # 18

Pharmacoeconomic policy expert, researcher and professor affiliated
with the University of Minnesota
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Table 2: Description of participants whose written statements were used
for this study

Participant

Dr. Michael Maves, Dr. Bill
Soller and Ms. Eve Bachrach
Mr. DougHo~
Dr. Ratcliffe Anderson Jr.
Dr. Sidney Wolfe
Mr. Antho~Baruetta
Ms. Linda Golodner
Mr. Steve Francesco
Mr. Peter Barton Hutt
Mr. Russell Bantham
Ms. Judie Brown
Ms. Tara Shochet
Ms. Suzanne Hughes
Mr. Robert Seidman
Dr. Randy Juhl

Dr. David Bradford
Mr. Robert G Pineo
Mr. David Steinberg_

Description/Affiliation

Country

Consumer Health Products Association

USA

National Communi.!.}'._ Pharmacist's Association
American Medical Association
Physician and consumer activist affiliated with
Public Citizen
L~er and executive with Kaiser Permanante
National Consumer's League
Head of Rx-to-OTC Switch Consulting firm
Francesco International

USA
USA
USA

Food & Drug lawyer and Ex-FDA staff member
associated with the OTC Dru_g_ Review_]>focess
Pharmaceutical Research and Manufacturers
Association{PhRMA)
American Life Leagti_e
American Soci~ for Emerg_en~ Contracc:E_tion
Registered Nurse and President Lipid Nurse Task
Force
Chief Pharmac:.t Officer, Wel~oint Health Network
Ex-FDA Advisory Committee chairman,
Pharmacist, CHP A associate and Dean, Unversity
of Pittsburg_h, School of Pharma~
Clinical researcher specializing in Rx-to-OTC
switches with P~s Research
Food & Drug lawyer and Ex-FDA staff member
associated with the OTC Dru_g_ ReviewJ>fOCess
Food & Dru_g_l~er
British Medical Association
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USA
USA
USA
USA
USA
USA
USA
USA
USA
USA

USA
USA
USA
United
Ki!_!g__dom

SECTION III
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The following is a list of the journals in which manuscripts from this dissertation
have been or will be published:
I. Achanta A.S. , Willey-Temkin C., and Rhodes C.T., "Attitudes and Opinions

Towards Regulatory Aspects of Nonprescription Medicines", accepted for
publication in Regulatory Affairs Journal. (Manuscript VII)
2. Achanta A.S. and Rhodes C.T., "Examination of Proposed OTC status for
Nonsedating Antihistamines", Clinical Research & Regulatory Affairs, 19(1 ): 1-12
(2002). (Manuscript VI)
3. Achanta A.S. and Rhodes C.T., "Evaluation of Proposed OTC Switch for
Lovastatin", Clinical Research & Regulatory Affairs, 18(1 &2): 83-104 (2001 ).
(Manuscript V)
4. Achanta A.S. and Rhodes C.T., "The Metaproterenol OTC Switch in the USA",
Regulatory Affairs Journal, 12(8): 641-644 (2001). (Manuscript IV)
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APPENDIXB
Appendix B collates a variety of supporting information that would aid clearer
understanding of the methodological details, discussion and inferences presented in the
earlier manuscripts. The data included here are the appropriate transcripts, briefing
material used at the FDA advisory committee meetings discussed in this dissertation,
electronic files pertaining to the electronic survey administered and the database of the
results collected from the survey. Due to the voluminous and digital nature of this
supporting data, the information is presented in electronic format on a compact disk.
The compact disk is attached to the dissertation.
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APPENDIXC
This appendix presents a brief chronological list of some key milestones in the
history of food and drug regulation in the United States that are relevant to this
dissertation. This information is presented to help the reader provide a historical
perspective on developments related to drug regulation and obtain a detailed
understanding of some discussions presented in the dissertation. The list provided below
is an abridged version of "Milestones in U.S. Food and Drug Law History" published by
the

US

FDA.

The

complete

list

may

be

accessed

at

http://www. fda.govI opacom/backgrounders/miles.html
1820
Eleven physicians meet in Washington, D.C., to establish the U.S. PHARMACOPEIA,
the first compendium of standard drugs for the United States.
1862
PRESIDENT LINCOLN appoints a chemist, Charles M. Wetherill, to serve in the new
Department of Agriculture. This was the beginning of the Bureau of Chemistry, the
predecessor of the Food and Drug Administration.
1880
PETER COLLIER, chief chemist, U.S. Department of Agriculture, recommends
passage of a national food and drug law, following his own food adulteration
investigations. The bill was defeated, but during the next 25 years more than 100 food
and drug bills were introduced in Congress.
1883
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DR. HARVEY W. WILEY becomes chief chemist, expanding the Bureau of
Chemistry's food adulteration studies. Campaigning for a federal law, Dr. Wiley is
called the "Crusading Chemist" and "Father of the Pure Food and Drugs Act".
1898
Association of Official Agricultural Chemists (now AOAC International) establishes a
COMMITTEE ON FOOD STAND ARDS headed by Dr. Wiley. States begin
incorporating these standards into their food statutes.
1902
The BIOLOGICS CONTROL ACT is passed to ensure purity and safety of serums,
vaccines, and similar products used to prevent or treat diseases in humans.
Congress appropriates $5,000 to the Bureau of Chemistry to study CHEMICAL
PRESERVATIVES AND COLORS and their effects on digestion and health. Dr.
Wiley's studies draw widespread attention to the problem of food adulteration. Public
support for passage of a federal food and drug law grows.
1906
The original FOOD AND DRUGS ACT is passed by Congress on June 30 and signed
by President Theodore Roosevelt. It prohibits interstate commerce in misbranded and
adulterated foods, drinks and drugs. The MEAT INSPECTION ACT is passed the same
day. Shocking disclosures of unsanitary conditions in meat-packing plants, the use of
poisonous preservatives and dyes in foods, and cure-all claims for worthless and
dangerous patent medicines were the major problems leading to the enactment of these
laws.
1911
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In U.S. v. JOHNSON, the Supreme Court rules that the 1906 Food and Drugs Act does

not prohibit false therapeutic claims but only false and misleading statements about the
ingredients or identity of a drug.
1912
Congress enacts the SHERLEY AMENDMENT to overcome the ruling in U.S. v.
Johnson. It prohibits labeling medicines with false therapeutic claims intended to
defraud the purchaser, a standard difficult to prove.
1913
GOULD AMENDMENT requires that food package contents be "plainly and
conspicuously marked on the outside of the package in terms of weight, measure, or
numerical count."
1927
The Bureau of Chemistry is reorganized into two separate entities. Regulatory functions
are located in the FOOD, DRUG, AND INSECTICIDE ADMINISTRATION, and
nonregulatory research is located in the BUREAU OF CHEMISTRY AND SOILS.
1930
The name of the Food, Drug, and Insecticide Administration is shortened to FOOD
AND DRUG ADMINISTRATION (FDA) under an agricultural appropriations act.
1933
FDA recommends a complete revision of the obsolete 1906 FOOD AND DRUGS ACT.
The first bill is introduced into the Senate, launching a five-year legislative battle.
1937
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ELIXIR OF SULFANILAMIDE, containing the poisonous solvent diethylene glycol,
kills 107 persons, many of whom are children, dramatizing the need to establish drug
safety before marketing and to enact the pending food and drug law.
1938
THE FEDERAL FOOD, DRUG, AND COSMETIC (FDC) ACT of 1938 is passed by
Congress, containing new provisions:
0

Extending control to cosmetics and therapeutic devices.

0

Requiring new drugs to be shown safe before marketing-starting a new system of
drug regulation.

0

Eliminating the Sherley Amendment requirement to prove intent to defraud in drug
misbranding cases.

0

Providing that safe tolerances be set for unavoidable poisonous substances.

0

Authorizing standards of identity, quality, and fill-of-container for foods.

0

Authorizing factory inspections.

0

Adding the remedy of court injunctions to the previous penalties of seizures and
prosecutions.

Under the WHEELER-LEA ACT, the Federal Trade Commission is charged with
overseeing advertising associated with products otherwise regulated by FDA, with the
exception of prescription drugs.
1940
FDA TRANSFERRED from the Department of Agriculture to the Federal Security
Agency, with Walter G. Campbell appointed as the first Commissioner of Food and
Drugs.
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1941
INSULIN AMENDMENT requires FDA to test and certify purity and potency of this
life-saving drug for diabetes.
1943
In U.S. v. DOTTERWEICH, the Supreme Court rules that the responsible officials of a

corporation, as well as the corporation itself, may be prosecuted for violations. It need
not be proven that the officials intended, or even knew of, the violations.
1944
PUBLIC HEALTH SERVICE ACT is passed, covering a broad spectrum of health
concerns, including regulation of biological products and control of communicable
diseases.
1945
PENICILLIN AMENDMENT requires FDA testing and certification of safety and
effectiveness of all penicillin products. Later amendments extended this requirement to
all antibiotics. In 1983 such control was found no longer needed and was abolished.
1949
FDA publishes GUIDANCE TO INDUSTRY for the first time. This guidance,
"Procedures for the Appraisal of the Toxicity of Chemicals in Food," came to be known
as the "black book."
1950
In ALBERTY FOOD PRODUCTS CO. v. U.S. , a court of appeals rules that the
directions for use on a drug label must include the purpose for which the drug is
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offered. Therefore, a worthless remedy cannot escape the law by not stating the
condition it is supposed to treat.
1951
DURHAM-HUMPHREY AMENDMENT defines the kinds of drugs that cannot be
safely used without medical supervision and restricts their sale to prescription by a
licensed practitioner.
1952
In U.S. v. CARDIFF, the Supreme Court rules that the factory inspection provision of
the 1938 FDC Act is too vague to be enforced as criminal law.
FDA CONSUMER CONSULTANTS are appointed in each field district to maintain
communications with consumers and ensure that FDA considers their needs and
problems.
1953
FEDERAL SECURITY AGENCY becomes the Department of Health, Education, and
Welfare (HEW).
FACTORY INSPECTION AMENDMENT clarifies previous law and requires FDA to
give manufacturers written reports of conditions observed during inspections and
analyses of factory samples.
1955
HEW SECRETARY OVETA CULP HOBBY appoints a committee of 14 citizens to
study the adequacy of FDA's facilities and programs. The committee recommends a
substantial expansion of FDA staff and facilities, a new headquarters building, and more
use of educational and informational programs.
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The DIVISION OF BIOLOGICS CONTROL became an independent entity within the
National Institutes of Health, after polio vaccine thought to have been inactivated is
associated with about 260 cases of polio.
1958
FDA publishes in the Federal Register the first list of SUBSTANCES GENERALLY
RECOGNIZED AS SAFE (GRAS). The list contains nearly 200 substances.
1962
THALIDOMIDE, a new sleeping pill, is found to have caused birth defects in
thousands of babies born in western Europe. News reports on the role of Dr. Frances
Kelsey, FDA medical officer, in keeping the drug off the U.S. market, arouse public
support for stronger drug regulation.
KEFAUVER-HARRIS DRUG AMENDMENTS passed to ensure drug efficacy and
greater drug safety. For the first time, drug manufacturers are required to prove to FDA
the effectiveness of their products before marketing them.
1965
DRUG ABUSE CONTROL AMENDMENTS are enacted to deal with problems caused
by abuse of depressants, stimulants and hallucinogens.
1966
FDA contracts with the National Academy of Sciences/National Research Council to
evaluate the EFFECTIVENESS OF 4,000 DRUGS approved on the basis of safety
alone between 1938 and 1962.

232

FAIR PACKAGING AND LABELING ACT requires all consumer products in
interstate commerce to be honestly and informatively labeled, with FDA enforcing
provisions on foods, drugs, cosmetics, and medical devices.
1968
FDA forms the DRUG EFFICACY STUDY IMPLEMENTATI ON (DESI) to
implement recommendations of the National Academy of Sciences investigation of
effectiveness of drugs first marketed between 1938 and 1962.
1970
In UPJOHN v. FINCH the Court of Appeals upholds enforcement of the 1962 drug
effectiveness amendments by ruling that commercial success alone does not constitute
substantial evidence of drug safety and efficacy.
FDA requires the first PATIENT PACKAGE INSERT: oral contraceptives must
contain information for the patient about specific risks and benefits.
The COMPREHENSIVE DRUG ABUSE PREVENTION AND CONTROL ACT
replaces previous laws and categorizes drugs based on abuse and addiction potential
compared to their therapeutic value.
1972
OVER-THE-COUNTER DRUG REVIEW begun to enhance the safety, effectiveness
and appropriate labeling of drugs sold without prescription.
REGULATION OF BIOLOGICS-including serums, vaccmes, and blood products-is
transferred from NIH to FDA.
1973
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THE U.S. SUPREME COURT upholds the 1962 drug effectiveness law and endorses
FDA action to control entire classes of products by regulations rather than to rely only
on time-consuming litigation.
CONSUMER PRODUCT SAFETY COMMISSION created by Congress; takes over
programs pioneered by FDA under 1927 Caustic Poison Act, 1960 Federal Hazardous
Substances Labeling Act, 1966 Child Protection Act, and PHS accident prevention
activities for safety of toys, home appliances, etc.
1976
VITAMINS AND MINERALS AMENDMENTS ("Proxmire Amendments") stop FDA
from establishing standards limiting potency of vitamins and minerals in food
supplements or regulating them as drugs based solely on potency.
1982
TAMPER-RESISTANT PACKAGING REGULATIONS issued by FDA to prevent
poisonings such as deaths from cyanide placed in Tylenol capsules. The Federal AntiTampering Act passed in 1983 makes it a crime to tamper with packaged consumer
products.
FDA publishes first RED BOOK (successor to 1949 "black book"), officially known as
Toxicological Principles for the Safety Assessment of Direct Food Additives and Color
Additives Used in Food.
1983
ORPHAN DRUG ACT passed, enabling FDA to promote research and marketing of
drugs needed for treating rare diseases.
1984
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DRUG PRICE COMPETITION AND PATENT TERM RESTORATION ACT
expedites the availability of less costly generic drugs by permitting FDA to approve
applications to market generic versions of brand-name drugs without repeating the
research done to prove them safe and effective. At the same time, the brand-name
companies can apply for up to five years additional patent protection for the new
medicines they developed to make up for time lost while their products were going
through FDA's approval process.
1985
AIDS TEST FOR BLOOD approved by FDA in its first major action to protect patients
from infected donors.
1987
INVESTIGATIONAL DRUG REGULATIONS REVISED to expand access to
experimental drugs for patients with serious diseases with no alternative therapies.
1988
FOOD AND DRUG ADMINISTRATION ACT of 1988 officially establishes FDA as
an Agency of the Department of Health and Human Services with a Commissioner of
Food and Drugs appointed by the President with the advice and consent of the Senate,
and broadly spells out the responsibilities of the Secretary and the Commissioner for
research, enforcement, education, and information.
1991
Regulations published to ACCELERATE THE REVIEW OF DRUGS for lifethreatening diseases.
1992
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GENERIC DRUG ENFORCEMENT ACT imposes debarment and other penalties for
illegal acts involving abbreviated drug applications.
PRESCRIPTION DRUG USER FEE ACT requires drug and biologics manufacturers to
pay fees for product applications and supplements, and other services. The act also
requires FDA to use these funds to hire more reviewers to assess applications.
1994
DIETARY SUPPLEMENT HEALTH AND EDUCATION ACT establishes specific
labeling requirements, provides a regulatory framework, and authorizes FDA to
promulgate good manufacturing practice regulations for dietary supplements. This act
defines "dietary supplements" and "dietary ingredients" and classifies them as food. The
act also establishes a commission to recommend how to regulate claims.
FDA announces it could consider REGULATING NICOTINE in cigarettes as a drug, in
response to a Citizen's Petition by the Coalition on Smoking or Health.
1995
FDA declares CIGARETTES to be "drug delivery devices." Restrictions are proposed
on marketing and sales to reduce smoking by young people.
1997
FOOD AND DRUG ADMINISTRATION MODERNIZATION ACT reauthorizes the
Prescription Drug User Fee Act of 1992 and mandates the most wide-ranging reforms in
Agency practices since 1938. Provisions include measures to accelerate review of
devices, regulate advertising of unapproved uses of approved drugs and devices, and
regulate health claims for foods.
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SUMMARY OF CONCLUSIONS
Synopsis
The use of over-the-counter (OTC) medicines and interest in self-care is rapidly
increasing worldwide. This dissertation presents the first and, perhaps, the most
comprehensive analysis of the classification of nonprescription medicines and Rx-toOTC switch criteria in the United States, United Kingdom, Canada, Japan and
Australia. The US FDA's overall switch regulatory policies were investigated through
the application of case-history evaluations. An innovative investigational method that
utilized a combination of web-based global electronic survey instrument and a
telephone interview survey instrument has been applied to measure and study the
attitudes and opinions of important stakeholders on global issues of vital interest to
regulation of nonprescription medicines. The data collected has been used to provide
answers to some questions posed by the US FDA as part of its overall review of
regulation of OTC products in the US.
This study demonstrates the utility of electronic communication in the rapid and
effective completion of a global survey. Also, the electronic survey instrument is
presented as an efficient alternative to traditional questionnaire-by-mail survey
technique. Data shows that the OTC regulatory model in the United States may be
improved. Evidence indicates that principles upon which approaches for improvements
must be based are: an objective evaluation of pharmacist class of OTC medicines,
development of effective consumer education tools, increase in regulation of nontraditional OTC medicines, not all disease conditions and drug classes are suitable for
self-treatment, a collaborative approach by FDA towards switching that includes all
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stakeholders is more favored, decisions on switch petitions must be case-specific
without a presumptive bias and public health benefit must be the paramount evaluation
criterion.
The significance of information presented in this dissertation is amplified as this
area has received little academic attention and information is not readily available. It is
proposed that an examination of the interactive effects between scientific, regulatory
and economic principles affecting nonprescription medicines and their optimization to
maximize public health benefit would be appropriate for subsequent research.
List of conclusions
Presented below in detail are some of the significant and original findings resulting
from this study:
1. Globally, healthcare systems are changing significantly to affect the use and
attitudes toward over-the-counter (OTC) medicines and interest in self-care is
rapidly increasing. In recent years, self-medication has undergone a dramatic change
due to the advent of herbal medicines, dietary supplements, nutraceuticals and
health foods in addition to traditional nonprescription medicines, and, increasing
societal preferences towards greater individual control over the use of medicines. It
is widely believed that responsible use of OTC medicines can lead to overall cost
savings and public health benefit. Hence, the regulatory framework related to
nonprescription medicines has become an important priority for regulatory
authorities, academicians and the industry.
2. This dissertation presents the first and, perhaps, the most comprehensive analysis of
the classification of nonprescription medicines and Rx-to-OTC switch criteria in the
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United States, United Kingdom, Canada, Japan and Australia. A new approach to
investigating US FDA's overall switch regulatory policies through the application of
case-history evaluations has been utilized. The significance of information elicited
through this dissertation is amplified as this area has received little academic
attention and only sparse data is available.
3. A comparative examination of the OTC regulatory structures in the United States,
United Kingdom, Canada and Australia shows universal recognition of OTC
medicines as vital for public health care and remarkable differences in the
classification of OTC medicines and criterion used for evaluation of Rx-to-OTC
switch applications. A substantial majority of all survey respondents endorsed the
development of globally acceptable monographs for OTC drug products within the
developed world, so that scientific knowledge and best practices may be shared
leading to efficiencies in regulation of nonprescription medicines and positive
public health outcomes.
4. An overwhelming majority of survey respondents stated that the paramount criterion
for deciding OTC status must be overall public health benefit. Examination of
FDA's application of switch regulatory policy in the case of nicotine replacement
therapy, wherein nicotine, a recognized addictive drug, was made available without
a prescription as a smoking cessation aid, demonstrates that FDA's action was in
line with the survey finding. Post switch evidence showed that OTC reclassification
of Nicorette® achieved the anticipated goal of balancing increased access with
decreased control and led to public health benefit. This switch case also emphasizes
the need to expand the use of innovative consumer education, communication tools

239

and behavioral support programs successfully pioneered and demonstrated by the
sponsor.
5. The case of metaproterenol OTC switch by the FDA upon its own initiative offers
valuable information in the comprehension of FDA's application of OTC switch
regulatory policy. The FDA is encouraged to initiate switch proposals that it
considers to be safe and effective in an OTC environment and offer overall public
health benefit. The learning from the failed metaproterenol switch emphasizes that a
collaborative effort with the sponsor and all interested parties is more likely to result
in a scientifically robust switch decision. Hence, the Agency must properly manage
the consideration of switch proposals that it has initiated by ensuring active
participation of all possible stakeholders that may be impacted by its rulemaking.
6. It is possible to reason that for drugs such as lovastatin, used for chronic and
asymptomatic conditions, where FDA maintains that the involvement of a learned
intermediary is necessary, it may be feasible to favorably balance the benefit to risk
by classifying them under an intermediate, pharmacist controlled class of drugs,
where a physician's prescription is not required, but pharmacists may dispense
medication based upon patient consultation and their professional judgment.
7. An overwhelming majority (80%) of American respondents surveyed believed that
the US should adopt a regulatory framework that includes an intermediate,
pharmacist-controlled class of nonprescription medicines. Also, respondents from
outside the United States endorsed the utility of a pharmacist-controlled class of
nonprescription medicines. The physician and industry interest groups vigorously
opposed such a class. Evidence collected strongly supports the consideration and
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evaluation of a pharmacist-controlled class of nonprescription medicines in the
United States. Efforts to bridge the gap between physicians, pharmacists and
patients to enhance the quality of healthcare delivery must be seriously considered.
8. An innovative investigational method that utilized a combination of web-based
global electronic survey instrument and a telephone interview survey instrument has
been applied to measure and study the attitudes and opinions of important
stakeholders on global issues of vital interest to regulation of nonprescription
medicines. This study demonstrates the utility of electronic communication in the
rapid and effective completion of a global survey. Also, the electronic survey
instrument is presented as an efficient alternative to traditional questionnaire-bymail survey technique. A total of 473 responses were received from United States,
Australia, United Kingdom and Canada through the electronic survey instrument.
Additionally, the opinions of thirty-six stakeholders (to include interest groups and
key opinion leaders) in great detail from United States, Australia, United Kingdom
and Canada were collected and examined.
9. Some significant inferences based on the evidence presented in this dissertation on
OTC issues of global interest and, in particular to the FDA, are:
a. A majority of American respondents believed that the current regulatory
environment for marketing OTC medicines in the US was inadequate
b. Two thirds of the respondents believed that the US FDA could learn
from different OTC regulatory environments and marketing systems
within developed nations.
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c. More than 8 in 10 Americans opined that US FDA should issue a
"guidance for industry" document on the reclassification of prescription
products to OTC status describing the nature of the evidence required to
substantiate such applications.
d. On the issue of a regulatory agency actively proposing OTC marketing
of a drug in the absence of support from the sponsor, the response was
varied. American opinion was evenly split with 40% disagreeing, 39%
agreeing and 21 % being undecided. On the related question of a
regulatory agency unilaterally initiating switches of prescription
medicines to OTC use, American opinion was unclear with 43%
agreeing, 42% disagreeing and 15% being undecided. Roughly 70% of
Australians disagreed and 52% of Britains agreed with this idea. A
majority of Canadians (45%) rejected this notion. Again, the industry
interest groups vigorously opposed this proposal. This observation is
most pertinent in the current context of proposed OTC status for secondgeneration antihistamines. Also, if the FDA unilaterally switches the
three antihistamines to OTC status, it will be setting a precedent and the
procedural details of such an action are unknown. However, there was
universal agreement that a collaborative switch process between the
FDA and all stakeholders is most favored.
e. The ambivalence of Americans on the adequacy of US FDA
reclassification criteria reinforces the dissatisfaction of Americans with
their OTC regulatory framework.
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f.

The respondents almost unanimously stated that the risks and benefits to
individuals and public health should be assessed and weighed in any
decision on OTC marketing of drug products. 9 in 10 Americans stated
that initiatives to market at least some nontraditional medicines (dietary
supplements and nutraceuticals) as regular OTC products by subjecting
them to the same rigorous premarketing scientific evaluation and clinical
review criteria should be promoted. Most respondents added that this is
perhaps the most important public health issue that FDA should address
in the area of OTC medicines regulation.

g. Conditions like asthma, hypertension and medications like diuretics,
antihypertensives, oral antidiabetics and antinfectives are unsuitable for
self-treatment. The opinions over hypercholesterolemia and osteoporosis
are complex and divided. Whereas complete lack of healthcare
professional intervention does not have any support, support exists for
nonprescription use with pharmacist or nurse intervention. Oral
contraceptives could also be classified similarly, but some women's
health interest groups opposed OTC status.
h. Consumers may not always posses the knowledge and commitment to
responsibly use OTC medicines without being assisted by a learned
intermediary. It is important for consumers to responsibly use OTC
medicines and the burden of effectively educating the general public and
managing the consumer behavior lies on the industry, public and
professional groups, regulatory authority and consumers themselves.
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L

The approval of new OTC medicines should not in any way affect the
status of existing or already available OTC products.

J.

A drug's safety profile cannot be understood based solely on controlled
clinical trials during development and surveillance during real-world
clinical practice is necessary.

10. At the time of this study, tremendous activity related to scientific and regulatory
aspects of nonprescription medicines is underway globally. These aspects of OTC
medicines are beginning to receive attention and scientific examination. The body of
relevant reports currently available on this subject matter is not substantial. The
author believes that this dissertation serves as an early and comprehensive
exploration of this subject and contributes to filling the existing vacuum. It is not
possible to have addressed all issues in this dissertation, and, numerous challenging
questions in this area remain that present opportunities for subsequent research.
Some findings, observations and proposals in this dissertation allow for the
formulation of specific constructs suitable for further examination. This dissertation
did not focus on economic aspects of global nonprescription medicines. An
examination of the interactive effects between scientific, regulatory and economic
principles affecting nonprescription medicines and their optimization to maximize
public health benefit would be intellectually stimulating and invaluable.
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